var title_f20_52_21312="Tracheostomy button";
var content_f20_52_21312=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F58958&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F58958&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tracheostomy button",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 446px; height: 300px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEsAb4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKK8z8Y/FNPDvxF0vw7/Zv2iwleCK/1AS4FnJcFxCpXHOdhJOQADQB6ZRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXmuv8AwY8K6/Jr1xqy3s+oavcC4e+Mqia3wFCJEQuAqhQBuDHk5Jr0qmTSxwRmSeRI416s7AAfiaAEt4zDbxRNI8pRQpkkxufA6nAAyfYCpKKKACiori4htk33EscSE43SMFGfTmuc1Xx1oGnblN59pkH8FsN+fx+7+tJyS3NKdKdR2grnUVHcTR21vLPO4SGJS7seiqBkmvK9V+Kdw+V0uwjiHZ523H8hjH5muC8WeJ9Z1XSb8XmoTNG0D5jQ7E+6ewwD+NYuvFbHfTyqtJXnoe0aF8QdC1q9+zWr3kZdHlglntJIo7lE+80bkYYDr64IIBHNZNp8S4JtVMT2Eo0+RwkM6t8/JxuZD0BPvkDtXjfgebVo9Y8NRS6pc3cih7J0uGDxsH3xgrwCnytHkZIynoa1IJPKihlcECIq7DuNpBI/SssVVlTa5TvyPL6GMhU9qrtWS12vf/I+k6CcDJ6V534VsdU8V6Umqap4o1KMNJNELXTxHbpEySujBiFLMw2Y5OBg8d62D4A0S4/5C51HWM9U1K+mniPsYi3l/wDjtdh86aPiHxRpeg6IdWvJ99jvEfmQDzMknHauXtPHWpazbR3mjabbQ2MgJje9mJkcZxnYgwv/AH0fwrivjx4YsdMgsJdAtINN+1rMtzFbRCOO58tVkXcqjG9VjchuuAw6dE+Eszy+DIFdtwjlkRfYbs4/WvGzzGVsHh1Uouzvb8zrwdKFWpyz7HqfhbxSNWuZdP1C3Flq0KhzEH3pMn9+NsDIz1BGR+RPTV81fFK6n0nxR4e1SFpUEOSHjODlWBIz7g19JQSpPBHNE26ORQ6n1BGRXXluJlisLCtPd/52MsRTVKo4IfRRRXcYhRRWPqerPZ+IdF05YlZL/wA7c5PKbEDDH1zQBsUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVwXxkAfw5p0D/NDNqlqsiHo4DbgD6jcqnHtXe1538WAbi/8MWzNiFbqW7K/wB5kiKqD7DzCfqBUz0izbDrmqwXmvzMWo5JY4tvmOibmCruOMk9APepKwdb8Pw+KNe0vSZwu+aC8MEjDPkzCL93KPRlbBBrghHmdj67EVvY03UtexmfEFy8mi2gIVXujMx7kRoSAPxYH6A+tZlQ6zqLavqXhqZ0Mb/YJ55Yz/yzkLRLt/AiQfhU1J6aDpNSvJf1ogqnq/8AyCb3/rg//oJq5VHW3WPRr93IVFt5CSew2mkty5/Cws72PTb3TXEi/brWeO7mt2UiSOFJraYTDPBRk81Cex79RXR6lG0dzqETD50mmRh7h2BqefXIdS8ESWc+kz29le6bPpdtqz7Nks0cB3xjncBlZNpPBMbY7Zk1tmk1aeeRcG6SK6x/10iVz+patsavdTPO4YqWq1Id0n9z/wCCejfCadPset2nzLNDfmVkZCvySxo6MM8EMCTkd8967yvL/DGk6udNsta0DWLLT4rixS0vxeWzTqPs7Mqyp86hW27lOTjAU44wbN3Lb7DLrfxQSG0Tki2ltLRT/vOQzfkVrrg7xTPn8VD2dacH0bX4ln4x2ceoaLpFo2PNn1FYouecvDKpx77Wf8M15n8FJ9+gX0BOTHdbvwZF/qDXpnhBfB1/rkdzp+vvresW4Jh+16i00kSlSC0cRIABBYb1XkZGTXlHw3RtH8ceI9Ek+XYzAD/rnIV4/Bq8jP6XtMDO3Sz/ABNMDLlrLzLvxqh3+HLKYDmO6A/Ao39QK9w8G3iX/hLRrqP7stnE2PQ7BkfgcivIvitB53gm8YdYnjk/8fAP6E16N8IpUm+G2gtGcqICv4hiD+oNc/DM+bB27N/o/wBTTMVatfujr6KKK+hOAK5TxIQvjnweW4DNdoD6t5OcfkrH8K6uuU8eDbceFplJEkWtQ7CO26OSNvzV2H40AdXRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXnnxeVoT4Yvl6JqJt5Ov3JYZAP/H1jr0OuK+McefAF7cAHNnPbXmRzgRTxu3/AI6rfnUyV00a0ZclSMuzRy1RaRIkPxB8PSyuqRpFdszMcBQIwSTUtZWv6DYa9DBFqUbSJDJ5ihWK54KlTjqrAkFehHWuCEuWSbPrcVSdalKnHdnn7DFz4cuArKl5YXUi7hg4Msbpkeu2QnHbmtGr3j6IRah4dlRQq+dLbAAYA3RF8f8AkL9Ko0Sd9SqEeROPb/JBWdrSxSw29tc5+zXFxHHPjkmLO5wPcqrD8a0aqXnlLdaXJdKGtkv4BMD3R3EbfkHJ/CiHxIWLv7CduzPT/EGjsf2d4La5YJdi1t7oOh/1UrSLJwe4BYj3GfWubvpjeaR4Xv2UK91ott5ijBxKgKuPwOB+FdLLdyyfBbV9MupWlu9GlGmysxyzKkiGJj7tE0TH3Y1kzWn/ABQ4AB36PrV5aH5cYillaRB+AeIV04qPNTfkeJkVVU8ZFP7V1/l+NiPw1BbanrGg6frsf23RnuLi1WyldvJFwU+0Ru6Z2yZVJ1w4OCBjrXs1voek20yzW2l2EMqnKvHborA+xArwnTrlrO6jugu+K0ubW9lTIDFEmEbFfcLOxx3AIr6How0uamic8peyxs7dbP79/wAbnK/E3RbbWPBmq+bFF9straW4s7lkBe2mVSySIeoIIHT6V5FrA8j4y6VqOzyo9asUuio6AtCQR/30n619CyxpLE8cqh43BVlYZBB6g180+M3l0qy8K3TOJl0C/uNIM4JPmxQSKI8/7WzKtz94NSxlJ1qE6a6pr8DzaUuScZdmd74qs/t/hvU7YDLSW7hf97GR+uKl/Zy1VbzwRNYk/vLG4YY/2H+YH89/5VfBBAIOQehrgfgPMdH+I+uaKx2xyJIqj1aN/l/8dLV8xwpV0qUn5P8AR/oejmcfhkfQtFFFfYHlBXJfE4mDw7b6gOP7O1Gzu2PPEa3CCQ8f9M2eutqjrumQ61omoaXdf8e97byW8nH8LqVP86AL1FYHgHUp9W8HaTd3uftpgEdzn/nsnySf+Pq1b9ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFZHjDTP7a8Ja1peA322ymtsH1dCv8AWteigDw/w5ff2n4f0y/zn7TaxTZ/3lB/rWlWJ4OAXw9bIv3UaVAPQCRgB+GMVt15slZtH21KXNCMn1SPK/EmpapLFp1xq32f7M+pTGFEQh7ZophblHbo2UnWQEAcZ64rQp3jj7DcfD7XNLmlii1ez1xbiEeYBL5dwgRZEXOWG5ypAz9w8cCqemXa3+m2t2n3Z4llA9MgGtKsUkmjiwNWUpThN6plqs3xHG8mgagIf9aIHaP2cAlf1ArSorJOzuehKPNFxfU6vxTelLPULizXzbHxLpiSw7Dw11ApmVR7yxBgD6xKO9aloYdQsPHkVmyywXENlrkLJ0ZWi2hh9fsnb+tc18P45NQ0bUPDAufs1xpdxDf6bcbdxiTzPMQbcjcFkRlIz9wgcZrqfAGjyaH4l07SL5oJPtmh3EEjQKVjJinQhVB6DbcNgc4wa9B2nC3c+Pg5YXEJveLX4M5nS4ra6vls78A2N/G9jP7JKu0H8GKnPtXfJHqCr9k8TfEKxt47UCMppwjtpZQo+9M8rSMGPUhNvTqc4rzOWOSCGSInE8OUJ9HU4/mK9N+Fml6Nd+HZ4rjStPkvbS9njnka3Rmcu3nI5JGctHLG3/Aq5MFLRxPoOJ6KUqdZdbr7tV+bM4XPgC6cm98T3+uRoSq77+eeEHvjyvkY+5yR7VkfEO68N6l8P5NC0a0vLD7NuvNPW4sJreO42bml8tpFG47TIx7n73I5r21VCqFUAKBgADAArlfijov9u+BNXt4ow97FC1zZnus8YLIQe2SMH1BI6Eiu4+WOH8EXp1Dwlpdwxy5hCMfVl+Un81Ncncv/AMI58bdG1H7sF66Bj2G8GJvyyD+NTfBzUEl0q808NuFvIJoj/eikGVP8z+IpfjJYtJolnqMWRJZzAFh2V+M/99Ba+FwT+o5vKk9FJtfJ6r9D2q377CqXb+mfRFFYvgzXYfEvhmw1WAj9/GPMUfwSDhl/Ag1tV90eKFFFFAHI/DvFv/wkumDA+w61c4UdhPtuh/6UV11cfYP/AGZ8UNUtZCVi1mxhvIM9GlhJjmA99jW59evpXYUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeI2EQtNW8R2C8LbatcbR6CUicD/yNTbvW9MtLuO2ub63juHO0RlxnPTn059avaunkfEXxTHz++a1u/8AvqBY8/8AkH9K8ingja61Wzd45mE8iySqQwfcdwJPr83I7EEVxSgnNn3WTUFiqUYt20/LQ9A8UahHps9jKNKW+uZDII2JRCpSNpCAzcbiFbAyMkVxOiBIlu7WPIjguHMQIwfKk/ex/kkij8DWzHHquueCX+yywyalZzt5HmphZNgxtODwSCRn1waqazZvpep6HLIuz7ZYraTL6SxLuX8dpk/75FS0krdTnqRqUsQ1LZafo/xsS0UUVmdA7R9R/sPxdpGpMcW8jmwuT6JKVCsfpII+ewLV6nrz/Yde8Lar0W31JbaU9tlwrQgf9/HiP4V4/qlr9u066td23zo2QN/dJHB/A816Tc3c3ij4TtfW+Fv5rAXKDH3LmMbgMD0kT9K68PK8bHzmb0eWqqi6/oZfjC3+yeLNXhxgfaDKOOu8B/5sa6P4T3/ka1PZ3Q2nULOOS1fPDm2JhkT/AHlXyW91cehql8REju59I161B+zapaI34gBl/NW/8dqt4K0861O+nx3ktjeWkq6nY3cSqzQyAeXIMHhlZHCke/rg1zUv3ddxfX/hz2sevrmVQqx3ik/u91/5ntdQ3t3bWFpLdX1xDbW0S7pJpnCIg9Sx4Arl28Ftfnd4i1/WtTz/AMsUuDZwY9NkGwsP99m/pWRqVh8NdAv4RqX9ki+jfdFbTzG4l3joVhJYlh6hcivRPjjyHQVHh3xdpV5ArJoeq+fa2crDaJYEmZIWA7DasOD3B3cZr07XdPTVdGvbF+BPEyAnsccH8Dg1h/GfU9O8VeGGayjv7bVNKZbtYryzltpHt2IRpEDqCV3FM45BHIFaXg/Vf7a8OWN6xBldNsv++vDfqM/jXxvE2HdOpDFw9PmtV/Xketl1RSjKkyh+zTqji21nQ7g7ZIJFuEQnkZ+Vx+BVfzr26vmYXv8AwhHxkgvydljeMGl9PLk4cn6MC34Cvpkc19Xhq6xFGNWPVXPMqQcJOL6BRRRW5Bx3xQUWmh2muqMTaHew328cEQ7gk4z6GF5PbgeldjVTVrCDVdKvNOvFL2t3C9vKo7o6lWH5E1hfDvULm50N9P1Rg2raPMdOvG6eYyAFJfo8bI/tuI7UAdRRRRQAUUUUAFFFFABRRRQAUVFLcwRSrHLPEkjdFZwCfwqWgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8l8aR+T8UJ3AAW60e37dTHNPk/lIPyHpXjdq2JbqIfMsUzqJFB2yDcTkZx9PrXt3xNQRePfDc3/PbT72E9Oqvbsv6b/0rxmWEW1/f26MzJFcuq7uuM5x+tc0/jZ9/wpO9O3r+ZoeFHlj15bSG4mjgu45TJGr8BgB8656H3FYdvsHh5UE00iaZeWgm3yvIYZvnhlOHJK7mOSM4G4kcVf8AD4ew8TWVxFNIzTyCCQOcgowPA9OQDx6V0l9a6Gmv6los28XfiKAySJs+Q7UK5z2YhSf+Ak+tRJ20HnVD/aIzWn63/wCCZlFZ+gTyXOi2UtxnzzEolz/fAw36g1oVg1Ywi+ZJoK6/4QXQ+x61o0mGFpdGaNT08qcb/wD0Z51chWh4EuvsPxDtVJxHqVnJbH3kjPmJ/wCO+dW1B2lY87NafPQ5ux3FrbG++COnRnJuNEUW7Z6g2zNA+f8AgKsfyrA8KXYsvEVm7SPFHMTayOhwyiQbQQexDbTn2rt/Baxp4j8W6DOv+j3SxajGvYrMhikA/wCBQ7j7yV5jNA8Xm2ztiWJmiZh/eUlc/mKjFrkmpr+rG/D8liMNUw09v0krfhb8T0HwD4O0bUtAaLX7Br7VbK5lsr2e4uZZRdSRsR5p3Oc7xtbB6bsYwK7/AEjRNK0WIx6Ppljp8ZGNtrbpEPyUCuR+EepjULTXPNVkujqBuJFI4xLGjgg9CPvD2KkV31d6d1dHyc4OnJwlutDgfizpsNzDod3OAIlvP7PuHx0hu1MHXt+9eBv+ACvLvg7NLbjWdIucrJazBth7E5Vh+aj86968VaVba34c1HTr2UwQTwspmVsGEjkSA9ipAYH1FfNGm6tPYePNM1i78tY9cgjlmeL/AFchk+VpF/2TKpYexrzc4wzxODnBb7r5amuEqezqps6j4waP9t0GPUIlzNYtlsDkxtgH8jg/nXqvwq8Qw+IvBOnTpLvubeJba5B+8JFABJ+owfxrEuIY7iCSGZA8UilHU9GBGCK4z4LSSeFviLqvhq5Y+Tdx74Cf4ymWU/ihbPutePwxjeem8NJ6x1Xp1/H8zrzGjaSqLqe+0UUV9WeYFcZf/wDEi+JNjegbbLxBD9gnPYXUQaSFj/vR+cpP+wgrs65/x5o82t+F7y2sWCajFturKQ/wXETCSI/TcoB9iaAOgorN8N6tDr2gafqtuCsV5AkwRuqEjlT7g5B9xWlQAUUUUAFFFFABRRRQB8z/ALRXhfUdb+JFxPb6TqF1bt4YEFvNBo73qNdC5dliDgYhYjrJnKqT/er6G8M/av8AhG9K/tC2+y3v2SLz7ffv8qTYNybv4sHIz3xWlRQAUUUUAFFFRzzRW8TSTypFGOrOwUD8TQG5JRXJ6r4/0Cwyq3LXcg/ht13D/vo4H614xffFO9udR1nU01fWLQ6ferDFbQ2qPaRxctiY7SSXRZOeMbOCD1lSTdkzWdCpCPPKNkfSLOiuqMyhmztBPJx6U6vCPGl5JqPim9lkuGlSCTZbMrcRpgEFCOmeuRXcaD450+00TTrS7mvdQ1lokLW1tbyXEzbs4J2ggcDOWIHHWsadf2k3G2x6ONyp4TDwruV+a2na6ud/RXJnxbfTHZp3hHX55PWZYbZF+pkkB/75BNZXiTxP4n0HRbnU9a0bT4dOwEZ7K+eae03EKrspiUOAWBbafl7butdB5J3V9d29haS3V7NHBbRKWeSRtqqB3Jpmm6hZ6pZpdadcw3Vu/SSJwy/TI7+1fPvw0upfE32++8QSHUbyGVBG9x8/ljb/AAg8D6iuh8R6vL4LkXxFpUEDSOwgu4WBVbhW6EkfxKRwfQmvFlnNOON+puPlfz9DrWEk6Ptkz2uis7w7q0Ou6HZapbI6Q3UQkVX6rnsa0a9o5AooooAKKZLIkMZeV1RB1ZjgD8afQAUUUUAFFFFABRRRQAUUV4j8WIY47T4ia0PM/tDSra0ls5PNcCJtueADjk9aAOs+L0RjXw1qAHEGpeRIT2SWJ0H/AI/5dePa5ouqW99qV3HapPatI04ZJQG24GflOORg96bounDXdJ8MzXN3fQyajpS6hdeTcMBLOtzuViDnGCBjHpXQSeGxLG0cmsayyMCrA3XUH8KynBuV0e5lOb/2emrXucNJ/pC2qxIzvLLH5YA5zuBB/Suo8USx6frk80zQkSCyvUEuFc+RM0brEx6kJc7tvXrjqaIPAGmwSQvFfaurQndGftZO0/lV248Kw3Oz7Rqeqy7DuXzJw20+oyvFL2budma57Rx1uWLVrdu/qcVaX1ro9lcQ6lcRW5true3JkbG4iRiCPXKlT+NbEMsc8SSwSJJE4yroQQw9QR1q/L4fXQLuXU9F06bVtau22Ga7uQBENvLFj90HaoO0EnAzXOeH7e609r/S78obi0uGwEGF8t/nTae4+Yj14rGpS5VzEYLMFWqeytZW0Niqd9cnTp9O1QHH9n3kNwx9I922T/yGz1cqvf2yXtjc2sn3J42jb6MMH+dYxdmmejWp+0pyh3R6/dy/2V468Oaqx2wXHmaTOew87a0RP/bSJUHvJXL+OLBtO8WahGRhJ2+1Rn1D5J/8eDVpaVu8ZfC6zJl2Xl1ZJ+9Bz5N0mPm+qSpn6rU3jC4PiLwb4d8TpF5bNGI7mPvEz4DKf92RSv1NdGLhzU79jxcgxHscXyPaWnz3X+XzKnw8sdVN5c33hy4so7qNPs13BeB/LmjLeZE428hlYzj3D+wruH07xpfMRda9pmlw+mnWJllPvvlYqPp5Zrh/hrqIsPFUcUjYivYzAfTePmX+TD/gVdB4V8Pw+LNLGreJL7Ub+Z7q6BszdPHb27LM6bBGhGSgXb82eQT1NVhZ81NeRGe4f2OMk+ktf8/xuWdb8LaHa6eX8Y+JdSudNHMyapqKxW83tIqhFK/7P3T3FeTfGvWbHxELOew028tIbVWS0u5YxHFfQAqrNEOoCOVAyBkPkZHNe66Z4J8NaZeC8s9EsVvR925eMSSr9HbLAfQ1g/GnSItS8MWkspC/Zr6FWf8AupM3kOT6hRLvx/sA9QK6DxjnvB2qHWPDVheucyvHtk/31O1v1BNcx8RzJomu+H/FFspL2c6xy4/iXO4D6Ebx/wACqt8ILyS1bVdBvAUubaYyBD1HO1x+BA/Ou28T6WutaDe2DY3SxnYT2ccqfzAr87v/AGXml9op/wDkr/yTPe/3nDedvxR6ra3EV1bQ3Fu4khmQSI69GUjII/Cpa8q/Z512fUPC1zpV5nz9KlEY3dQjZIU/Qhh9Meleq1+iHghRRRQBxnhWQaF4o1bw3ODHFcSyapphP3XikIM6KfVJWZiP7sqe9dnXO+M9Jvb+LTb3R2iXVdMu1uYPN+7IpBjkjbkcFHb6EKe1dFQAUUUUAFFFFABRRRQBBf3UdjY3N3Nu8qCNpX2jJwoJOPyriNC8e3N5o1ldXumRx3E8SyOkc+VXcMgZ284BFb/xAvY9O8DeILuUFlisJiFHVjsICj3JwB9a810qBrXS7O3kxvihSNseoUA1hXm42seplmGp13L2ivax3X/Caf8ATh/5G/8Asapax8QF07SL69axULbQPMS0/HyqTz8vtXGa/fS6bpFzdW8SSzoAI0dtqliQoycHAyRmuc8VahNc+Ar83kKwXyTCyuIVbcqTCcRMoJAypbpxyCPWsVUqPW56VTBYSLceXW193/mdBd/EzXtQto2hWGw3oCyxpuYEjkZbP6AVy99f3d/L5l7czXD+srlv51XorKU3LdndSw9OirQikFYmmQGeS5jjCrJPdeVuPGSZmVQT9XwP973rbq34R8L3et6PczWF/HbB7+S3u45ofMWSESpKCvQrIrIMHOOTkdK2w/xM87Of4UfUuTSQTxadd2p/c3mm2dyB6boE/wAP512XwdmeHXdQtiQ0VzZpMPVWjlkQ/gVdAPTafWuKWDyLCwjwQIRc2XP/AEwupoxz/ueX+lbvhHUYdC1TTNXvLn7LYfaJtMvJZCoiRZEWWFnJ5X94rLuzjLAHqMZ0vdxDXqdmYP2uUU5b25fwVj3Gua+JVpLe+AdfityBcLZySxbum9BvUH2yozVdviJ4YKg2moSX5bhBYWs10ZP9zy0bcPccVS13xDqWtaJfafofhnWDd3lu8KS30S28MW5SA7lmDEDPRQW9h1HoHyB478MXW28ca5aQqYreWNpY0PZQ42f+OvXY/Ea0F54M1NSOY4/OU+mwhv5A1zU9mvhz42/YQ26KS3jhVyMbv3C8492Su91mD7Vo99b4z5sEkePqpFfCZ5ehmcKv+F/c7foe1g/fw7j6ovfAK5kn+G9osj7/ACZpY1z2XdnH616LXjn7MtxI/hbVIGOY47sOvsWQZ/8AQRXsdfdnihRRRQByvxR/5ETU/wDtl/6NSuqrmviXbS3XgDX0txm4SzkmiH954xvUH2JUCt+yuY7yzguoCTFPGsiEjnawyP50ATUUUUAFFFFABRRRQAV4t8WlZ/DHxZVFLM1naAADJJ2V7TXP6r4N0DVtSa/1DTYp7ttm6Qsw3bPu5AODj3oA8D8I3MFjoXggXs0duf8AhHtv75gnInORz3rp/wC2dM/6CNl/3/X/ABrqviH4O8PaT4D8UXWn6Pax302nzwxyFS5V5AQpXOcHewPGOa5pND0pEVV02ywowMwKf6VlUqcljuweCeK5rO1iL+2dM/6CNl/3/X/Gj+2dM/6CNl/3/X/Gp/7F0r/oG2X/AH4X/CorrQdNmtpY47Gzid0KrItumVJHUcdqz+srsdv9iy/n/Ay/Eep6VPod5E987oyfMunzAzkZ52bTnOPTnGa888PDSINdmi8P3GoS201qs0q3yvvWQMVHLgHp9R0qUaPBB4Gv2sUe2m0+K01KORG3SQsOZtjkbip2SEBs43Y5AxWrFDeS6gL3UNQN5KIBCp8pU+XOc/LwTTq1E4uLIwGEqRqwqx26/ii9RRRXIfRHSfCO6a21jXdIJP2dxHqEK9lZyyygenKq31c12/hK1iml8WeFLniCR/t9vx92O43Fse4mSVvbev4+V+GtRbRPGmn3j4Nndo1jcZ/5Z5+dH+gZdp9nz2r1nT7W5vvEuj6/ogWWCHzbO735QSQSANuUn7xWSOM/QsM813U2pQsz5XG050MQ5xVtbp/15nmRE8DlSfLu7eTGR/BIjf0YV6l8P9RQ69qtsMJDqcUWtWydlLjy7hB/uyIGPvNXN/EzRm03XTfxqfsl+ck9kmA5H4gZ+u6oPD32lNIstX063murzQNQbzLeBS0k1lOo81FUfeIb94F7mIAcmuTDXp1XTZ9BnXJjMDDFQ6fro18nY9orI8X6QNf8LatpO7Y15ayQo/8AcYqQrfUHB/CsmPx3Y3S79N0rX76H/nrFpkqLn0HmBc/hnHTrRH4j8QXOXs/Bt+kH8JvbyCF299qsxA+uD7V6B8eeD69qf9m+NdE8VqvlQatbpPdIP+Wcn+ruIzj+JXViR6166jK6qyMGUjIIOQRWr4X8Jwvp0k3ibS7B72a/ur5bcqJUtvNfO0EjBOApJxyxNdLp+k6fp9rHbWVnBDDGMIioPlHtXg5vkv8AaE41Iy5WtH6HbhcX7BOLV0eK/Du21jQ/i1qkVnZmbS70+ZcMCAI0csyuO/Dbl/P2r3io1hiWTzFjQPt27gozj0z6VJXsYenKnSjCbu0rXOSclKTaCiiitiQooooAKKKKACiiigAooooA5T4qt5fw+1mVvuQxLM59ER1Zj+ABNcZXpviTTl1jw7qumOAVvbWW2IIyCHQr/WvHfC92b/w1pN4xJae0ikbPXJQE1zYnoe5kr1mvT9SLxf8A8gCf/rpF/wCjFrJ+LkQt/EmvQxDbby6np1zIvbewQEj6mNCffJ6mtrxVBPceH7xLOLzrhVEiRZx5hRg20HsTjH41z3jZ7zU9A1zXtTtja3V7eWt0tsWDNbxRSRbEY9N2ELNjuxAPSs4NclvM7MRTk8QppaKLKVFFFYnpCGtL4T+E5fFuj61cS31zbXUQ8/SmhlZEt5ZmaVJWAOHJQQZB425H8RrD1bP9lXmOvkvj/vk17B8CHiTQtTtCuy8S4imkGPvxvbxeU4Pddq7R6bCO1dOGW7PDzqbtCPqef6Xd/wBs+DYNYaLyZn1e6jmiIwY3dEdkP0KV0PhDxBbaJbapHd2UmoG7e2it7RNn72VnZFBLkKASU5J/PgVz/hG2z4W8U2qgbori21kLz0cyQMfytzUUyCa0v7fd5ZuLKeNJMZ8uQL5kT/hJHGfwrGp7mIT7/wDDHoYNfWcnnTX2b/g+Y9jik8dTRBzb+G7QtyITLNMYx2BYBQxHfAA/nQ9l44iBuI9b0K5mx/x6PpskMLewkErMp/2sMP8AZro9Iuzf6TZXhUIbiBJio7blBx+tW69A+RPm34naibzXPC3iwWptJXle0uoN+/ypracpIpbAz3AOBkDOK9MrhfinYo3hbxVasoW603XVvSB3huIxtYD0LMy/70bV12kXa32lWd2hys8KSZ+oBr47iunrSqLzX5f8E9bLJfFEwP2cZvsepeJ9HfhopFZV7/Kzo3/ste4186eF7s+HvjwyZ2waifLb38xQR/5EAr6Lr6rC1fbUYVO6T/A8ypHkm49gooorcgzfEsTz+HNVhhUtJJaSoqjuShAFV/BM8d14M0G4hYNFLYW8iMO4MakGtquS+F/+jeF/7IbiTRrmbTSuMYSNz5X5xGI/jQB1tFFFABRRRQAUUUUAFFFFAHFfGKby/AN7CuTNdTW9rEo6lnmQZ/AZJ9ga5at34uSmRPDunpgNNf8A2hmJxhIo2Y49SWKDHoSe1YVcmIeqR9Dk0bU5S8/6/MKKt6TYnULoxeYI0VC7uRnaB7flVjVdKWytop4bj7RE7FCdm3B/P61yc8U+W+p6jrQU1Tb1PONFiEt9Fpd9ZyW7xaZJYzl8BblRcSFGQ9WGyQnpxuIrnPDjSf2NBDOc3FtutZT6vExjY/mpNdBfwpb+P476VA0++3iVjyfIkSdML6bZQpI7iTPOKyXVbTxNrlkSof7QLpQDyySKDnH+8HH4V0Tu9TlwqUHyLo2v1LNIBnp1qaytZ726jt7SJ5p5DhUQZJr2TwR4Eg0fy73Uwk+o/eVeqQ/T1b3/AC9amFNzehrisXTw0by37HP+B/h60+y+19GSL70dqeGb3f0Ht1+nf1eNFjjVI1VUUYVVGAB6CnUV2wgoKyPl8TiamIlzTZQ1vSbTWrBrO/RmhLK3ysVIIOQQRWbonhW10TUnutNnnjSVNksDEMr4+6c4yCMnv3NdDRQ4Rb5mtRQxVaFN0oyfK+nT7goooqzAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvCfDEX2Wyu7A8Gwvrq0Azn5UncJ+abT+Ne7V4xeQ/ZPHfi22H+re6hu0AGMeZBGCP++kY/8CrDEL3T1Mony17d0Wa5Xx/fWLeH9W0mS7hj1G40+eSCBmAaQhTgqO/I6CuqrlNY0QajeeKBbRRPdDSbfUFD4+Z7acuFDH7u5S6Ht81c1OPNKx7mNq+xpOX9amHE4kiR16MAw/Gn1keFJ/P8P2fLFolNuxf7xMZKZPudufxrXqGrOx0QlzRUu40gMCGAIPBB712XwkvWsH8IXTt+6vrOTQZ2PeW2Z/JJP0jnXnqXH48fWn4KT+09K1zwqZRbX8Mv9q6ZcAcoxcOHHukw59Q6jvXRh3q0eTnNNunGa6P8zofh3CravpttL/qNX0e+tX54LR3AKjHf5ZZT+BrA06Vbe4sZrpRshmjaVWAIwrDcD7YBFWvA2tx3GvaNPD5axW2tZeJW5tjeW8pkt2HOClw+MegWpPEtoLTxFq1qVwq3LkD0V/nA/JhUY1W5ZI6OGpp+1oy62f6P80dp4K8XaL4c8Ox6Bq9+keqaVPJp4sYy1xcSIjHyjHEoMjKY9hHy+3at9vGFxKoWx8LeIriZvuLJbpAv1LSOoA/X2J4rmvCGv67rjeTo1ro4l060hgnur0uZZWJcYAUcL8mevJJ44rpF03xldOXu/EOmWK/ww2WnF8f7zySHP4KtdkZcyUl1Pmq1J0akqct4tr7jm/Evh3WPEsHia+1PTIdPaTSUtLaBZlmeZ0kaXLMBgAHaFHPVjXK/CO9N34QSJjlrWV4ffHDD/wBCx+Fej33hvxM1vJc23jG8bU4lLW0bW0CWjMB92RAhZgehO7I6rg9fH/hTfx/2/r9mIGtfNfz0tnOTCVZlePI4JUkLkf3TXi8RUfa4KT/laf6fqdGAny1ku5D8VQ+leKtC1uIcxleR/ejcOP8A0L9K+mIpEmiSSNgyOoZSO4PQ14V8VtP+3eD55FGZLR1nH0HDfoSfwr0n4Tap/a/w90WdmzJHD9nf1zGdnP1AB/Gjh7Ee2wSj1i2v1/UMfDlrN9zrqKKK9w4grktG/wBD+JXiS06Je2dnqC8/ef8AeQvx7LFD+Yrra5HWSLP4l+Grnol7Z3mntx95x5cyc+yxTfmaAOuooooAKKKKACiiigAoornvHXiRPC+gSXgiFxeysLeyts4M87Z2p7Dglj2VWPagaTbsjz7xJeSa58QNQkeQmy0M/YbaNeFMrxo8sh9T8yoPTa3qafVXwro8sFvbWTSm4vZnaW5uCOZZnYtJIfqxY+w47V3d0ludOvrdYo/stvF8jAc+Z0DZ9zXlV66U0n12PqKUlg6cKVrvr8zP0WL7LpU10R+8uSYk9lHX9eKsJH9q0u9terBfNT6jr+lP1BfIW2tR0giCn/ePJpumOyX8BXnLBT9DxXhVcQ/ral0WhhKTknVW+6+WxwuuWLahp0sEJSOcvFIkrDlWjkWRffqv6kdzXO2ei3fiT4haxDYReZJCkELzMTthXZv2k9vv5wOua7rUI1iv7mOP7iSso+gJrrfh3pMWmaTdzRKQ9/dNdSFjkk7VT8sIMV9JSXO7M3xtb2FNVoLV/wCTLXhPwtY+HLbEC+bdMMSXDD5m9h6D2roKKK7UklZHzNSpKpJym7sKKKKZAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV5F4nja2+JusI/S6sbW5jPrgyxsPw2Kf+BCvXa8v+JaeT488PzDpcafeRN9UkgZf0Z/8ms6yvBnbl0uXExKNZt7BfRanDqGlNaGYW81ncQXSsY54JMEqSpBBDKpB/3h3rn/ABR4ivrbVJNP04QxGONHeaRdxy2eFXOOg6n8qiGqnxH4O1WzmlEOqRW8m8Q56qPlcD0JA4+orjipRtJH12JwcpYfnnG8Wc3pGmT6BqF7o91cfaJI44LhZduNwZNhx/wOJz6881r1kbrc/YtX09lawlu5bIBJTIiJIFkjAYknar7lAzx5mPpr0VFaRy4SalSVv6vqFRRXo0fXNI1kkKlpcBJ2/wCmEvyPn2GVc/7lS1Dd28d3azW867opUMbr6gjBFTGXK0zSvSVWnKD6nqfj1I7Tw5danHEolsprfUXdVAZhbzJKcn/dRh9Cao/FG3EPivzkwUurZJMjuQSp/QLT/AFz/wAJF8PobbU286VY5NOuyerlCYyT7soDf8Cqjqjzah8PfB+oznfcW0T6ddMOnnJ+7f8A8fhf866cUualc8XIajpY1RfVNfr+aJvhlP8AZPF1oIyP9MintJ19Qm2aJvwL3Ax/t17RXz5pMdw90z6Wm7WbXbf6eucebLEG3wZ9JInlT8j2FepQ/ELTLy3ibSbDW9SuXQMba30+RXjz/C7SBURu2GYd6eFlzU15GeeUXSxs30lZ/fv+Nzsa+Y/GcB8KfF6e6X5IGvhOcf8APG4G5mI95PtP/fFe3/294peMtF4NZGIO1J9ThUj03bdwH4Z/GuK+I3gnUtU8J67revz21xriwRNDDZoyw2sUTOzKpY5ckSOSxAzgYAxWlWmqsJU5bNWPKjJxakuhrXlvHd2k9tMMxTI0bj1BGD/OuP8A2e9Wn0vxDq3hW9fjLSRg9pEO1sfVcH/gNbvg/Uf7V8M6ddk5d4gsh/21+Vv1BrhvEk//AAiPxV0rX1Ui3mZXkx6Y2SY/4CQfqa+N4cqvD4qphZ9fzX9M9bMIqpTjVX9XPpiikR1kRXRgyMMgjkEUtfbHjhXL/ESwurrw+t7pah9U0mZdStEPSR4wd0f/AAONpEz235rqKKAKmk38Gq6VZ6jZsXtbuFLiJj3R1DKfyIq3XHfC9haaHd6ExxNod7NY7DwRDuLwHHoYXj9uD6V2NABRRRQAUUUUAI7KiszsFVRkknAArxKfUm8X+In8QOc6ZAGt9IjI/wCWZOHuPrIQMeiBf7zV0fxY1hr6WLwhp8jB7pBNqcqEgw2hJHl57NKQV/3Q59Kq6Lp4urmK2jURwIMttGAiD09PSubEVLLlPYyzDpXxFTZbGvocH2Oxkvn4llBjhHoO7VPZzLDIRIu6GRSki+qmi+nE0wEY2woNka+iiiyhE837whYkBeRj2Uda+Sr4iVaunDpsdcnzJzn1/pf13DU9Tjtb6W3vLNbmSMgCUSFCwwCMgDriqcmvbEIsLSO2c9XLbyPpnpWdq12L7UZ7gDCu3A9gMD9BVWvdVCnfm5Vc66WEhyR51rbXV2+7Ykt4nubmOJOZJGCjPqTXqtrAltbxQx/cjUKPwrlfBmj4xqFyvP8AyxU/+hf4V19elQhZXZ4+a4lVJqnHaP5hRRRW55IUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFec/F1PLv/CFznA/tCW2PP8AftpW/nGPzFejVwXxkTHh3TLnB/0bVrRs88b38n/2rjn1qZq8WbYaXLWg/NHi/jGRp/FTDCIttAqEgHdIG+bk56DBxx3NR+HdSi0rXPOu1k8ieMQeYoyEYtxuHXHuM0vjBGbxhI8gZNtugjwuA6nOSTj5sH34/GsS9uFjkhSRJRD5iNLMEysaBgSffgVzJXSR+rUqcZ4LlfY3daks20vxHoen6ZLabZJpoZiybGukRLj7udyjJQg4wecdKS2lFxbRTKCBIgcA9sjNaupabcSeO7GZQJ9IvoJPOwM7JFjKjkfwsrD8V965/RRNDbSWN2S1zYSNaSN/f242t/wJSrfjWUrW0PkqHMpyU/NL03X5mhRRRUHWdJ8J7z7Pr+uaWxwtwseoRD1OPKk/LbEf+BGur0ew+3eGfHGkKuZLXU5J4F93iiuBj6u7j868y0e7Om+M/D17nCPcNYy/7ky4Uf8AfxYq9f8ADkv9nfEm6gPEOsaesq/9dbd9rfiUmT/v2a7afv07M+Xxd8LjPaR6NNf16nnOk3q2Wp6ffZwkM8crH/YyN3/jpNert4uv7vWdV0/RPDtxef2ZKsFxLLdRQAuUDjapJYrtZTuIAOeM4NeWa5YDTtY1CwK4SGZlUf7B+Zf/AB0iu2+Ht4L3xXBODieTREhuiD/rHhnZFZh0zhic+jVzYOVpODPc4jpKpSp4mG23yeq/U32l8cX4AittA0VD/HNLLfSAe6KIlB/4GR/KsfxZYa34f0G61648R3uqCzTzb6xlghS2mtRjzlVFTcrBNzBtxORg5BwPRqgv7WK+sbi0uV3wXEbRSL6qwwR+RrvPkTwX4cFtK1HXfDc75exuWeEk/ejJxke3AP8AwOpvivpDal4YaeFd01k3n8dSmMMPy5/4DXJ3N5L4f8UaBqF4xFxHENK1TPB86DELsfYoIZR6hga9fYK6lWAZSMEHkEV8JnEJZfmEcVDZ6/5r+u57WEar0HTfTT/ItfA/XG1v4f2YmbdPYsbNz6hQCv8A46VH4V31fOnwk1aXwp8Tb3w5IxXT72Zo1Rv4WALRMPqML75HpX0XX3FOaqQU47PU8aUXFtMKKKKsRxmuj+wvH2j6wg22mrL/AGTe44HmcvbOfx8yPPrKo7V2dY3jLRf+Eh8M6hpiyeTNNHugmHWKZSGjkHurqrfhR4N1r/hIfDOn6m0fkzTR7Z4T1imUlZIz7q6sv4UAbNFFFABVfUZbiCxmlsrYXVyq5jhMgj3n03HgfWrFFAHjGm6FqumwTXeuRO+rX0hub2cAlTIQPlU/3VACKOyqK7G3t20vSzDJhbqdsyAHJVR0FdtVO5021uHLSxZc/wAQJBrzcZhKlWDVN6vueqsxThGnKNkuxxtS3jfY9DnLnbLc4RB329SfpXQSeH4CcxyyKPQ4NWZtIsZ5Vknt1kdVCjcTgAdsZxXmYLKqtOrzVOhpLHUrrex5gK6bw94bknkWfUIykA5EZ4L/AF9BXYwWdtB/qLeGPH91AKsV7sMOk7yFiM3lOPLTVvMRVCqAoAAGAB2paKK6DxwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooqtqd2thpt3eOpdbeF5So6kKpOP0oAs0Vx1j4l8R3tlb3UHhEmGeNZUzqUQO1hkdvep/7b8T/wDQo/8AlSi/woA6quN+MEXmfDnV5On2URXhPoIZUlJ9sBM5pb7xL4jsrK4up/CJEMEbSvjUoidqjJ7e1cdq3xX0jxFoF/DYafNqOi3MaafcXVtKrFJLiM/IE6sRyDigadndHC+Of+Rhtf8Ar1P/AKHWDOhkhkQYBZSK6CG8t9Q0nTRrvhvVJb6G3RZD9lztfaNwBB6ZFcvcR6hE95HZaDrPkb2+z7o8kKegyWzx71yxi7WsfpeX51hFTVOc0reZ1GpXt/e+FtCi027GmXVwrsJmOVzDBJIIyf8AbaML9Ce4AOY063HiTVZ0XYLmO2uSmc4LQgfyUD8K0BeyQ6FplvZaTqq3VhJFOguLTzI3ZTllcZ5VgWHHrXOwafrIvdMh0vS7hZDZCzmmukKQwhHLIeTuYBXYAdTgDjrSdNtWSPmamMpxxDnzXh/w6/U3aKzLS4lt9cvtGvL23vLm2RJVlij8vcrZByNzAEMCOvpxWnWEouLsz0KNWNaCnDZmdr8csmj3Jtv+PmJfOh/66IQ6f+PKK9Z1XUong8I+KLY/uIr23mLf9MLlfJbPsBMrH/dzXm9dj8PLWHW/hjNod0TshNxprYPKIGPlkehCNGR6GujDPdHjZzT+Gp8jQ+Klt5HixZQMLcWqNn1ZSwP6bawvCWproPiqz1OZzHY7vst4+7CpHMVVXYHgBZUiGeMeaT0zXSa1PJ4j+Gemaxdgf2rp0n2e9A7Sq3kzD6bwGHtisLwhPFb+JrEXUaSW1wxtZUdQVZX4AIPH3glc8v3WIv3/AFPXo2x2UOC3irfOOq/C33nrGoeM/DOnRCS98QaVEpOFBukJY+igHJPsKoDx3azoz6ZoviLUIgPlki02SNXPopl2Z+vT3qK/1XSNC1mWw0Pw3Lf6xHCkjx6baxrsEhYIHkJVUzsY8noM+mZpNV8YT4jtPDFhbuest7qnyL+EcbFj7cfWvSPizy/4peFNUvPCereJ9XtILTUJb2O4NnCwcwQBBEA7jhnOELEcDAAyBmtH4d6t/a/hSzldt08I+zy+u5eMn6jB/Gtbx94Q1q90HUdb1bWZbvU7K2aSCxsUaC18sZMsWwuTI0iZTcx4OCAteb/CG5Njrmq6RI4ZXUSxsOjbTjI+oYH6CvB4iw3tsI5reGv6P/P5HbgKnJVt3JPi3aSaZrOk+ILL5JlcKWHaRDuQ/Xg/98ivo3RNRi1fR7LUbf8A1N1Cky+wYA4/DpXl3ivRY9f0O4sJDtdhuif+446H/H2Jp37PfiE3GiXXhy8O290t2KKTyYyxyP8AgLZH0K1HDmMVbDexb96H5dP8iswpclTmWzPXKKKK+hOAK4/w+P7G8da5o5G221FRrFoO24kR3Cj6OI3PvMa7CuU+Iljcf2XHrulh/wC19E3XcCoM+egX97AR3DoCB6MEPagDq6KraXf2uqadbX+nzx3FncxiWKWM5V1IyCDVmgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACsrxZ/yKus/9eU3/oBrVqjr1tJe6HqNrBgyz20kSZOBuZSB/OgCDwn/AMiro3/XlD/6AK1a4nRtQ8U2Gj2Nm/hMO1vBHCWGpRYJVQM9Parn9t+J/wDoUf8Aypxf4UAaviz/AJFXWf8Arym/9ANfIXwF/wCSb3//AGMVl/6A1fTms6h4pv8AR76zTwmEa4gkhDHUosAspGenvXlnhr4QeIfCmkvoejpBcwXF9aag17dTBVidEIdCi8kZPBFAHR0VzlnN4mumuwo0dRb3dxaZPm/MYZWiZh7EoaseX4o/6gv/AJFrN1YJ2bOuOBxE0pRjozbqvf2qX1lPazNIscyFGMTlGAPow5FZnl+KP+oL/wCRa5+DxD4lm1W9sVsdPBhaSOCU+ZsuJI1VnQEE7WAdeGxkHIyKaqRezFLBV4W5o7+hzUrxWfiDTVsvDF7odgvm2vnSIAk+75lyBkg5UkEnuR3rpK5CPU/7VtNJmi8Qalcia7inOm3dsA0QIJ4k25KjPByQePeuvrmxHxHt5Q37Fp9GFbnwx1L+zvFV/pU3EOqKLyBv+m0aqkin6oEI/wB1qw6iinSz8Q+Hr2R/KWDUY1Mh6KJA0Rz6A78fjUUZWmjozGkqmHl5a/ceweHoYl8UeI/D90P9D1m2GoRLn+MAQzgemB5Dcd3J+vnV3bT2VzPaTMUuraQxlhwQynhh+hFd74pnGk3WjeIC2xNMvFFw2cD7NL+6kJ9l3LIf+udUfirpptPEMV8q4hvYwGP/AE0Tg/mu3/vk1eMheKl2OfhvFclaVB7S1Xqv+B+RteDdWFx4u+0PgLrumpMB/cuLZjHMmfcSRkD/AGWP09DrwXS76Sx0ye+hVnl0K5TWAq8loNpiulH/AGyYsB/eAr3iKRJYkkiYPG4DKynIIPQit6M+eCZ5OZ4ZYXFTprbdej1FdVdWV1DKwwQRkEV8o6vBJ4Wv/Dmrxhv9FMml3IHJLWjmBs/70SoR65zX1fXjnj/wnNr2ua/oOntAZblLfXIA7Y8qbm3kB9FdUVh/tK3HeqqQjUi4S2ehwxk4u6Nm3mjuII5oXDxSKHRh0YEZBrznSWHhD42211dSCKw1B3PmHgYkBBBPs+CfbBr0bwP4M1nSdJTTdVltWFt8sU8TlhIp5xggEYzj8BV7xF8NNN8QmyOp3ErfZpC2Ixt3KfvKT1GcDkelfJ5Rl2LwOMd4+5qr6bdGepisRSrUlr7x3lFR28S29vFCmSkahBuOTgDHJqSvrzygooooAr6fZW2nWkdrYwpDbx52Rp0GSSf1JqxRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFUNfu20/QtSvYyoe3tpJlLdAVUnn24oA8Z8LEPoyyDrJNPI3+80rlv1JrXrJ8K2yWfhrSoELEJbRgl/vMdoyT7k5JrWrzZO7bPtaEeWnGPZIK5CaAw+JZ9QQDZHqcEEq9D+9tWUN7nciD6H2rr64jx0F0++s9QtIpHuXdZJ0MxSExwBmDuB95l3kD/AHueBVU97dzHGL3FK9uVpmFpkP2KfU9Nxj7FeSxqPSNj5if+OyKPwrQpfEUP2bxxOyfcvLKORh/tozKT+KlB/wABpKl7m9LSNuwVDd2A1S2lsDG0n2lTFtUZJzxx71paRpl3q96lpp8LSzNzgdFHqT2HvXtngzwbaeHolmk23GokfNMRwnqE9B79T+lXTpub0ObGYynh42lq30Kvhjw5fXGj+X4rdLhZoPJe0KghlK7T5h6kkZyM45/LZ8SaBBq3hx9NRNnloDbEf8s3UfL1/I+xNbdFdrimuVnzEa8oVFVho1tY8c8K6fqeh63a3eq6ZcJZTI1tcZj3hVfH3gM8bgvXtXX6f4GnsbaOwg8Va9HpFuuy1tI3iQwoBgJ5vl72VegBbpwc4FdpRUUqXslZM6cfjnjpqpKKTStocl/wgOkzyb9UudY1Rh90XmpTMi/RFYJn3xn3rX0Hw5pOgNcNpFkls9xt81wSzPtztBJJOBk4Hua1qK1OAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArh/jFfw2/gq509syXWqutjBbgZM24/OD/siMOWP90H2FdxXkPjG/GtfEUpAd1poVs1szZ4a5m2OwHrsRI/8Av4R2NROXLFs6MLR9vVjAToOKuaRbfa9St4tu5S4LD/ZHJ/SrWmaLJe23nNMkKuSsQbq7f4e9XNEt2s7O/nlG2Xd9mX2P8X+favJqVYwjKXY+orYiKjJQeu33mpJO2pG8s3YNHIrCLgcEcj+Vea67ow1f7PEzpEUMqOZASrRyQvE6kehEn6A9hXcW8phnjkHVWBrN8RW4t9Wm2f6uT96n0P8A9fNceWYiU003qjloU4vmoPaS/wCH/Q8j1qd76y8G30YP2tkeObzOSE8seYCQeodU9Qa6Twp4XvvEd1ttl8u2Q/vLhh8q+w9T7fyrVsvC/wDwkfjbSbeVWh0qxtp7iVowBvdmjVYx6cFyT9K9psrSCxtY7a0iSGCMYVFGAK9qFLn1exlisc8NenHWX/ARR8PaFY6BZC3sIsZwXkbl5D6k/wBOlatFFdSSWiPAlKU3zSd2FFFFMkKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKiubiG1tpbi5lSKCJDJJI5wqKBkknsAKAOZ+I3id/DujJHp4jl1u/c29hC/TfjJkYf3EGWb6AdWFcJ4a0b7NDb6fbu80ruWlnkOXlkYlnkc9ySSxqpb303iXWrnxNdo6JcL5GnQuMGG0ByCR2aQ/O3tsH8Ndro0H2DTzduMXFwCsX+yvdvxrzsZiFCLb2R9Bg6P1Wj7R/HLb+vxZe86GLULeNR/o1vhF/D+L8+akltJXgFsjK9wkskki5wW3NkMPbFZdM8Sf8eWmb/8AW7HznrtyNteBhJfWXOnPrqNUbzjFP+rNl86ZcIC0+yGMdXdxgVi+ILqK6vYxbtvihiWIP/exnn9azafbwyXM6QwqWkc4UCvSw2DhQd46tnfTw/s5c85Xt8v8zsfAlnstp7thzIdi/Qdf1/lXVVX0+2WzsYLdekagZ9T3P51Yr24R5YpHy+Kre2qyn3CiiirOcKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvLPihqp1zVh4StGP2GEJPrDjoynmO2/4F95/9jA/jr1OuZ/4QnRovPNjA1o88pmkMbZ3uQAWOc5PA/KonzOPunRhXSjVTq7I5XRLEXt6qMdsCDfIfRRWxez/aJywG1ANqL6KOgrVXRJLGxMFkqyySZEsh+VmGcgAZ/CsyWxuof9ZBIB67civl8zVVvl5XZeR7TxMK8+ZPRbf5/MTT4RPeRRkZUnJ+g61h6tdte38spPy52oPRR0FdRBZXa6a8lnDvuZsoCzBdievPes+DwhfPzLLBGPqWP8q6cswso0+a25dHEUYTc5yStp/mc2ASQAMk9AK73wpopsIjc3S/6S44U/wL/jU+jeHbXTmWVz59wOjsMBfoK269qlR5dZHFj8xVVezpbdX3Ciiiug8cKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Figure A shows&nbsp;a tracheostomy button when properly inserted into the upper airway. Figure B shows that when the inner cannula is withdrawn an adapter may be attached to permit suctioning or assisted ventilation with an Ambu bag.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_52_21312=[""].join("\n");
var outline_f20_52_21312=null;
var title_f20_52_21313="Interstitial pneumonitis CT";
var content_f20_52_21313=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F58132&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F58132&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Interstitial pneumonitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 348px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest CT scan in a patient six months after liver transplantation reveals both interstitial and consolidative infiltrates. This pattern suggests a dual infection with cytomegalovirus and Pneumocystis jirovecii, both of which were documented by transbronchial biopsy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jay Fishman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_52_21313=[""].join("\n");
var outline_f20_52_21313=null;
var title_f20_52_21314="Patient information: Uterine fibroids (The Basics)";
var content_f20_52_21314=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15421\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/31/2548\">",
"         Fibroid locations in the uterus",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?0/8/143\">",
"         Patient information: Endometrial ablation (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?14/25/14738\">",
"         Patient information: Heavy periods (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/16/11523\">",
"         Patient information: Infertility in women (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/25/11666\">",
"         Patient information: Painful periods (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/21/2386\">",
"         Patient information: Uterine artery embolization (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?20/20/20804\">",
"         Patient information: Uterine fibroids (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Uterine fibroids (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/uterine-fibroids-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H458187729\">",
"      <span class=\"h1\">",
"       What are fibroids?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Fibroids are tough balls of muscle that form in the uterus (",
"      <a class=\"graphic graphic_figure graphicRef64122 \" href=\"UTD.htm?2/31/2548\">",
"       figure 1",
"      </a>",
"      ). The uterus, also called the womb, is the part of the woman's body that holds a baby if she is pregnant.",
"     </p>",
"     <p>",
"      People sometimes refer to fibroids as &ldquo;tumors.&rdquo; But fibroids are",
"      <strong>",
"       not",
"      </strong>",
"      a form of cancer. They are simply abnormal growths in the muscle of the uterus.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H458187736\">",
"      <span class=\"h1\">",
"       What are the symptoms of fibroids?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Fibroids often cause no symptoms at all. When they do cause symptoms, they can cause:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Heavy periods",
"       </li>",
"       <li>",
"        Pain, pressure, or a feeling of &ldquo;fullness&rdquo; in the belly",
"       </li>",
"       <li>",
"        The need to urinate often",
"       </li>",
"       <li>",
"        Too few bowel movements (constipation)",
"       </li>",
"       <li>",
"        Difficulty getting pregnant",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H458187743\">",
"      <span class=\"h1\">",
"       How are fibroids treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There are several treatment options. Each option has its own pros and cons. The right treatment for you will depend on:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        The symptoms you have",
"       </li>",
"       <li>",
"        Your age (because most fibroids shrink or stop causing symptoms after menopause)",
"       </li>",
"       <li>",
"        Whether you are done having children",
"       </li>",
"       <li>",
"        Whether your fibroids cause so much bleeding that you have a condition called anemia",
"       </li>",
"       <li>",
"        The size, number, and location of your fibroids",
"       </li>",
"       <li>",
"        How you feel about the risks and benefits of the different options",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you are thinking about treatment, ask your doctor or nurse which treatments might help you. Then ask what the risks and benefits of those options are. Ask, too, what happens if you do NOT have treatment. And be sure to mention whether or not you would like to have children.",
"     </p>",
"     <p>",
"      Here are the options:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Medicines &ndash;",
"        </strong>",
"        The pills, patches, vaginal rings, injections, and implants used for birth control can all reduce how much you bleed during your period. A device known as the intrauterine device, or IUD, can also make your periods lighter. There are also other medicines that can reduce the amount a woman bleeds during her period. If bleeding is your main symptom, birth control methods or medicines might help you.",
"       </li>",
"       <li>",
"        <strong>",
"         Surgery to remove the fibroids",
"        </strong>",
"        (doctors call this surgery &ldquo;myomectomy&rdquo;) &ndash; During this operation, the doctor removes the fibroids but leaves the uterus in place. It is effective, but it is not always a permanent fix, because fibroids can come back. Myomectomy is often a good choice for women who may want (more) children.",
"       </li>",
"       <li>",
"        <strong>",
"         Treatment to destroy the lining of the uterus",
"        </strong>",
"        (doctors call this procedure &ldquo;endometrial ablation&rdquo;) &ndash; During this procedure, the doctor inserts a thin tube into the vagina, through the cervix and into the uterus. Then he or she uses tools inserted through that tube to destroy the lining of the uterus. This procedure reduces bleeding from heavy periods. But it is not an option for all women. It is also not appropriate for women who may want to get pregnant.",
"       </li>",
"       <li>",
"        <strong>",
"         Treatment to cut off the blood supply to the fibroids",
"        </strong>",
"        (doctors call this procedure &ldquo;uterine artery embolization&rdquo; or &ldquo;uterine fibroid embolization&rdquo;) &ndash; During this procedure, the doctor inserts a thin tube into an artery in the leg and threads it up to the uterus. Then he or she uses tiny plastic beads to block the artery that brings blood to the fibroid. After the procedure, the fibroid no longer gets blood, so it shrinks. This procedure is not appropriate for women who may want to get pregnant.",
"       </li>",
"       <li>",
"        <strong>",
"         Surgery to remove the uterus",
"        </strong>",
"        (Doctors call this surgery &ldquo;hysterectomy&rdquo;) &ndash; This surgery gets rid of fibroids and the problems they cause forever. Women who have this surgery cannot have fibroids come back. But they can never bear children.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H458187750\">",
"      <span class=\"h1\">",
"       How do I choose which option is right for me?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You work with your doctor to understand how the different treatment options would affect you. Then the two of you work together to choose the option that's right for you. For women who may still want to have children, medicines or myomectomy is often the best choice. Women who do not want to have (more) children can often choose from all the options. They need to consider how invasive each surgery is and whether they prefer surgery over taking medicines. One thing to consider is that fibroid-related symptoms often go away with menopause.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H458187757\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/25/14738?source=see_link\">",
"       Patient information: Heavy periods (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/25/11666?source=see_link\">",
"       Patient information: Painful periods (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/16/11523?source=see_link\">",
"       Patient information: Infertility in women (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/21/2386?source=see_link\">",
"       Patient information: Uterine artery embolization (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/8/143?source=see_link\">",
"       Patient information: Endometrial ablation (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?20/20/20804?source=see_link\">",
"       Patient information: Uterine fibroids (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?20/52/21314?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15421 Version 5.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-8BB6C55152-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_52_21314=[""].join("\n");
var outline_f20_52_21314=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H458187729\">",
"      What are fibroids?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H458187736\">",
"      What are the symptoms of fibroids?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H458187743\">",
"      How are fibroids treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H458187750\">",
"      How do I choose which option is right for me?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H458187757\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15421\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/31/2548\">",
"      Fibroid locations in the uterus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/8/143?source=related_link\">",
"      Patient information: Endometrial ablation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/25/14738?source=related_link\">",
"      Patient information: Heavy periods (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/16/11523?source=related_link\">",
"      Patient information: Infertility in women (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/25/11666?source=related_link\">",
"      Patient information: Painful periods (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/21/2386?source=related_link\">",
"      Patient information: Uterine artery embolization (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/20/20804?source=related_link\">",
"      Patient information: Uterine fibroids (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_52_21315="Sentinel node biopsy";
var content_f20_52_21315=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F74726&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F74726&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sentinel node biopsy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 382px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Identification of the sentinel lymph node. Note the blue node with a blue lymphatic channel leading directly to the node.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Harris, JR, Lippman, ME, Morrow, M, Osborne, CK. Diseases of the Breast, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_52_21315=[""].join("\n");
var outline_f20_52_21315=null;
var title_f20_52_21316="Phenylephrine (nasal): Patient drug information";
var content_f20_52_21316=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Phenylephrine (nasal): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/7/19572?source=see_link\">",
"     see \"Phenylephrine (nasal): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/10/17572?source=see_link\">",
"     see \"Phenylephrine (nasal): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9504768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      4 Way&reg; Fast Acting [OTC];",
"     </li>",
"     <li>",
"      4 Way&reg; Menthol [OTC];",
"     </li>",
"     <li>",
"      Little Noses&reg; Decongestant [OTC];",
"     </li>",
"     <li>",
"      Neo-Synephrine&reg; Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Neo-Synephrine&reg; Mild Formula [OTC];",
"     </li>",
"     <li>",
"      Neo-Synephrine&reg; Regular Strength [OTC];",
"     </li>",
"     <li>",
"      Rhinall&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9504785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Neo-Synephrine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691980",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat nose stuffiness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692146",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It may be given to you for other reasons. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702730",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to phenylephrine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s4194403",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This is not a list of all drugs or health problems that interact with this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s4194405",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe for you to take this drug with all of your drugs and health problems. Do not start, stop, or change the dose of any drug without checking with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10024558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696923",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use for more than 3 days. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10024559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s4186184",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor if any of these side effects or any other side effects bother you:",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nose irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10024561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s4186185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these side effects:",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2699690",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects at",
"       <a href=\"file://www.fda.gov/medwatch\" target=\"_blank\">",
"        file://www.fda.gov/medwatch",
"       </a>",
"       .",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2699689",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may report side effects to Health Canada's Canada Vigilance Program at 1-866-234-2345.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10024556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696083",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use this drug as ordered by your doctor. Read and follow the dosing on the label closely.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695945",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The nose spray is for the nose only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694567",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blow your nose before use.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10024557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10024562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4194563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check with your pharmacist about how to throw out unused drugs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10024563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12285 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-92133E1D40-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_52_21316=[""].join("\n");
var outline_f20_52_21316=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504768\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504785\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024554\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024553\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024558\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024559\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024561\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024556\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024557\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024562\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024563\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?19/7/19572?source=related_link\">",
"      Phenylephrine (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/10/17572?source=related_link\">",
"      Phenylephrine (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/7/23668?source=related_link\">",
"      Phenylephrine (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/50/37668?source=related_link\">",
"      Phenylephrine (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/13/40147?source=related_link\">",
"      Phenylephrine (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/47/6903?source=related_link\">",
"      Phenylephrine (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/59/33717?source=related_link\">",
"      Phenylephrine (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/23/13686?source=related_link\">",
"      Phenylephrine (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/53/30547?source=related_link\">",
"      Phenylephrine (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/36/20036?source=related_link\">",
"      Phenylephrine (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/16/5379?source=related_link\">",
"      Phenylephrine (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_52_21317="Pelvic AP compression fracture type II";
var content_f20_52_21317=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F72320&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F72320&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Pelvic AP compression fracture: Type II",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 420px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Three images of a Type II AP compression fracture: (A) Schematic; (B) AP radiograph; (C) CT scan.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sagi C. Lower extremity: Pelvic ring fractures. In: Rockwood and Green's Fractures in Adults,&nbsp;7th ed, Bucholz RW, Court-Brown CM, Heckman JD, Tornetta P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_52_21317=[""].join("\n");
var outline_f20_52_21317=null;
var title_f20_52_21318="Mixe gonadal dysgenesis 1";
var content_f20_52_21318=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60214%7EPEDS%2F70901&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60214%7EPEDS%2F70901&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Mixed gonadal dysgenesis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 236px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Laurence Baskin, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mixed gonadal dysgenesis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 291px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Laurence Baskin, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_52_21318=[""].join("\n");
var outline_f20_52_21318=null;
var title_f20_52_21319="Scleritis";
var content_f20_52_21319=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F63762&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F63762&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Scleritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An angry, erythematous eye secondary to scleritis in the setting of rheumatoid vasculitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John Stone, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_52_21319=[""].join("\n");
var outline_f20_52_21319=null;
var title_f20_52_21320="Techniques and interpretation of measurement of the CD4 cell count in HIV-infected patients";
var content_f20_52_21320=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Techniques and interpretation of measurement of the CD4 cell count in HIV-infected patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/52/21320/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/52/21320/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/52/21320/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/52/21320/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/52/21320/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/52/21320/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/52/21320/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;CD4 T-cell laboratory testing through flow cytometry is considered an essential part of HIV care, since this parameter is used to stage disease and guide clinical management. Certain CD4 T cell thresholds are used as benchmarks to either initiate prophylaxis against opportunistic infections (OIs)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    to begin antiretroviral therapy (ART). The CD4 cell count is also a relatively consistent indicator of treatment response [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21320/abstract/1\">",
"     1",
"    </a>",
"    ]. Thus, it is important for clinicians to learn about the techniques and interpretation of flow cytometry and to understand the factors that may lead to variations in test results.",
"   </p>",
"   <p>",
"    This topic will address flow cytometry and other techniques for measuring CD4 T cells and the various factors that can affect CD4 cell counts, such as medications, infections, and other conditions. Issues related to the immunology and pathogenesis of HIV infection and the use of HIV RNA testing are discussed elsewhere. Guidance on when to start ART or OI prophylaxis is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/34/5674?source=see_link\">",
"     \"Immunology of HIV-1 infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39623?source=see_link\">",
"     \"Techniques and interpretation of HIV-1 RNA quantitation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33450?source=see_link\">",
"     \"Primary prevention of opportunistic infections in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H800928\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15695274\">",
"    <span class=\"h2\">",
"     CD4 and CD8 T cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human T lymphocytes can be functionally divided into cells that provide help for other immune cells and those that mediate cellular cytotoxicity. Helper T lymphocytes express cluster determinant 4 (abbreviated as &ldquo;CD4&rdquo;) whereas cytotoxic T cells express cluster determinant 8 (abbreviated as &ldquo;CD8&rdquo;). The CD4 and CD8 molecules are members of the immunoglobulin superfamily and mediate adhesion to major histocompatibility complex class II and class I molecules, respectively. In addition, CD4 and CD8 amplify stimulatory signals through the T cell receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21320/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A CD4:CD8 ratio is calculated by dividing the number of CD4+ T cells by the number of CD8+ T cells; this ratio is usually greater than 1 in immunocompetent individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21320/abstract/5\">",
"     5",
"    </a>",
"    ]. However, in HIV infection, the CD4:CD8 ratio is less than 1. This reflects increasing numbers of CD8+ T cells and depletion of CD4+ T cells in chronic infection. This ratio usually increases with the initiation of antiretroviral therapy (ART) although the CD4:CD8 ratio normalizes in only a minority of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21320/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H801004\">",
"    <span class=\"h2\">",
"     How does HIV affect CD4 T cells?",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV infection leads to severe depletion of CD4 T cells in the gut-associated lymphoid tissue with subsequent reduced levels of circulating CD4 lymphocytes in the peripheral blood [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21320/abstract/7\">",
"     7",
"    </a>",
"    ]. CD4 cells are reduced precipitously in acute HIV infection, but usually rebound over several weeks as HIV-specific CD8 T cells help to lower plasma viremia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21320/abstract/8\">",
"     8",
"    </a>",
"    ]. In the untreated patient, CD4 T cells subsequently decline over several years. Population-based studies of the natural history of HIV infection among men who have sex with men (MSM) show that the mean CD4 count prior to seroconversion is about 1000",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ;",
"    </span>",
"    CD4 T cell counts decline to a mean of 780",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    at six months post-seroconversion and to 670",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    at one year of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21320/abstract/9\">",
"     9",
"    </a>",
"    ]. Subsequently, the CD4 cell count declines at an average yearly rate of approximately 50",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ,",
"    </span>",
"    but there is substantial variation among patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21320/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Significant depletion of CD4 T cells can lead to opportunistic infections and mortality in the untreated patient. The stages and natural history of HIV infection are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13353?source=see_link\">",
"     \"The stages and natural history of HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISMS OF CD4 T CELL DEPLETION IN HIV INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although other viruses can infect CD4 T cells, HIV selectively targets and infects activated, expanding CD4 T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21320/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During acute infection, viral replication occurs at an extremely rapid rate, often producing the highest level of circulating virus observed at any time during infection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21320/abstract/13\">",
"     13",
"    </a>",
"    ]. Rapidly proliferating virus-specific CD4 T cells become activated and expand in the presence of high viremia, resulting in subsequent infection, functional impairment, and death of these CD4 T cells. Viremia declines with the recruitment of HIV-specific CD8 T cells.",
"   </p>",
"   <p>",
"    Within the first weeks of infection there is a massive loss of T cells in the gut-associated mucosa associated with disruption of mucosal integrity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21320/abstract/14\">",
"     14",
"    </a>",
"    ]. This is followed by a progressive loss of CD4 cells in the peripheral blood, which is a hallmark of HIV infection. Disruption of the integrity of the gut mucosa is associated with translocation of microbial products from the gut, including lipopolysaccharide (LPS) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21320/abstract/14\">",
"     14",
"    </a>",
"    ]. This &ldquo;leaky gut&rdquo; is associated with chronic immune activation, as evidenced by markers of T cell activation (ie, CD38 and HLA-DR) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21320/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. Chronic activation of the immune system is a hallmark of progressive HIV infection and may be a better predictor of disease outcome than plasma viral load.",
"   </p>",
"   <p>",
"    Treatment with ART leads to viral suppression and immunologic improvement; the extent of the immune recovery is dependent on the degree of immune compromise prior to treatment. Incomplete immunologic recovery among patients with advanced disease may be related to collagen formation in the gut and lymphoid tissues leading to disruption of normal architecture [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21320/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/34/5674?source=see_link\">",
"     \"Immunology of HIV-1 infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=see_link\">",
"     \"When to initiate antiretroviral therapy in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TECHNIQUES FOR MEASURING CD4 CELL COUNTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CD4 cell count is usually determined by flow cytometry in which blood specimens must be processed within 18 hours of collection.",
"   </p>",
"   <p>",
"    Alternative systems include: FACS Count System (Becton Dickinson); VCS",
"    <span class=\"nowrap\">",
"     Technology/Coulter",
"    </span>",
"    Cyto-Spheres (Coulter Corp); Zymmune",
"    <span class=\"nowrap\">",
"     CD4/CD8",
"    </span>",
"    Cell Monitoring Kit (Zynaxis Inc); and TRAx CD4 Test Kit (T Cell Diagnostics). These systems perform well compared with standard flow cytometry and are cheaper and less technically demanding [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21320/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Absolute counts may differ when different assays are used, or even when done by the same test in different laboratories [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21320/abstract/21\">",
"     21",
"    </a>",
"    ]. As a result, sequential samples that are processed using different methods or by different laboratories should be interpreted with caution.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H801717\">",
"    <span class=\"h2\">",
"     What is a normal CD4 cell count?",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal adult CD4 count for most laboratories falls in a range of 800 to 1050",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ;",
"    </span>",
"    furthermore, when considering laboratory variations of two standard deviations, the normal CD4 cell count range falls within 500 to 1400",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21320/abstract/22\">",
"     22",
"    </a>",
"    ]. This broad range in normal values reflects the fact that the CD4 cell count is the product of three variables: the white blood cell count, the percentage of lymphocytes, and the percentage of lymphocytes that bears the CD4 receptor. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Variability of CD4 cell counts'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Laboratory testing also reports CD4:CD8 ratios, which are greater than 1 in a normal host.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H801811\">",
"    <span class=\"h2\">",
"     Absolute CD4 counts and percentages in HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flow cytometry reports CD4 percentages; the absolute CD4 cell count is calculated by multiplying the percentage and the total white cell count (WBC). In general, these two numbers are concordant; corresponding values are listed below:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An absolute CD4 count &gt;500",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      corresponds to a CD4 percentage of &gt;29 percent",
"     </li>",
"     <li>",
"      An absolute CD4 count between 200 to 500",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      corresponds to a CD4 percentage of 14 to 28 percent",
"     </li>",
"     <li>",
"      An absolute CD4 count &lt;200",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      corresponds to a CD4 percentage of &lt;14 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Laboratory testing in HIV-infected patients typically demonstrates an inversed CD4:CD8 ratio of &lt;1. It is important for clinicians to be aware that significant changes in the total WBC will have an effect on the absolute CD4 cell count, while the CD4 percentage will remain the same. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Variability of CD4 cell counts'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    HIV-infected patients with a CD4 count &lt;200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    are classified as having AIDS by the Centers for Disease Control (CDC) and the World Health Organization (WHO) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21320/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Patients with CD4 counts &lt;200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    are at risk for opportunistic infections and should be initiated on prophylaxis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33450?source=see_link\">",
"     \"Primary prevention of opportunistic infections in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22439973\">",
"    <span class=\"h2\">",
"     What is a significant change in CD4 cell counts?",
"    </span>",
"    &nbsp;&mdash;&nbsp;A significant change (eg, 2 standard deviations) between two tests is approximately a 30 percent change in the absolute count or an increase or decrease in CD4 percentage by 3 percentage points [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21320/abstract/25\">",
"     25",
"    </a>",
"    ]. An adequate response on treatment is defined as an increase in CD4 count in the range of 50 to 150",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    per year. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/17/38167?source=see_link\">",
"     \"Patient monitoring during HIV antiretroviral therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34797445\">",
"    <span class=\"h2\">",
"     Definition of AIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A CD4 count of &lt;200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    indicates the clinical stage of AIDS, which implies a high susceptibility to opportunistic infections, such as Pneumocystis pneumonia. Information on prophylaxis against opportunistic infections is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33450?source=see_link\">",
"     \"Primary prevention of opportunistic infections in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     VARIABILITY OF CD4 CELL COUNTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15695529\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although CD4 cell count monitoring is a major parameter that influences clinical management, there is significant intraindividual variability; prior to the era of ART, a study of 1020 untreated patients found that the intraindividual coefficient of variation averaged by 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21320/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, a number of factors other than HIV infection influence CD4 cell counts. Significant changes in the total WBC can lead to marked changes in the absolute CD4 cell count. Certain medications or infections associated with leukopenia may result in depression of the absolute CD4 cell count. In contrast, specific medications or infections which lead to leukocytosis can result in elevated CD4 cell counts. In such cases, the absolute CD4 cell count and percentage may be discordant. These types of changes do not indicate a true change in the patient&rsquo;s immunologic status per se and should be interpreted with caution. If the CD4 cell count changes dramatically without significant changes in the CD4 percentage, the clinician needs to assess other factors that may be leading to artifactual changes in the absolute count. Flow cytometry results that would lead to a therapeutic intervention may need confirmation if the result is dramatically different from a prior result performed within three to six months.",
"   </p>",
"   <p>",
"    The CD4 cell percentage is sometimes used in preference to the absolute number since there is less variation with this parameter [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21320/abstract/26\">",
"     26",
"    </a>",
"    ]. In the AIDS Clinical Trial Group laboratories, the within-subject coefficient of variation for the CD4 percentage was 18 percent compared with 25 percent for the CD4 cell count [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21320/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even among healthy adults, there are seasonal or month-to-month changes in the CD4 cell count [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21320/abstract/27\">",
"     27",
"    </a>",
"    ]. There are also diurnal changes with the lowest levels of CD4 cell counts in the evening and peak values in the morning [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21320/abstract/28\">",
"     28",
"    </a>",
"    ]. These variations have only a minor impact on results of flow cytometry.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Factors that affect laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following conditions are not known to have an appreciable effect on the CD4 cell count: gender, HIV risk category, or psychologic or physical stress [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21320/abstract/22\">",
"     22",
"    </a>",
"    ]. There are, however, concurrent diseases that can reduce or increase the CD4 cell count.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22439763\">",
"    <span class=\"h3\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Modest decreases in the CD4 cell count have been noted in various acute infections (eg, cytomegalovirus, EB virus, hepatitis B, tuberculosis, some bacterial infections, and histoplasmosis). A study of patients coinfected with HIV and HTLV-I found that CD4 cell counts were 80 to 180 percent higher than in HIV-infected controls at comparable levels of immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21320/abstract/29\">",
"     29",
"    </a>",
"    ]. Some data suggest that hepatitis C virus (HCV) coinfection is associated with a less robust immune recovery after initiation of ART compared with patients who are HCV-seronegative [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21320/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22439770\">",
"    <span class=\"h3\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depending on the effect of the medication on the total WBC count, absolute CD4 cell counts may rise or decline. These changes do not reflect true changes in the patient&rsquo;s immunologic status.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For example, declines in absolute CD4 cell counts have been observed in",
"      <span class=\"nowrap\">",
"       HIV/HCV",
"      </span>",
"      coinfected patients who are undergoing interferon therapy; however, CD4 T-cell percentages usually remain the same or increase throughout HCV therapy.",
"     </li>",
"     <li>",
"      In humans and laboratory animals, one dose of corticosteroids leads to a rapid and transient decline in the numbers of peripheral blood lymphocytes through a redistribution of circulating lymphocytes. This may lead to a profound drop in the absolute CD4 cell count [",
"      <a class=\"abstract\" href=\"UTD.htm?20/52/21320/abstract/31\">",
"       31",
"      </a>",
"      ]. With chronic administration however, corticosteroids may lead to a leukocytosis; this may in turn lead to an elevated absolute CD4 cell count.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15694737\">",
"    <span class=\"h3\">",
"     Alcohol abuse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcohol use is associated with depression of CD4 cell counts, which improve after alcohol abstinence [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21320/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22439816\">",
"    <span class=\"h3\">",
"     Chronic conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splenectomy also may lead to deceptively high CD4 counts. In contrast, one study of HIV-seronegative cirrhotics found that the majority of patients had depressed CD4 counts, which were associated with splenomegaly, leukopenia and thrombocytopenia; however, CD4 percentages were unaffected [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21320/abstract/33\">",
"     33",
"    </a>",
"    ]. Two studies of HIV-infected patients coinfected with HCV infection found that advanced liver disease was associated with lower absolute CD4 cell counts relative to CD4 percentages [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21320/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]; this discordance may be related to splenic sequestration and lymphopenia, which characterize advanced HCV-related liver disease. In HIV-infected patients who have a history of splenectomy, advanced liver disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    splenomegaly, the CD4 percentage may be a more reliable indicator of immunologic status than absolute CD4 cell counts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H114430117\">",
"    <span class=\"h3\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy can also affect CD4 testing. A longitudinal analysis was performed of 51 HIV seronegative patients who had CD4 cell count testing during pregnancy and the post partum period; 25 HIV-negative nonpregnant controls were also selected [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21320/abstract/36\">",
"     36",
"    </a>",
"    ]. The following results were found:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mean white blood cell count was elevated in pregnant subjects above that in the non-pregnant controls and this difference increased throughout the pregnancy.",
"     </li>",
"     <li>",
"      The mean absolute lymphocyte cell count, lymphocyte percentage, and absolute CD4+ cell count were significantly lower during pregnancy than during the 12-week post-delivery period. In contrast, the mean absolute CD8 count was not significantly different.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data are important to bear in mind when evaluating the HIV-infected patient who is pregnant. In this situation, the absolute CD4 count should be interpreted in the context of the CD4 percentage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13746655\">",
"    <span class=\"h1\">",
"     THE CD4 T CELL RESPONSE TO ANTIRETROVIRAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;With antiretroviral therapy and effective viral suppression, the expected CD4 cell response is an increase of 100 to 150",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    at one year and an additional 20 to 50",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    annually for the next three to five years [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21320/abstract/37\">",
"     37",
"    </a>",
"    ]. When ART is discontinued there is generally a rapid viral load rebound and sharp decline in CD4 count with a decrease of up to 100 to 150",
"    <span class=\"nowrap\">",
"     cells/mL",
"    </span>",
"    in three to four months [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21320/abstract/38-40\">",
"     38-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factors that correlate with reduced CD4 recovery are older age, male sex, and the type of ART used [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21320/abstract/41\">",
"     41",
"    </a>",
"    ]. Some studies have demonstrated that the baseline CD4 cell count affects the extent of immune recovery, suggesting that patients with advanced immune compromise may have limited immunologic reserve [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21320/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Interleukin-2 administration in HIV-infected patients has been associated with absolute increases in CD4 cell counts, but no discernible clinical benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21320/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CD4 T CELL TESTING IN RESOURCE-LIMITED SETTINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Health Organization (WHO) recommends CD4 cell count monitoring to assess when to start prophylaxis against OIs and when to initiate ART [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21320/abstract/23\">",
"     23",
"    </a>",
"    ]. CD4 counts were previously advocated as a surrogate to monitor the response to ART; however, subsequent studies have shown that this, by itself, is an inadequate way to evaluate treatment response and that the viral load is also an invaluable parameter, when available [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21320/abstract/39,40,44,45\">",
"     39,40,44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The total lymphocyte count (TLC) is a crude surrogate for the CD4 cell count, but is advocated by the WHO in areas where flow cytometry may not be available.",
"   </p>",
"   <p>",
"    Other alternatives to flow cytometry have been investigated in resource-poor areas:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study demonstrated that microcapillary flow cytometry correctly identified those individuals with a CD4 T cell count &lt;200",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      (95 percent sensitivity and 100 percent specificity) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/52/21320/abstract/46\">",
"       46",
"      </a>",
"      ]. Although this technology is easier to use, requires little training of personnel, and is less expensive than flow cytometry, it still requires significant initial capital investment for the instrument.",
"     </li>",
"     <li>",
"      Manual immunobead-based methods have the advantage of only requiring routine light microscopy [",
"      <a class=\"abstract\" href=\"UTD.htm?20/52/21320/abstract/47\">",
"       47",
"      </a>",
"      ]. However, the results with this technique may be less reproducible.",
"     </li>",
"     <li>",
"      The &ldquo;CD4 Select&rdquo; method, which utilizes only an automatic hematoanalyzer to assess both CD4 absolute counts and percentages, was found to have greater than 90 percent correlation with standard flow cytometry [",
"      <a class=\"abstract\" href=\"UTD.htm?20/52/21320/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     IDIOPATHIC CD4 LYMPHOCYTOPENIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic CD4 lymphocytopenia (ICL) is a rare syndrome characterized by low CD4 cell counts that are unexplained by HIV infection or other known medical conditions. Criteria for the definition of this disorder are [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21320/abstract/49\">",
"     49",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A CD4 cell count less than 300",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      or a CD4 percentage less than 20 on two or more measurements",
"     </li>",
"     <li>",
"      Lack of laboratory evidence of HIV infection",
"     </li>",
"     <li>",
"      Absence of an alternative explanation for the CD4 lymphocytopenia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The characteristics of this syndrome are similar to HIV infection and include susceptibility to opportunistic infections and abnormalities of T cell homeostasis and chronic immune activation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21320/abstract/32,50\">",
"     32,50",
"    </a>",
"    ]. No etiologic infectious agent has been identified to date. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30009?source=see_link\">",
"     \"Idiopathic CD4+ lymphocytopenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/25/21907?source=see_link\">",
"       \"Patient information: HIV/AIDS (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/13/10451?source=see_link\">",
"       \"Patient information: Tests to monitor HIV (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15695829\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CD4 T-cell laboratory testing through flow cytometry is considered an essential part of HIV care, since this parameter is used to stage disease and guide clinical management. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the untreated HIV-infected patient, CD4 T cells subsequently decline over several years. Significant depletion of CD4 T cells can lead to opportunistic infections and mortality in the untreated patient. (See",
"      <a class=\"local\" href=\"#H800928\">",
"       'Background'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During acute infection, virus titers are extremely high. Rapidly proliferating virus-specific CD4 T cells become activated and expand in the presence of high viremia, resulting in subsequent infection, functional impairment, and death of CD4 T cells. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mechanisms of CD4 T cell depletion in HIV infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The normal CD4 cell count for most laboratories falls in a range of 800 to 1050",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       .",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H801717\">",
"       'What is a normal CD4 cell count?'",
"      </a>",
"      above.) Flow cytometry reports CD4 percentages; the absolute CD4 cell count is calculated by multiplying the percentage and the total white cell count (WBC). In general, these two numbers are concordant. (See",
"      <a class=\"local\" href=\"#H801811\">",
"       'Absolute CD4 counts and percentages in HIV infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A significant change (eg, 2 standard deviations) between two tests is approximately a 30 percent change in the absolute count or an increase or decrease in CD4 percentage by 3 percentage points. (See",
"      <a class=\"local\" href=\"#H22439973\">",
"       'What is a significant change in CD4 cell counts?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A CD4 count of &lt;200",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      indicates the clinical stage of AIDS, which implies a high susceptibility to opportunistic infections, such as Pneumocystis pneumonia. (See",
"      <a class=\"local\" href=\"#H34797445\">",
"       'Definition of AIDS'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of factors other than HIV infection influence CD4 cell counts. Significant changes in the total WBC can lead to marked changes in the absolute CD4 cell count. Certain medications or infections, which are associated with leukopenia, may result in depression of the absolute CD4 cell count. In contrast, specific medications or infections, which lead to leukocytosis, can result in elevated CD4 cell counts. These types of changes do not indicate a true change in the patient&rsquo;s immunologic status per se and should be interpreted with caution. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Variability of CD4 cell counts'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21320/abstract/1\">",
"      Graham NM, Park LP, Piantadosi S, et al. Prognostic value of combined response markers among human immunodeficiency virus-infected persons: possible aid in the decision to change zidovudine monotherapy. Clin Infect Dis 1995; 20:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21320/abstract/2\">",
"      Miceli MC, von Hoegen P, Parnes JR. Adhesion versus coreceptor function of CD4 and CD8: role of the cytoplasmic tail in coreceptor activity. Proc Natl Acad Sci U S A 1991; 88:2623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21320/abstract/3\">",
"      Norment AM, Salter RD, Parham P, et al. Cell-cell adhesion mediated by CD8 and MHC class I molecules. Nature 1988; 336:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21320/abstract/4\">",
"      O'Rourke AM, Rogers J, Mescher MF. Activated CD8 binding to class I protein mediated by the T-cell receptor results in signalling. Nature 1990; 346:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21320/abstract/5\">",
"      Margolick JB, Gange SJ, Detels R, et al. Impact of inversion of the CD4/CD8 ratio on the natural history of HIV-1 infection. J Acquir Immune Defic Syndr 2006; 42:620.",
"     </a>",
"    </li>",
"    <li>",
"     Leung, V, Gillis J, Raboud J, Ndumbi P, Tsoukas C, Klein M. Predictors of CD4/CD8 ratio normalization and its affect on health outcomes in the era of combination antiretroviral therapy (cART). 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). September 17-20, 2011. Chica (Accessed on October 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21320/abstract/7\">",
"      Brenchley JM, Schacker TW, Ruff LE, et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004; 200:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21320/abstract/8\">",
"      Schacker T, Collier AC, Hughes J, et al. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med 1996; 125:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21320/abstract/9\">",
"      Stein DS, Korvick JA, Vermund SH. CD4+ lymphocyte cell enumeration for prediction of clinical course of human immunodeficiency virus disease: a review. J Infect Dis 1992; 165:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21320/abstract/10\">",
"      Margolick JB, Mu&ntilde;oz A, Vlahov D, et al. Changes in T-lymphocyte subsets in intravenous drug users with HIV-1 infection. JAMA 1992; 267:1631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21320/abstract/11\">",
"      Hughes MD, Stein DS, Gundacker HM, et al. Within-subject variation in CD4 lymphocyte count in asymptomatic human immunodeficiency virus infection: implications for patient monitoring. J Infect Dis 1994; 169:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21320/abstract/12\">",
"      Douek DC, Brenchley JM, Betts MR, et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 2002; 417:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21320/abstract/13\">",
"      Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection. N Engl J Med 1998; 339:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21320/abstract/14\">",
"      Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21320/abstract/15\">",
"      Eggena MP, Barugahare B, Okello M, et al. T cell activation in HIV-seropositive Ugandans: differential associations with viral load, CD4+ T cell depletion, and coinfection. J Infect Dis 2005; 191:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21320/abstract/16\">",
"      Sousa AE, Carneiro J, Meier-Schellersheim M, et al. CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J Immunol 2002; 169:3400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21320/abstract/17\">",
"      Giorgi JV, Hultin LE, McKeating JA, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999; 179:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21320/abstract/18\">",
"      Nies-Kraske E, Schacker TW, Condoluci D, et al. Evaluation of the pathogenesis of decreasing CD4(+) T cell counts in human immunodeficiency virus type 1-infected patients receiving successfully suppressive antiretroviral therapy. J Infect Dis 2009; 199:1648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21320/abstract/19\">",
"      Estes J, Baker JV, Brenchley JM, et al. Collagen deposition limits immune reconstitution in the gut. J Infect Dis 2008; 198:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21320/abstract/20\">",
"      Johnson D, Hirschkorn D, Busch MP. Evaluation of four alternative methodologies for determination of absolute CD4+ lymphocyte counts. The National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor Study. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21320/abstract/21\">",
"      Sax PE, Boswell SL, White-Guthro M, Hirsch MS. Potential clinical implications of interlaboratory variability in CD4+ T-lymphocyte counts of patients infected with human immunodeficiency virus. Clin Infect Dis 1995; 21:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21320/abstract/22\">",
"      Laurence J. T-cell subsets in health, infectious disease, and idiopathic CD4+ T lymphocytopenia. Ann Intern Med 1993; 119:55.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.who.int/hiv/pub/arv/adult2010/en/index.html (Accessed on October 15, 2010).",
"    </li>",
"    <li>",
"     file://www.aidsinfo.nih.gov/guidelines/ (Accessed on October 15, 2010).",
"    </li>",
"    <li>",
"     Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents - January 10, 2011. file://www.aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&amp;Search=Off&amp;GuidelineID=7&amp;ClassID=1 (Accessed on October 12, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21320/abstract/26\">",
"      Taylor JM, Fahey JL, Detels R, Giorgi JV. CD4 percentage, CD4 number, and CD4:CD8 ratio in HIV infection: which to choose and how to use. J Acquir Immune Defic Syndr 1989; 2:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21320/abstract/27\">",
"      van Rood Y, Goulmy E, Blokland E, et al. Month-related variability in immunological test results; implications for immunological follow-up studies. Clin Exp Immunol 1991; 86:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21320/abstract/28\">",
"      Malone JL, Simms TE, Gray GC, et al. Sources of variability in repeated T-helper lymphocyte counts from human immunodeficiency virus type 1-infected patients: total lymphocyte count fluctuations and diurnal cycle are important. J Acquir Immune Defic Syndr 1990; 3:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21320/abstract/29\">",
"      Schechter M, Harrison LH, Halsey NA, et al. Coinfection with human T-cell lymphotropic virus type I and HIV in Brazil. Impact on markers of HIV disease progression. JAMA 1994; 271:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21320/abstract/30\">",
"      Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356:1800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21320/abstract/31\">",
"      Bloemena E, Weinreich S, Schellekens PT. The influence of prednisolone on the recirculation of peripheral blood lymphocytes in vivo. Clin Exp Immunol 1990; 80:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21320/abstract/32\">",
"      Pol S, Artru P, Th&eacute;pot V, et al. Improvement of the CD4 cell count after alcohol withdrawal in HIV-positive alcoholic patients. AIDS 1996; 10:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21320/abstract/33\">",
"      McGovern BH, Golan Y, Lopez M, et al. The impact of cirrhosis on CD4+ T cell counts in HIV-seronegative patients. Clin Infect Dis 2007; 44:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21320/abstract/34\">",
"      Hull MW, Rollet K, Odueyungbo A, et al. Factors associated with discordance between absolute CD4 cell count and CD4 cell percentage in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis 2012; 54:1798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21320/abstract/35\">",
"      Claassen CW, Diener-West M, Mehta SH, et al. Discordance between CD4+ T-lymphocyte counts and percentages in HIV-infected persons with liver fibrosis. Clin Infect Dis 2012; 54:1806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21320/abstract/36\">",
"      Towers CV, Rumney PJ, Ghamsary MG. Longitudinal study of CD4+ cell counts in HIV-negative pregnant patients. J Matern Fetal Neonatal Med 2010; 23:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21320/abstract/37\">",
"      Maartens G, Boulle A. CD4 T-cell responses to combination antiretroviral therapy. Lancet 2007; 370:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21320/abstract/38\">",
"      Hawley-Foss N, Mbisa G, Lum JJ, et al. Effect of cessation of highly active antiretroviral therapy during a discordant response: implications for scheduled therapeutic interruptions. Clin Infect Dis 2001; 33:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21320/abstract/39\">",
"      Bahrani A, Ramaswamy R, Oldfield EC 3rd. Effects of virologic rebound on CD4 cell counts. Clin Infect Dis 2001; 32:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21320/abstract/40\">",
"      Lawrence J, Mayers DL, Hullsiek KH, et al. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med 2003; 349:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21320/abstract/41\">",
"      Loutfy MR, Genebat M, Moore D, et al. A CD4+ cell count &lt;200 cells per cubic millimeter at 2 years after initiation of combination antiretroviral therapy is associated with increased mortality in HIV-infected individuals with viral suppression. J Acquir Immune Defic Syndr 2010; 55:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21320/abstract/42\">",
"      Moore RD, Keruly JC. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis 2007; 44:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21320/abstract/43\">",
"      INSIGHT-ESPRIT Study Group, SILCAAT Scientific Committee, Abrams D, et al. Interleukin-2 therapy in patients with HIV infection. N Engl J Med 2009; 361:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21320/abstract/44\">",
"      Mee P, Fielding KL, Charalambous S, et al. Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS 2008; 22:1971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21320/abstract/45\">",
"      Stevens WS, Scott LE, Crowe SM. Quantifying HIV for monitoring antiretroviral therapy in resource-poor settings. J Infect Dis 2010; 201 Suppl 1:S16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21320/abstract/46\">",
"      Balakrishnan P, Solomon S, Mohanakrishnan J, et al. A reliable and inexpensive EasyCD4 assay for monitoring HIV-infected individuals in resource-limited settings. J Acquir Immune Defic Syndr 2006; 43:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21320/abstract/47\">",
"      Crowe S, Turnbull S, Oelrichs R, Dunne A. Monitoring of human immunodeficiency virus infection in resource-constrained countries. Clin Infect Dis 2003; 37:S25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21320/abstract/48\">",
"      Srithanaviboonchai K, Rungruengthanakit K, Nouanthong P, et al. Novel low-cost assay for the monitoring of CD4 counts in HIV-infected individuals. J Acquir Immune Defic Syndr 2008; 47:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21320/abstract/49\">",
"      Unexplained CD4 + T-lymphocyte depletion in persons without evident HIV infection--United States. Infect Control Hosp Epidemiol 1992; 13:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21320/abstract/50\">",
"      Zonios DI, Falloon J, Bennett JE, et al. Idiopathic CD4+ lymphocytopenia: natural history and prognostic factors. Blood 2008; 112:287.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3740 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-5115C1355F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_52_21320=[""].join("\n");
var outline_f20_52_21320=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15695829\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H800928\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15695274\">",
"      CD4 and CD8 T cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H801004\">",
"      How does HIV affect CD4 T cells?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISMS OF CD4 T CELL DEPLETION IN HIV INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TECHNIQUES FOR MEASURING CD4 CELL COUNTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H801717\">",
"      What is a normal CD4 cell count?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H801811\">",
"      Absolute CD4 counts and percentages in HIV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22439973\">",
"      What is a significant change in CD4 cell counts?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34797445\">",
"      Definition of AIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      VARIABILITY OF CD4 CELL COUNTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15695529\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Factors that affect laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22439763\">",
"      - Infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22439770\">",
"      - Medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15694737\">",
"      - Alcohol abuse",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22439816\">",
"      - Chronic conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H114430117\">",
"      - Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13746655\">",
"      THE CD4 T CELL RESPONSE TO ANTIRETROVIRAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CD4 T CELL TESTING IN RESOURCE-LIMITED SETTINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      IDIOPATHIC CD4 LYMPHOCYTOPENIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15695829\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30009?source=related_link\">",
"      Idiopathic CD4+ lymphocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/34/5674?source=related_link\">",
"      Immunology of HIV-1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/25/21907?source=related_link\">",
"      Patient information: HIV/AIDS (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/13/10451?source=related_link\">",
"      Patient information: Tests to monitor HIV (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/17/38167?source=related_link\">",
"      Patient monitoring during HIV antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33450?source=related_link\">",
"      Primary prevention of opportunistic infections in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39623?source=related_link\">",
"      Techniques and interpretation of HIV-1 RNA quantitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13353?source=related_link\">",
"      The stages and natural history of HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=related_link\">",
"      When to initiate antiretroviral therapy in HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_52_21321="Agammaglobulinemia";
var content_f20_52_21321=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Agammaglobulinemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/52/21321/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/52/21321/contributors\">",
"     Jerry A Winkelstein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/52/21321/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/52/21321/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/52/21321/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/52/21321/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/52/21321/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunoglobulins are produced by plasma cells, which themselves are the result of the development and differentiation of B cells. Any factor that impedes the development of the B cell lineage",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the function of mature B cells may result in levels of serum immunoglobulins that are reduced (ie, hypogammaglobulinemia) or nearly absent (ie, agammaglobulinemia). Primary agammaglobulinemia is most commonly inherited as an X-linked trait, but autosomal recessive forms have also been reported. Only those inherited defects that are intrinsic to, and limited to, cells of the B cell lineage will be considered in this topic.",
"   </p>",
"   <p>",
"    The following related issues are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Other primary immunodeficiency diseases that have agammaglobulinemia or hypogammaglobulinemia associated with combined B and T cell defects, and therefore are part of a broader immunodeficiency (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=see_link\">",
"       \"Severe combined immunodeficiency (SCID): An overview\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20362?source=see_link\">",
"       \"T cell negative, B cell negative, NK cell positive severe combined immunodeficiency\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/22/40295?source=see_link\">",
"       \"Syndromic immunodeficiencies\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Hypogammaglobulinemia that is secondary to extrinsic factors such as malignancy, medications, and excessive loss of immunoglobulin (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7561?source=see_link\">",
"       \"Secondary immune deficiency due to miscellaneous causes\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The various causes of hypogammaglobulinemia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24326?source=see_link\">",
"       \"Primary humoral immune deficiencies: An overview\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/36/41544?source=see_link\">",
"       \"Transient hypogammaglobulinemia of infancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/60/13258?source=see_link\">",
"       \"IgG subclass deficiency\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17209?source=see_link\">",
"       \"Selective antibody deficiency with normal immunoglobulins\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35078?source=see_link\">",
"       \"IgG subclasses: Physical properties, genetics, and biologic functions\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/29/9688?source=see_link\">",
"       \"Pathogenesis of common variable immunodeficiency\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The development of B cells from hematopoietic stem cells, immunoglobulin genetics, and the generation of the humoral immune response (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=see_link\">",
"       \"Normal B and T lymphocyte development\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37702?source=see_link\">",
"       \"Immunoglobulin genetics\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27624?source=see_link\">",
"       \"The humoral immune response\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     X-LINKED AGAMMAGLOBULINEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;X-linked agammaglobulinemia (XLA; MIM 300755) is a primary humoral immunodeficiency characterized by severe hypogammaglobulinemia, antibody deficiency, and increased susceptibility to infection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Clinical symptoms (infections) are generally first noted between 3 and 18 months of age.",
"   </p>",
"   <p>",
"    XLA is due to defects in a signal transduction molecule called Bruton tyrosine kinase (Btk) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Patients who present because of clinical symptoms are usually initially identified by significant",
"    <span class=\"nowrap\">",
"     hypogammaglobulinemia/agammaglobulinemia",
"    </span>",
"    and the near absence of CD19+ B cells. The diagnosis is then confirmed with molecular studies identifying a mutation in the BTK gene. The cornerstone of treatment for XLA is replacement therapy with immune globulin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;An accurate estimate of the incidence or prevalence of XLA is difficult to obtain because the disease is uncommon and population screening has not been performed. However, results from a United States registry of patients with XLA provided a minimal estimate of approximately",
"    <span class=\"nowrap\">",
"     1/379,000",
"    </span>",
"    live births",
"    <span class=\"nowrap\">",
"     (1/190,000",
"    </span>",
"    male births) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;XLA is caused by mutations in the Bruton tyrosine kinase (BTK) gene, named in honor of the clinician who described the first case in 1952, located on the long arm of the X chromosome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/1-5,7\">",
"     1-5,7",
"    </a>",
"    ]. Approximately 40 percent of patients with XLA are born into a family with a previously affected family member [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Btk is a member of the Tec family of nonreceptor tyrosine kinases, which are signal transduction molecules. Btk is expressed in all stages of B cell lineage development, as well as in myeloid and erythroid cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Its major role appears to be in promoting pre-B-cell expansion at the pre-B1 to pre-B2 stage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a consequence of the failure of B cell development, patients affected by a mutation in BTK have significantly reduced levels of B lymphocytes in their blood and tissues, fail to generate plasma cells, and have severely decreased production of all classes of immunoglobulins with markedly defective antibody responses [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/1-3,6,10,11\">",
"     1-3,6,10,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=see_link\">",
"     \"Normal B and T lymphocyte development\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37702?source=see_link\">",
"     \"Immunoglobulin genetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a result of their deficient humoral immune response, patients with XLA have an increased susceptibility to infection by encapsulated bacteria and certain blood-borne viruses [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/1-3,6,10-13\">",
"     1-3,6,10-13",
"    </a>",
"    ], reflecting the important role of antibody in opsonization of encapsulated bacteria and neutralization of blood-borne enteroviruses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27624?source=see_link\">",
"     \"The humoral immune response\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Impairment is also seen in T cell memory responses to mucosal colonizing bacteria (eg, Neisseria meningitidis), but not to obligate respiratory pathogens (eg, influenza virus) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients present with recurrent infection, although some are identified at an earlier stage due to a positive family history. Unfortunately, two-thirds of patients with a positive family history are NOT diagnosed at, or soon after, birth, but rather are diagnosed after they have presented with clinical symptoms. Nevertheless, the presence of a positive family history does influence the average age of diagnosis; it is 2.6 years in boys with a positive family history and 5.4 years in boys with a negative family history [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The newborn with XLA has been effectively treated by his mother with IgG actively transported across the placenta during the last trimester of pregnancy. Hypogammaglobulinemia and an increased susceptibility to infection develop as the maternally acquired IgG is catabolized after birth and the infant is unable to make his own (",
"    <a class=\"graphic graphic_figure graphicRef73913 \" href=\"UTD.htm?31/25/32157\">",
"     figure 1",
"    </a>",
"    ). Thus, patients generally do not present with clinical symptoms until after three months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/6\">",
"     6",
"    </a>",
"    ]. Nearly 50 percent of patients develop clinical manifestations by one year of age and well over 95 percent develop symptoms by five years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 50 percent of patients are diagnosed by 2 years of age. There are rare reports of individual patients with well documented XLA who did not have sufficient clinical symptoms to be diagnosed with agammaglobulinemia until well into adult life [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/15-20\">",
"     15-20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is only one characteristic physical finding of XLA, and that is the absence, or near absence, of the B cell-rich tonsils and adenoids. Palpable lymphoid tissue is absent in some patients. However, peripheral lymph nodes can appear normal because of hypertrophy of the T cells areas. Recurrent bacterial respiratory tract infections are the most common manifestation of XLA.",
"   </p>",
"   <p>",
"    Clinical signs and symptoms of recurrent and chronic sinopulmonary infections and their sequelae include chronic cough, chronic rhinitis and post nasal drainage, and digital clubbing. Growth charts should be examined for evidence of failure to",
"    <span class=\"nowrap\">",
"     thrive/growth",
"    </span>",
"    delay.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Bacterial infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial infections are the most common clinical manifestations of XLA both before and after diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/1-3,6,10-13\">",
"     1-3,6,10-13",
"    </a>",
"    ]. The infections are usually caused by encapsulated pyogenic bacteria, organisms for which opsonization by antibody is a primary host defense.",
"   </p>",
"   <p>",
"    Several bacterial species account for the majority of episodes of sepsis, osteomyelitis, septic arthritis, and CNS infections in patients with XLA [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Streptococcus pneumoniae",
"     </li>",
"     <li>",
"      Hemophilus influenzae type B",
"     </li>",
"     <li>",
"      Streptococcus pyogenes",
"     </li>",
"     <li>",
"      Pseudomonas species",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The specific infectious etiology of lower respiratory tract infections is usually unknown. However, these same organisms are also the major causes of lower respiratory infections when an etiologic agent can be identified.",
"   </p>",
"   <p>",
"    Salmonella and Campylobacter species can cause gastroenteritis. Organisms of the",
"    <span class=\"nowrap\">",
"     Flexispiral/Helicobacter",
"    </span>",
"    family cause characteristic chronic bacteremia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lymphatic infections.",
"   </p>",
"   <p>",
"    Before diagnosis, recurrent otitis media is the most common respiratory tract infection, with pneumonia and sinusitis following close behind [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/6,11,12\">",
"     6,11,12",
"    </a>",
"    ]. After diagnosis, pneumonia and acute and chronic sinusitis are the most common of the respiratory tract infections, even after replacement therapy with immune globulin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/6\">",
"     6",
"    </a>",
"    ]. Bronchitis and pneumonia are of special significance since they can lead to chronic lung disease (bronchiectasis and airflow obstruction) and pulmonary insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/6,10,11,13,21-23\">",
"     6,10,11,13,21-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Systemic blood-borne bacterial infections such as",
"    <span class=\"nowrap\">",
"     bacteremia/sepsis,",
"    </span>",
"    osteomyelitis, septic arthritis, and meningitis were more common in the first few decades following the initial description of the disease by Bruton in 1952 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. In fact, the first patient described presented with recurrent episodes of sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/7\">",
"     7",
"    </a>",
"    ]. Systemic blood-borne bacterial infections have become less frequent with the advent of adequate immune globulin replacement therapy, although these infections still occur [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/6,11\">",
"     6,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     Intravascular/lymphatic",
"    </span>",
"    infection caused by organisms of the",
"    <span class=\"nowrap\">",
"     Flexispiral/Helicobacter",
"    </span>",
"    family has been described in XLA patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. These infections are blood-borne, and usually persistent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    recurrent. A clue to their diagnosis is the presence of characteristic brawny, indurated, violaceous cutaneous and subcutaneous lesions on the extremities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Viral, fungal, and parasitic infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with XLA are also more susceptible to certain viral, fungal, and parasitic infections.",
"   </p>",
"   <p>",
"    Chronic and unremitting systemic infections with enteroviruses such as ECHOvirus and coxsackievirus can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. These chronic enteroviral infections were more common in the period before adequate treatment with immune globulin was available [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/6,10\">",
"     6,10",
"    </a>",
"    ]. However, they still occur in some isolated cases, even in the face of adequate levels of IgG with replacement therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/30\">",
"     30",
"    </a>",
"    ]. Enteroviral infections can take the form of chronic meningoencephalitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chronic hepatitis, or they may masquerade as dermatomyositis with direct infection of muscle and skin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/28,29,31\">",
"     28,29,31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/49/34585?source=see_link\">",
"     \"Clinical manifestations and diagnosis of enterovirus and parechovirus infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/26/41383?source=see_link\">",
"     \"Epidemiology, pathogenesis, treatment, and prevention of enterovirus and parechovirus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The earliest signs of enteroviral meningoencephalitis may be a change in behavior",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    developmental regression, which then progresses to full blown neurologic impairment and coma over a period of months to years. A variety of therapies have been attempted for this difficult infection, including high dose intravenous immune globulin, intrathecal immune globulin, and an antiviral drug, pleconaril [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/28-31\">",
"     28-31",
"    </a>",
"    ]. Unfortunately, none has provided reliable and consistent long-term improvement, although there are cases where each appeared to have some benefit.",
"   </p>",
"   <p>",
"    Other, less common, viral, fungal, and parasitic infections also occur. Lower respiratory infections caused by Pneumocystis jirovecii (formerly P. carinii) are usually only seen in patients who are debilitated [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/32-34\">",
"     32-34",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     Mycoplasma/ureaplasma",
"    </span>",
"    cause some cases of arthritis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    osteomyelitis, most often in patients receiving inadequate immune globulin replacement therapy. Other examples include chronic rotavirus gastroenteritis, described in isolated cases, and Giardia lamblia gastrointestinal infection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/1-3,6,11,35\">",
"     1-3,6,11,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with XLA are also prone to develop vaccine-related polio after receiving the live attenuated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/58/35749?source=see_link\">",
"     poliovirus vaccine",
"    </a>",
"    directly, or less commonly, after close contact with an individual who received the live attenuated vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/6,36\">",
"     6,36",
"    </a>",
"    ]. Vaccine-related poliomyelitis is characterized by a relatively long incubation period, a chronic encephalomyelitis, and a high mortality rate. This complication has not been seen in patients who live in countries that have replaced the live attenuated vaccine with a killed vaccine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of malignancies have been reported in patients with XLA [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/6,36-41\">",
"     6,36-41",
"    </a>",
"    ]. These include lymphoreticular malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/6,37\">",
"     6,37",
"    </a>",
"    ], gastric and colorectal adenocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/38-41\">",
"     38-41",
"    </a>",
"    ], and squamous cell carcinoma of the lung [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/42\">",
"     42",
"    </a>",
"    ]. In one report, colorectal cancer was found in 3 of 52 patients (6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/39\">",
"     39",
"    </a>",
"    ]. However, no malignancies were found in two other series of 73 and 44 patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/11,13\">",
"     11,13",
"    </a>",
"    ]. The risk of malignancy is therefore uncertain, given the conflicting data. Epidemiologic studies are needed to determine if patients with XLA are at any increased risk for particular tumors, and if so, to what degree.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients also have been reported to suffer from a higher incidence of sensorineural hearing loss [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/43\">",
"     43",
"    </a>",
"    ] and eczema [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Atypical XLA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The large majority of patients have classic XLA, with near absence of B cells and the typical clinical phenotype. However, \"atypical\" forms of XLA, characterized by low numbers of B cells, low-level antibody production, and less severe disease, have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/45-48\">",
"     45-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some patients with atypical forms of XLA are initially incorrectly diagnosed with other causes of humoral immunodeficiency, including transient hypogammaglobulinemia of infancy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/47\">",
"     47",
"    </a>",
"    ], selective antibody deficiency with normal immunoglobulins [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/48\">",
"     48",
"    </a>",
"    ], and common variable immunodeficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/19\">",
"     19",
"    </a>",
"    ]. These patients develop more severe disease and laboratory abnormalities more characteristic of XLA later in life. Some patients with mild XLA have been diagnosed as late as 51 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory findings include",
"    <span class=\"nowrap\">",
"     hypogammaglobulinemia/agammaglobulinemia,",
"    </span>",
"    deficient antibody responses to immunizations and absent, or markedly reduced, B cells in the blood.",
"   </p>",
"   <p>",
"    The hallmark of patients with XLA is a marked reduction in all classes and subclasses of serum immunoglobulins and B cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/1-3,6,10-13\">",
"     1-3,6,10-13",
"    </a>",
"    ]. IgG, IgA and IgM levels are generally below 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    and may be below the level of detection in clinical laboratories. However, IgG levels may be as high as 200 to 300",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mature B cells (eg, immunoglobulin bearing B cells, or CD19 or CD20 positive B cells) are markedly reduced in both blood and tissues such as lymphoid follicles and germinal centers of lymph nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/1-3,6,10-13\">",
"     1-3,6,10-13",
"    </a>",
"    ]. Similarly, plasma cells are absent in the lymphoid tissue, bone marrow, and the lamina propria of the rectal mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/1-3,6,10-13\">",
"     1-3,6,10-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serum levels of antibodies to ubiquitous antigens (eg, isohemagglutinins and E. coli) or to immunizations (eg, polio, tetanus, diphtheria) are markedly reduced or undetectable [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/1-3,6,10-13\">",
"     1-3,6,10-13",
"    </a>",
"    ]. T cell number and function are normal.",
"   </p>",
"   <p>",
"    Fifteen to 25 percent of patients may have neutropenia at some point, which can be severe [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/49-52\">",
"     49-52",
"    </a>",
"    ]. Neutropenia is associated with the high bacterial burden seen with active infection, and it resolves with antimicrobial and immunoglobulin therapy.",
"   </p>",
"   <p>",
"    The performance of tests such as a complete blood count, serum chemistries,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    specific radiologic procedures can provide insight into whether the patient has an acute or chronic infection, as they can with any other patient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=see_link\">",
"     \"Laboratory evaluation of the immune system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of XLA is usually suspected based upon a combination of family history, clinical history, and physical examination. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Presentation'",
"    </a>",
"    above.) The initial laboratory evaluation of a patient with suspected XLA includes a complete blood count with differential, quantitative serum immunoglobulin levels (IgG, IgA, and IgM), and serum specific antibody titers in response to immunization and infection (eg, tetanus, diphtheria, H. influenzae type b, and pneumococcus). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=see_link\">",
"     \"Laboratory evaluation of the immune system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30458?source=see_link\">",
"     \"Approach to the child with recurrent infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The finding of low immunoglobulin levels indicates a need for further testing, including determination of lymphocyte subpopulations (T, B, and NK cell subsets) by flow cytometry to document markedly reduced to absent B cell numbers in the peripheral blood. Every effort should be made to document a mutation in the BTK gene once significantly decreased immunoglobulin levels and B cell numbers have been found.",
"   </p>",
"   <p>",
"    An international committee has established criteria for the diagnosis of XLA (",
"    <a class=\"graphic graphic_table graphicRef75514 \" href=\"UTD.htm?17/5/17500\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/53\">",
"     53",
"    </a>",
"    ]. A definitive diagnosis is made when a male patient with hypogammaglobulinemia or agammaglobulinemia and &lt;2 percent CD19+ B cells",
"    <strong>",
"     either",
"    </strong>",
"    has a male family member of maternal lineage who is documented to also have agammaglobulinemia and &lt;2 percent CD19+ B cells",
"    <strong>",
"     or",
"    </strong>",
"    has a defect in the BTK gene or Btk expression is confirmed (by DNA, mRNA, or protein analysis). A probable or possible diagnosis, based upon clinical history, quantitative serum immunoglobulin levels, and response to vaccines, is made if these criteria are not met, but other causes of",
"    <span class=\"nowrap\">",
"     agammaglobulinemia/hypogammaglobulinemia",
"    </span>",
"    are ruled out.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of XLA includes other causes of agammaglobulinemia and hypogammaglobulinemia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transient hypogammaglobulinemia of infancy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/36/41544?source=see_link\">",
"       \"Transient hypogammaglobulinemia of infancy\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Common variable immunodeficiency (CVID) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/29/9688?source=see_link\">",
"       \"Pathogenesis of common variable immunodeficiency\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/28/17866?source=see_link\">",
"       \"Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30457?source=see_link\">",
"       \"Treatment and prognosis of common variable immunodeficiency\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Autosomal recessive agammaglobulinemia (see",
"      <a class=\"local\" href=\"#H20\">",
"       'Autosomal recessive agammaglobulinemia'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      Combined T and B cell immunodeficiencies with agammaglobulinemia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=see_link\">",
"       \"Severe combined immunodeficiency (SCID): An overview\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20362?source=see_link\">",
"       \"T cell negative, B cell negative, NK cell positive severe combined immunodeficiency\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/22/40295?source=see_link\">",
"       \"Syndromic immunodeficiencies\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The measurement of B and T lymphocytes, antibody levels in response to immunizations, and ultimately, the identification of a mutation in BTK, usually leads to an accurate diagnosis. B cell levels are generally normal with most other causes of",
"    <span class=\"nowrap\">",
"     agammaglobulinemia/hypogammaglobulinemia.",
"    </span>",
"    The exceptions are some of the more uncommon forms of SCID (T-B-NK+ SCID) and autosomal recessive agammaglobulinemia.",
"   </p>",
"   <p>",
"    An accurate diagnosis of XLA is important not only for the patient, but also for the patient's female family members who may be carriers. For example, all of the female offspring of a patient with XLA will be carriers, and the carriers&rsquo; sons will have a 50 percent chance of being affected. Similarly, if his mother is a carrier, then his sisters have a 50 percent chance of being carriers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15880494\">",
"    <span class=\"h2\">",
"     Newborn screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advances have made it possible to screen for defects in B cell maturation, such as agammaglobulinemia, in newborns. Newborn screening is of value in these disorders, since early diagnosis and therapy will prevent some infections.",
"   </p>",
"   <p>",
"    Immunoglobulin kappa-deleting recombination excision circles (KRECs) are formed in the process of B cell maturation, during allelic exclusion. KRECs are not produced in patients with B cell maturation defects, such as XLA, that occur before this stage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=see_link\">",
"     \"Normal B and T lymphocyte development\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37702?source=see_link&amp;anchor=H12#H12\">",
"     \"Immunoglobulin genetics\", section on 'Allelic exclusion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    KRECs can be used to screen for early B cell maturation defects from dried blood spots on newborn screening cards using PCR, similar to using T cell receptor excision circles (TRECs) to screen for T cell defects [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/54\">",
"     54",
"    </a>",
"    ]. Simultaneous screening for both T and B cell deficiencies using TRECs and KRECs is under study [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=see_link&amp;anchor=H6#H6\">",
"     \"Severe combined immunodeficiency (SCID): An overview\", section on 'Newborn screening'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Carrier detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three available techniques for determining the carrier status of female family members:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Detection of the relevant mutation in BTK",
"     </li>",
"     <li>",
"      Linkage analysis",
"     </li>",
"     <li>",
"      Detection of altered X-chromosome inactivation in B cells",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Each technique has its advantages, and each is used in clinical practice.",
"   </p>",
"   <p>",
"    Identification of a mutation in BTK is the most direct method of detecting a carrier female [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/56\">",
"     56",
"    </a>",
"    ]. The detection of a mutation is usually only practical in a female family member of an affected patient with XLA in whom the BTK mutation is known.",
"   </p>",
"   <p>",
"    Linkage analysis depends upon the analysis of closely linked X chromosome genes, but requires a previously affected family member who expresses a specific allele of that closely linked gene. A known BTK mutation is not required for linkage analysis. A number of polymorphic loci that are closely linked to BTK have been used for this purpose [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/57-59\">",
"     57-59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Altered X-chromosome inactivation analysis can also be used for carrier detection and does not require either that the mutation is known or that a previously affected family member is available. This technique depends upon the fact that non-carrier females have two populations of B cells in their blood, one in which the maternal X chromosome is active and one in which the paternal X chromosome is active (the inactivation of one or the other X chromosome in every cell is also called Lyonization).",
"   </p>",
"   <p>",
"    In contrast, carrier females of XLA have only one population of B cells, in which only the X chromosome bearing the normal BTK allele is active [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/60\">",
"     60",
"    </a>",
"    ]. There are a number of",
"    <span class=\"nowrap\">",
"     tools/techniques",
"    </span>",
"    available for detecting non-random X chromosome inactivation; these are usually performed only in specialized laboratories. These techniques include analysis of methylation patterns of X-chromosome genes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/61\">",
"     61",
"    </a>",
"    ], examination of somatic cell hybrids that have selectively retained the active X chromosome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/62\">",
"     62",
"    </a>",
"    ], and flow cytometric analysis of intracellular Btk protein expression in monocytes or platelets [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Replacement of immunoglobulin is the cornerstone of treatment for XLA.",
"   </p>",
"   <p>",
"    Two forms of replacement immune globulin therapy are available: intravenous immune globulin G (IGIV or IVIG) and subcutaneous immune globulin G (IGSC or SCIG). The dose for each of these preparations is determined by a combination of the patient's weight, trough levels of IgG after treatment has commenced, and the clinical response and condition of the patient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=see_link&amp;anchor=H12#H12\">",
"     \"Immune globulin therapy in primary immunodeficiency\", section on 'Administration and dosing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of immune globulin therapy in patients with XLA has not been studied in randomized trials, and at this point it is very unlikely that a randomized trial will ever be performed. Clinical experience and observational studies in patients with XLA and other forms of",
"    <span class=\"nowrap\">",
"     agammaglobulinemia/hypogammaglobulinemia",
"    </span>",
"    overwhelmingly indicate that immune globulin therapy lowers morbidity and mortality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30457?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment and prognosis of common variable immunodeficiency\", section on 'Immunoglobulin replacement therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=see_link&amp;anchor=H3#H3\">",
"     \"Immune globulin therapy in primary immunodeficiency\", section on 'Indications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=see_link&amp;anchor=H7#H7\">",
"     \"Immune globulin therapy in primary immunodeficiency\", section on 'Efficacy in preventing infections'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data from observational studies show that immune globulin therapy lowers the rate of infection and reduces hospitalization rates in patients with XLA [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/21,64\">",
"     21,64",
"    </a>",
"    ]. Immune globulin therapy also helps prevent the development of long-term pulmonary insufficiency and lowers the risk for systemic enteroviral infections [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/21,64,65\">",
"     21,64,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 29 patients with XLA, a dose response to immune globulin replacement therapy was seen with regard to incidence of pneumonia and number of days hospitalized [",
"      <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/64\">",
"       64",
"      </a>",
"      ]. Bacterial meningitis, bronchiectasis, and chronic lung disease were not reported in patients who received IVIG, but these did occur in patients who received lower immune globulin doses intramuscularly. IVIG was most beneficial when it was started before five years of age.",
"     </li>",
"     <li>",
"      In another series of 31 patients with XLA, the incidence of bacterial infections requiring hospitalization also decreased after starting IVIG (from 0.40 to 0.06 per patient per year) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, replacement therapy has its limitations. The preparations available today only replace IgG, but not IgM or IgA that have some biologic functions unique from IgG. In addition, the commercially available preparations of immune globulin are isolated from pools consisting of thousands of donors. Thus, although they possess significant titers of antibodies against common pathogens, commercial preparations may not have significant titers against uncommon organisms that patients with XLA may encounter. Finally, the passive immunity conferred by immune globulin replacement therapy does not replicate the normal increase in antibody production against an infecting microorganism that occurs in immunocompetent individuals with active immunity.",
"   </p>",
"   <p>",
"    In addition to immunoglobulin replacement therapy, patients with XLA require aggressive antibiotic therapy for any documented",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    suspected infection. In some instances, prolonged antibiotic therapy may be indicated as a treatment for ongoing pulmonary infections or chronic sinusitis. Finally, immunizations with live viral vaccines are generally held to be contraindicated. There are no data on the safety or efficacy of other vaccines in patients with XLA. The general medical management of immunodeficiency is discussed separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=see_link\">",
"     \"Medical management of immune deficiency\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Monitoring the patient for subclinical, but progressive, pulmonary damage is also important since a number of studies have shown that these patients can develop chronic pulmonary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/6,10,11,13,21,22\">",
"     6,10,11,13,21,22",
"    </a>",
"    ]. Such monitoring may take the form of routine pulmonary function tests. High resolution CT examinations of the chest may be of value in detecting early and progressive pulmonary structural damage, although the accumulated risk of radiation should be taken into account when performing these exams.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     General supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other considerations in the care of patients with XLA include vaccinations and avoidance of infection. Patients with XLA will not generate significant antibody responses to prophylactic immunization. However, many clinicians still immunize these patients with killed viral and bacterial vaccines in the hopes that they will generate T cell-mediated immune responses that may afford some additional protection beyond that obtained with immune globulin replacement therapy. Live viral vaccines are contraindicated. Immunization against transmissible infectious agents is encouraged for close family members. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=see_link\">",
"     \"Medical management of immune deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Passive protection against certain infections, such as tetanus and varicella, with hyperimmune globulin is usually not necessary in patients already receiving standard immune globulin replacement therapy. Common sense approaches to lowering the patient's exposure to communicable infectious diseases, such as hand washing and avoidance of respiratory droplets, are advised. Finally, patients should avoid ingestion of untreated drinking water if possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=see_link\">",
"     \"Medical management of immune deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The average age of diagnosis has dropped significantly since the initial description of XLA over 50 years ago [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/6\">",
"     6",
"    </a>",
"    ]. In addition, immune globulin preparations have improved, allowing patients to maintain normal levels of IgG on replacement therapy. Most patients with XLA born in the last few decades and treated optimally can be expected to survive into adult life because of these improvements in initial diagnosis, immune globulin replacement therapy, and treatment of infections. In a 2006 report, over 40 percent of patients with XLA in a United States registry were adults. In the same series, only 3 of 80 patients followed prospectively over a four year period died, and, notably, two died of iatrogenic causes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients who survive into adulthood, the quality of life is generally good [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/22,66\">",
"     22,66",
"    </a>",
"    ]. Adults with XLA miss more days of",
"    <span class=\"nowrap\">",
"     school/work",
"    </span>",
"    and they are hospitalized more frequently than males in the general population. However, most lead productive and fulfilling lives despite these limitations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     AUTOSOMAL RECESSIVE AGAMMAGLOBULINEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are at least six forms of genetically determined agammaglobulinemia that are caused by autosomal recessive (AR) mutations in genes contributing to the maturation and function of B cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21321/abstract/67-76\">",
"     67-76",
"    </a>",
"    ]. The discovery of mutations in these genes in patients with agammaglobulinemia has provided important insights into the normal development of B cells. Each form of AR agammaglobulinemia (ARA) has only been described in a few families.",
"   </p>",
"   <p>",
"    ARA should be suspected when the patient's family history is consistent with an autosomal recessive pattern of inheritance, or when the patient with agammaglobulinemia is female, or when a mutation in BTK cannot be identified in a male with agammaglobulinemia.",
"   </p>",
"   <p>",
"    The clinical and laboratory features of these disorders resemble those of XLA and the treatment is the same. However, it is important to try to discriminate between ARA and XLA since the patterns of inheritance and implications for genetic counseling are different.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      X-linked agammaglobulinemia (XLA or Bruton type agammaglobulinemia) is a primary humoral immunodeficiency characterized by recurrent bacterial infections of the respiratory tract and increased susceptibility to enteroviral infection. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'X-linked agammaglobulinemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical symptoms of an increased susceptibility to infection are generally first noted between 6 to 18 months of age. The average age of diagnosis is 2.6 years in patients with a positive family history and 5.4 years in patients with a negative family history. Although uncommon, some patients have mild enough disease that they are not diagnosed until adult life. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The only characteristic physical finding of XLA is the absence, or near absence, of the tonsils and adenoids. The respiratory tract is the most common site of bacterial infections in XLA.",
"      <span class=\"nowrap\">",
"       Bacteremia/sepsis,",
"      </span>",
"      osteomyelitis, septic arthritis, meningitis, and",
"      <span class=\"nowrap\">",
"       intravascular/lymphatic",
"      </span>",
"      infections can also occur. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Streptococcus pneumonia, Hemophilus influenzae type B, Streptococcus pyogenes, and Pseudomonas species cause most of the bacterial infections. Chronic and unremitting systemic infections with enteroviruses such as ECHOvirus and coxsackievirus can also occur. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Bacterial infections'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Viral, fungal, and parasitic infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      XLA is due to defects in a signal transduction molecule called Bruton tyrosine kinase (Btk). The diagnosis is suspected in a male patient with",
"      <span class=\"nowrap\">",
"       agammaglobulinemia/hypogammaglobulinemia,",
"      </span>",
"      very low to absent CD19+ B cells, and a consistent clinical",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      family history. The diagnosis may be confirmed with a molecular study identifying a Btk defect (DNA, mRNA, or protein analysis). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathophysiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Laboratory findings'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend replacement immune globulin therapy for patients with XLA (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=see_link\">",
"       \"Immune globulin therapy in primary immunodeficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Autosomal recessive agammaglobulinemia should be suspected when the patient's family history is consistent with an autosomal recessive pattern of inheritance, when the patient with agammaglobulinemia is female, or when a mutation in BTK cannot be identified in a male with agammaglobulinemia. The clinical and laboratory features of these disorders resemble those of XLA and the treatment is the same. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Autosomal recessive agammaglobulinemia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/1\">",
"      Ochs HD, Smith CI. X-linked agammaglobulinemia. A clinical and molecular analysis. Medicine (Baltimore) 1996; 75:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/2\">",
"      Conley ME, Rohrer J, Minegishi Y. X-linked agammaglobulinemia. Clin Rev Allergy Immunol 2000; 19:183.",
"     </a>",
"    </li>",
"    <li>",
"     Ochs HD, Stiehm ER, Winkelstein JA. Antibody deficiencies. In: Immmunologic disorders in infants and children, 5th ed, Stiehm ER, Ochs HD, Winkelstein JA (Eds), Elsevier/Sanders, Philadelphia 2004. p.356.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/4\">",
"      Tsukada S, Saffran DC, Rawlings DJ, et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell 1993; 72:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/5\">",
"      Vetrie D, Vorechovsk&yacute; I, Sideras P, et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature 1993; 361:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/6\">",
"      Winkelstein JA, Marino MC, Lederman HM, et al. X-linked agammaglobulinemia: report on a United States registry of 201 patients. Medicine (Baltimore) 2006; 85:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/7\">",
"      BRUTON OC. Agammaglobulinemia. Pediatrics 1952; 9:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/8\">",
"      Lindvall JM, Blomberg KE, V&auml;liaho J, et al. Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling. Immunol Rev 2005; 203:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/9\">",
"      Conley ME, Broides A, Hernandez-Trujillo V, et al. Genetic analysis of patients with defects in early B-cell development. Immunol Rev 2005; 203:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/10\">",
"      Lederman HM, Winkelstein JA. X-linked agammaglobulinemia: an analysis of 96 patients. Medicine (Baltimore) 1985; 64:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/11\">",
"      Plebani A, Soresina A, Rondelli R, et al. Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia: an Italian multicenter study. Clin Immunol 2002; 104:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/12\">",
"      Conley ME, Howard V. Clinical findings leading to the diagnosis of X-linked agammaglobulinemia. J Pediatr 2002; 141:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/13\">",
"      Hermaszewski RA, Webster AD. Primary hypogammaglobulinaemia: a survey of clinical manifestations and complications. Q J Med 1993; 86:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/14\">",
"      Morales-Aza B, Glennie SJ, Garcez TP, et al. Impaired maintenance of naturally acquired T-cell memory to the meningococcus in patients with B-cell immunodeficiency. Blood 2009; 113:4206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/15\">",
"      Hashimoto S, Miyawaki T, Futatani T, et al. Atypical X-linked agammaglobulinemia diagnosed in three adults. Intern Med 1999; 38:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/16\">",
"      Kornfeld SJ, Haire RN, Strong SJ, et al. Extreme variation in X-linked agammaglobulinemia phenotype in a three-generation family. J Allergy Clin Immunol 1997; 100:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/17\">",
"      Morwood K, Bourne H, Gold M, et al. Phenotypic variability: clinical presentation between the 6th year and the 60th year in a family with X-linked agammaglobulinemia. J Allergy Clin Immunol 2004; 113:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/18\">",
"      Sarpong S, Skolnick HS, Ochs HD, et al. Survival of wild polio by a patient with XLA. Ann Allergy Asthma Immunol 2002; 88:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/19\">",
"      Stewart DM, Tian L, Nelson DL. A case of X-linked agammaglobulinemia diagnosed in adulthood. Clin Immunol 2001; 99:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/20\">",
"      Usui K, Sasahara Y, Tazawa R, et al. Recurrent pneumonia with mild hypogammaglobulinemia diagnosed as X-linked agammaglobulinemia in adults. Respir Res 2001; 2:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/21\">",
"      Quartier P, Debr&eacute; M, De Blic J, et al. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. J Pediatr 1999; 134:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/22\">",
"      Howard V, Greene JM, Pahwa S, et al. The health status and quality of life of adults with X-linked agammaglobulinemia. Clin Immunol 2006; 118:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/23\">",
"      Tarzi MD, Grigoriadou S, Carr SB, et al. Clinical immunology review series: An approach to the management of pulmonary disease in primary antibody deficiency. Clin Exp Immunol 2009; 155:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/24\">",
"      Cuccherini B, Chua K, Gill V, et al. Bacteremia and skin/bone infections in two patients with X-linked agammaglobulinemia caused by an unusual organism related to Flexispira/Helicobacter species. Clin Immunol 2000; 97:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/25\">",
"      Han S, Schindel C, Genitsariotis R, et al. Identification of a unique Helicobacter species by 16S rRNA gene analysis in an abdominal abscess from a patient with X-linked hypogammaglobulinemia. J Clin Microbiol 2000; 38:2740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/26\">",
"      Weir S, Cuccherini B, Whitney AM, et al. Recurrent bacteremia caused by a \"Flexispira\"-like organism in a patient with X-linked (Bruton's) agammaglobulinemia. J Clin Microbiol 1999; 37:2439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/27\">",
"      Simons E, Spacek LA, Lederman HM, Winkelstein JA. Helicobacter cinaedi bacteremia presenting as macules in an afebrile patient with X-linked agammaglobulinemia. Infection 2004; 32:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/28\">",
"      Wilfert CM, Buckley RH, Mohanakumar T, et al. Persistent and fatal central-nervous-system ECHOvirus infections in patients with agammaglobulinemia. N Engl J Med 1977; 296:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/29\">",
"      Halliday E, Winkelstein J, Webster AD. Enteroviral infections in primary immunodeficiency (PID): a survey of morbidity and mortality. J Infect 2003; 46:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/30\">",
"      Misbah SA, Spickett GP, Ryba PC, et al. Chronic enteroviral meningoencephalitis in agammaglobulinemia: case report and literature review. J Clin Immunol 1992; 12:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/31\">",
"      Bardelas JA, Winkelstein JA, Seto DS, et al. Fatal ECHO 24 infection in a patient with hypogammaglobulinemia: relationship to dermatomyositis-like syndrome. J Pediatr 1977; 90:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/32\">",
"      Saulsbury FT, Bernstein MT, Winkelstein JA. Pneumocystis carinii pneumonia as the presenting infection in congenital hypogammaglobulinemia. J Pediatr 1979; 95:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/33\">",
"      Dittrich AM, Schulze I, Magdorf K, et al. X-linked agammaglobulinaemia and Pneumocystis carinii pneumonia--an unusual coincidence? Eur J Pediatr 2003; 162:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/34\">",
"      Alibrahim A, Lepore M, Lierl M, et al. Pneumocystis carinii pneumonia in an infant with X-linked agammaglobulinemia. J Allergy Clin Immunol 1998; 101:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/35\">",
"      Agarwal S, Mayer L. Pathogenesis and treatment of gastrointestinal disease in antibody deficiency syndromes. J Allergy Clin Immunol 2009; 124:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/36\">",
"      Wright PF, Hatch MH, Kasselberg AG, et al. Vaccine-associated poliomyelitis in a child with sex-linked agammaglobulinemia. J Pediatr 1977; 91:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/37\">",
"      Gompels MM, Hodges E, Lock RJ, et al. Lymphoproliferative disease in antibody deficiency: a multi-centre study. Clin Exp Immunol 2003; 134:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/38\">",
"      Lavilla P, Gil A, Rodr&iacute;guez MC, et al. X-linked agammaglobulinemia and gastric adenocarcinoma. Cancer 1993; 72:1528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/39\">",
"      Bachmeyer C, Monge M, Cazier A, et al. Gastric adenocarcinoma in a patient with X-linked agammaglobulinaemia. Eur J Gastroenterol Hepatol 2000; 12:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/40\">",
"      van der Meer JW, Weening RS, Schellekens PT, et al. Colorectal cancer in patients with X-linked agammaglobulinaemia. Lancet 1993; 341:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/41\">",
"      Brosens LA, Tytgat KM, Morsink FH, et al. Multiple colorectal neoplasms in X-linked agammaglobulinemia. Clin Gastroenterol Hepatol 2008; 6:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/42\">",
"      Echave-Sustaeta JM, Villena V, Verdugo M, et al. X-linked agammaglobulinaemia and squamous lung cancer. Eur Respir J 2001; 17:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/43\">",
"      Berlucchi M, Soresina A, Redaelli De Zinis LO, et al. Sensorineural hearing loss in primary antibody deficiency disorders. J Pediatr 2008; 153:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/44\">",
"      Hunter HL, McKenna KE, Edgar JD. Eczema and X-linked agammaglobulinaemia. Clin Exp Dermatol 2008; 33:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/45\">",
"      Saffran DC, Parolini O, Fitch-Hilgenberg ME, et al. Brief report: a point mutation in the SH2 domain of Bruton's tyrosine kinase in atypical X-linked agammaglobulinemia. N Engl J Med 1994; 330:1488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/46\">",
"      Kornfeld SJ, Haire RN, Strong SJ, et al. A novel mutation (Cys145--&gt;Stop) in Bruton's tyrosine kinase is associated with newly diagnosed X-linked agammaglobulinemia in a 51-year-old male. Mol Med 1996; 2:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/47\">",
"      Kornfeld SJ, Kratz J, Haire RN, et al. X-linked agammaglobulinemia presenting as transient hypogammaglobulinemia of infancy. J Allergy Clin Immunol 1995; 95:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/48\">",
"      Wood PM, Mayne A, Joyce H, et al. A mutation in Bruton's tyrosine kinase as a cause of selective anti-polysaccharide antibody deficiency. J Pediatr 2001; 139:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/49\">",
"      Cham B, Bonilla MA, Winkelstein J. Neutropenia associated with primary immunodeficiency syndromes. Semin Hematol 2002; 39:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/50\">",
"      Farrar JE, Rohrer J, Conley ME. Neutropenia in X-linked agammaglobulinemia. Clin Immunol Immunopathol 1996; 81:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/51\">",
"      Kanegane H, Taneichi H, Nomura K, et al. Severe neutropenia in Japanese patients with x-linked agammaglobulinemia. J Clin Immunol 2005; 25:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/52\">",
"      Plo Rodr&iacute;guez F, Garc&iacute;a Rodr&iacute;guez MC, Ferreira Cerd&aacute;n A, Font&aacute;n Casariego G. [Neutropenia as early manifestation of X-linked agammaglobulinemia. Report on 4 patients]. An Esp Pediatr 1999; 51:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/53\">",
"      Conley ME, Notarangelo LD, Etzioni A. Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Clin Immunol 1999; 93:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/54\">",
"      Nakagawa N, Imai K, Kanegane H, et al. Quantification of &kappa;-deleting recombination excision circles in Guthrie cards for the identification of early B-cell maturation defects. J Allergy Clin Immunol 2011; 128:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/55\">",
"      Borte S, von D&ouml;beln U, Fasth A, et al. Neonatal screening for severe primary immunodeficiency diseases using high-throughput triplex real-time PCR. Blood 2012; 119:2552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/56\">",
"      Zhu Q, Zhang M, Rawlings DJ, et al. Deletion within the Src homology domain 3 of Bruton's tyrosine kinase resulting in X-linked agammaglobulinemia (XLA). J Exp Med 1994; 180:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/57\">",
"      Guioli S, Arveiler B, Bardoni B, et al. Close linkage of probe p212 (DXS178) to X-linked agammaglobulinemia. Hum Genet 1989; 84:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/58\">",
"      Kwan SP, Walker AP, Hagemann T, et al. A new RFLP marker, SP282, at the btk locus for genetic analysis in X-linked agammaglobulinaemia families. Prenat Diagn 1994; 14:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/59\">",
"      Parolini O, Hejtmancik JF, Allen RC, et al. Linkage analysis and physical mapping near the gene for X-linked agammaglobulinemia at Xq22. Genomics 1993; 15:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/60\">",
"      Winkelstein JA, Fearon E. Carrier detection of the X-linked primary immunodeficiency diseases using X-chromosome inactivation analysis. J Allergy Clin Immunol 1990; 85:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/61\">",
"      Fearon ER, Winkelstein JA, Civin CI, et al. Carrier detection in X-linked agammaglobulinemia by analysis of X-chromosome inactivation. N Engl J Med 1987; 316:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/62\">",
"      Conley ME, Puck JM. Carrier detection in typical and atypical X-linked agammaglobulinemia. J Pediatr 1988; 112:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/63\">",
"      Kanegane H, Futatani T, Wang Y, et al. Clinical and mutational characteristics of X-linked agammaglobulinemia and its carrier identified by flow cytometric assessment combined with genetic analysis. J Allergy Clin Immunol 2001; 108:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/64\">",
"      Liese JG, Wintergerst U, Tympner KD, Belohradsky BH. High- vs low-dose immunoglobulin therapy in the long-term treatment of X-linked agammaglobulinemia. Am J Dis Child 1992; 146:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/65\">",
"      Sweinberg SK, Wodell RA, Grodofsky MP, et al. Retrospective analysis of the incidence of pulmonary disease in hypogammaglobulinemia. J Allergy Clin Immunol 1991; 88:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/66\">",
"      Winkelstein JA, Conley ME, James C, et al. Adults with X-linked agammaglobulinemia: impact of disease on daily lives, quality of life, educational and socioeconomic status, knowledge of inheritance, and reproductive attitudes. Medicine (Baltimore) 2008; 87:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/67\">",
"      Minegishi Y, Coustan-Smith E, Wang YH, et al. Mutations in the human lambda5/14.1 gene result in B cell deficiency and agammaglobulinemia. J Exp Med 1998; 187:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/68\">",
"      Minegishi Y, Coustan-Smith E, Rapalus L, et al. Mutations in Igalpha (CD79a) result in a complete block in B-cell development. J Clin Invest 1999; 104:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/69\">",
"      Minegishi Y, Rohrer J, Coustan-Smith E, et al. An essential role for BLNK in human B cell development. Science 1999; 286:1954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/70\">",
"      Kubota K, Kim JY, Sawada A, et al. LRRC8 involved in B cell development belongs to a novel family of leucine-rich repeat proteins. FEBS Lett 2004; 564:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/71\">",
"      Conley ME, Rohrer J, Rapalus L, et al. Defects in early B-cell development: comparing the consequences of abnormalities in pre-BCR signaling in the human and the mouse. Immunol Rev 2000; 178:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/72\">",
"      Yel L, Minegishi Y, Coustan-Smith E, et al. Mutations in the mu heavy-chain gene in patients with agammaglobulinemia. N Engl J Med 1996; 335:1486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/73\">",
"      Ferrari S, Lougaris V, Caraffi S, et al. Mutations of the Igbeta gene cause agammaglobulinemia in man. J Exp Med 2007; 204:2047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/74\">",
"      Conley ME, Farmer DM, Dobbs AK, et al. A minimally hypomorphic mutation in Btk resulting in reduced B cell numbers but no clinical disease. Clin Exp Immunol 2008; 152:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/75\">",
"      Cliffe ST, Bloch DB, Suryani S, et al. Clinical, molecular, and cellular immunologic findings in patients with SP110-associated veno-occlusive disease with immunodeficiency syndrome. J Allergy Clin Immunol 2012; 130:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21321/abstract/76\">",
"      Conley ME, Dobbs AK, Quintana AM, et al. Agammaglobulinemia and absent B lineage cells in a patient lacking the p85&alpha; subunit of PI3K. J Exp Med 2012; 209:463.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3931 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.72.80.101-9C98E7F444-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_52_21321=[""].join("\n");
var outline_f20_52_21321=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      X-LINKED AGAMMAGLOBULINEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Bacterial infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Viral, fungal, and parasitic infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Malignancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Atypical XLA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15880494\">",
"      Newborn screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Carrier detection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - General supportive care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      AUTOSOMAL RECESSIVE AGAMMAGLOBULINEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/3931\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3931|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/25/32157\" title=\"figure 1\">",
"      Serum IgG levels less than 5 y",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3931|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/5/17500\" title=\"table 1\">",
"      X linked agammaglobulinemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30458?source=related_link\">",
"      Approach to the child with recurrent infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/49/34585?source=related_link\">",
"      Clinical manifestations and diagnosis of enterovirus and parechovirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/28/17866?source=related_link\">",
"      Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/26/41383?source=related_link\">",
"      Epidemiology, pathogenesis, treatment, and prevention of enterovirus and parechovirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/60/13258?source=related_link\">",
"      IgG subclass deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35078?source=related_link\">",
"      IgG subclasses: Physical properties, genetics, and biologic functions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=related_link\">",
"      Immune globulin therapy in primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37702?source=related_link\">",
"      Immunoglobulin genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=related_link\">",
"      Laboratory evaluation of the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=related_link\">",
"      Medical management of immune deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=related_link\">",
"      Normal B and T lymphocyte development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/29/9688?source=related_link\">",
"      Pathogenesis of common variable immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24326?source=related_link\">",
"      Primary humoral immune deficiencies: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7561?source=related_link\">",
"      Secondary immune deficiency due to miscellaneous causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17209?source=related_link\">",
"      Selective antibody deficiency with normal immunoglobulins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=related_link\">",
"      Severe combined immunodeficiency (SCID): An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/22/40295?source=related_link\">",
"      Syndromic immunodeficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20362?source=related_link\">",
"      T cell negative, B cell negative, NK cell positive severe combined immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27624?source=related_link\">",
"      The humoral immune response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/36/41544?source=related_link\">",
"      Transient hypogammaglobulinemia of infancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30457?source=related_link\">",
"      Treatment and prognosis of common variable immunodeficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_52_21322="Overview of the myeloproliferative neoplasms";
var content_f20_52_21322=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the myeloproliferative neoplasms",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/52/21322/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/52/21322/contributors\">",
"     Ayalew Tefferi, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/52/21322/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/52/21322/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/52/21322/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/52/21322/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/52/21322/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An overview of the classic myeloproliferative neoplasms (MPN, myeloproliferative diseases (MPD); eg, polycythemia vera, essential thrombocythemia, primary myelofibrosis, chronic myeloid leukemia) will be presented here [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Detailed information on each of these disorders is presented separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION OF HEMATOLOGIC MALIGNANCIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hematopoietic pluripotent stem cell is capable of both self-renewal and a stepwise differentiation, after a stochastic determination, into either the lymphoid or myeloid lineage [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/3\">",
"     3",
"    </a>",
"    ]. Thus, during normal hematopoiesis, there exists a cellular hierarchy headed by a stable population of pluripotent stem cells, which generate lineage-specific progenitors differentiating into the various types of mature blood cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/4\">",
"     4",
"    </a>",
"    ]. Effective hematopoiesis is facilitated by the interactive functions of hematopoietic growth factors, various sets of receptors, and the bone marrow microenvironment.",
"   </p>",
"   <p>",
"    An operational classification of hematologic malignancies separates lymphoid from myeloid processes (",
"    <a class=\"graphic graphic_figure graphicRef56283 \" href=\"UTD.htm?24/16/24835\">",
"     figure 1",
"    </a>",
"    ). Each of these is in turn classified as being acute or chronic, depending upon the proportion of morphologically and immunophenotypically immature precursors (blasts) in the bone marrow. Thus, the myeloid hematologic malignancies are divided into acute myeloid leukemia (bone marrow blasts of 20 percent or more) and the chronic myeloid disorders (bone marrow blasts less than 20 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     The chronic myeloid disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chronic myeloid disorders encompass several clinicopathologic entities. Conceptually, they can be organized into those which either display (the myelodysplastic syndromes) or do not display (myeloproliferative neoplasms) significant dysmyelopoiesis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The myelodysplastic syndromes (MDS) are characterized by dysplastic bone marrow hyperplasia or even occasional hypoplasia, associated with variable degrees of peripheral blood cytopenia with or without monocytosis [",
"      <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/6\">",
"       6",
"      </a>",
"      ]. The paradox between the proliferative bone marrow and the cytopenic peripheral blood picture in the MDS may be explained by increased intramedullary myeloid precursor cell apoptosis [",
"      <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The myeloproliferative neoplasms (MPNs), unlike MDS, usually exhibit terminal myeloid cell expansion in the peripheral blood [",
"      <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/8\">",
"       8",
"      </a>",
"      ]. According to the 2008 WHO Classification System, the MPNs are operationally classified into \"classic\" and \"atypical\" MPNs [",
"      <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/9\">",
"       9",
"      </a>",
"      ]. Classic MPNs include polycythemia vera, essential thrombocythemia, chronic myeloid leukemia (CML), primary myelofibrosis (PMF), chronic neutrophilic leukemia, chronic eosinophilic leukemia, and mast cell disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Atypical MPNs include those chronic myeloid disorders that are currently not classifiable as either MDS or classical MPN: chronic myelomonocytic leukemia, juvenile myelomonocytic leukemia, atypical CML, and unclassifiable",
"    <span class=\"nowrap\">",
"     MDS/MPN.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clonal studies in the chronic myeloid disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic and enzyme studies based upon X-chromosome inactivation patterns have revealed a multipotent progenitor cell origin for the neoplastic clone in both MDS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/10\">",
"     10",
"    </a>",
"    ] and MPN [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/11\">",
"     11",
"    </a>",
"    ]. Furthermore, the clonal process may develop at different progenitor cell levels in different patients, resulting in lineage heterogeneity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/12\">",
"     12",
"    </a>",
"    ]. The clonal progenitor cell may or may not involve T and B lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Potential significance'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Studies using refined methods of X-linked DNA analysis have demonstrated polyclonal hematopoiesis in some patients with essential thrombocythemia and monoclonal hematopoiesis in healthy elderly women [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/13\">",
"     13",
"    </a>",
"    ]. However, the utilization of JAK2V617F mutation analysis has revealed that patients with \"polyclonal\" essential thrombocythemia also display the mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/14\">",
"     14",
"    </a>",
"    ]. Therefore, X chromosome-based clonal assays might not be adequate in detecting a minor clonal population against a polyclonal background.",
"   </p>",
"   <p>",
"    These observations underline the heterogeneity, among patients, of the pathogenesis of the MPNs. They also raise the possibility that monoclonal hematopoiesis may antedate rather than follow the mutations described below which then give rise to MPN or MDS. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Potential significance'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Familial disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial clustering of polycythemia vera (PV), essential thrombocytosis (ET), and primary myelofibrosis (PMF) has been well described [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 458 adult patients with apparently sporadic disease, familial involvement was noted in 8.7, 6.0, and 8.2 percent of those with PV, ET, or PMF, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a population-based study from Sweden involving 11,039 patients with MPN, their 24,577 first-degree relatives had significantly increased risks of PV (Relative risk (RR) 5.7), ET (RR 7.4), and unclassifiable MPN (RR 7.5), and a borderline increased risk of CML (RR 1.9; 95% CI 0.9-3.8) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with familial disease developed similar complications and disease evolution as those with sporadic disease. Age distribution between parent and offspring and telomere length shortening provided evidence for disease anticipation in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/15\">",
"     15",
"    </a>",
"    ]. However, this age difference between parent and offspring was not seen in the large population-based study from Sweden [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Presence of the JAK2 mutation does not appear to represent the genetic predisposing factor [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/15,18-22\">",
"     15,18-22",
"    </a>",
"    ], although it might indicate which family members are at higher risk of developing one of the MPNs at a future date [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29978?source=see_link&amp;anchor=H25#H25\">",
"     \"Molecular pathogenesis of congenital polycythemic disorders and polycythemia vera\", section on 'Familial PV'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Observations such as the above, as well as diagnostic criteria for PV and ET, may not pertain to children, owing to known mutations in several other genes (eg, hereditary mutations of the erythropoietin receptor, thrombopoietin, MPL genes) in families with polycythemia or ET presenting in childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29978?source=see_link&amp;anchor=H13#H13\">",
"     \"Molecular pathogenesis of congenital polycythemic disorders and polycythemia vera\", section on 'Other polycythemias with defined molecular lesions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/28/18890?source=see_link&amp;anchor=H26#H26\">",
"     \"Diagnosis and clinical manifestations of essential thrombocythemia\", section on 'Familial essential thrombocythemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     THE CLASSIC MYELOPROLIFERATIVE DISEASES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the classic MPNs, only CML is genetically characterized by the reciprocal chromosomal translocation between chromosomes 9 and 22, t(9;22). This translocation is associated with a shortened chromosome 22 (the Philadelphia chromosome) in 95 percent of the cases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/25\">",
"     25",
"    </a>",
"    ]. In the remaining cases, t(9;22) can be demonstrated by either fluorescence in situ hybridization (FISH) or reverse transcriptase polymerase chain reaction techniques for detection of BCR-ABL. While cytogenetic abnormalities are common in primary myelofibrosis and uncommon in essential thrombocythemia, no specific cytogenetic abnormality in the MPNs other than CML has been identified to date [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31512?source=see_link\">",
"     \"Molecular genetics of chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The discovery that JAK2 mutations are found in virtually all patients with PV and approximately 50 percent of those with either ET or PMF, has refined current diagnostic criteria in classic MPN [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/2,27-29\">",
"     2,27-29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Polycythemia vera (PV) is considered to be present when an otherwise unexplained increased",
"      <span class=\"nowrap\">",
"       hematocrit/red",
"      </span>",
"      blood cell mass is accompanied by the presence of a JAK2 mutation along with a decreased erythropoietin level. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9738?source=see_link\">",
"       \"Diagnostic approach to the patient with suspected polycythemia vera\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Primary myelofibrosis (agnogenic myeloid metaplasia, chronic idiopathic myelofibrosis) is characterized by the presence of bone marrow fibrosis that cannot be attributed to another myeloid disorder such as CML, PV, ET, or MDS. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25064?source=see_link\">",
"       \"Pathogenetic mechanisms in primary myelofibrosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1018?source=see_link\">",
"       \"Clinical manifestations and diagnosis of primary myelofibrosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Essential thrombocythemia (ET) is a diagnosis of exclusion, representing clonal or autonomous thrombocytosis not classifiable as PV, PMF, CML, or MDS. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/28/18890?source=see_link\">",
"       \"Diagnosis and clinical manifestations of essential thrombocythemia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Within the context of the MPNs, an elevated red cell mass is specific for PV. Occasionally both CML and MDS may present with either isolated thrombocytosis suggesting ET [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/30\">",
"     30",
"    </a>",
"    ], or associated bone marrow fibrosis suggesting myelofibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. As a result, the diagnostic work up of patients with suspected MPN should always include cytogenetic studies and careful morphologic evaluation to exclude the presence of t(9;22) (CML) and dysmyelopoiesis (myelodysplastic syndrome), respectively.",
"   </p>",
"   <p>",
"    Although most of the chronic myeloid disorders are classifiable as MDS, CML, PV, ET, or PMF, some are difficult to categorize and may be referred to as atypical MPNs [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/33\">",
"     33",
"    </a>",
"    ]. Rare patients expressing both BCR-ABL and a JAK2 mutation have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The three major complications of the MPNs include clonal evolution, thrombosis, and bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2181740\">",
"    <span class=\"h3\">",
"     Malignancies and clonal evolution",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a group, the MPNs are predisposed to clonal evolution and disease transformation to myelodysplasia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    acute leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. The propensity to transform into acute myeloid leukemia differs among the subgroups, being highest for CML (greater than 90 percent in the absence of effective therapy) and least for ET (less than 5 percent). Patients with PV have an approximately 10 and 25 percent chance of transforming into a myelofibrotic stage at 10 and 25 years of follow-up, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1018?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical manifestations and diagnosis of primary myelofibrosis\", section on 'Transformation to acute leukemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28554?source=see_link&amp;anchor=H4#H4\">",
"     \"Prognosis and treatment of polycythemia vera\", section on 'Hematologic complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk for clonal evolution in the MPNs is related to disease-related as well as treatment-related factors. This was assessed in a nested case-control study of a nationwide cohort of 11,039 subjects with PV, ET, and PMF, which included 153 who developed AML, 9 who developed MDS, and 242 matched controls. Results included [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/39\">",
"     39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Forty-one of the 162 patients with MPN who developed AML or MDS (25 percent) had never been exposed to alkylating agents, radioactive phosphorus (P",
"      <sup>",
"       32",
"      </sup>",
"      ), or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      , indicating a substantial propensity of the MPNs to undergo clonal evolution in the absence of cytoreductive treatment.",
"     </li>",
"     <li>",
"      The risk of",
"      <span class=\"nowrap\">",
"       AML/MDS",
"      </span>",
"      was significantly associated with high exposures to P",
"      <sup>",
"       32",
"      </sup>",
"      (OR 4.6; 95% CI 2.1-9.8) and alkylating agents (OR 3.4; 95% CI 1.1-10.6), but not with exposure to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      (OR for the highest exposure 1.3; 95% CI 0.5-3.3).",
"     </li>",
"     <li>",
"      The risk of",
"      <span class=\"nowrap\">",
"       AML/MDS",
"      </span>",
"      was significantly increased in patients receiving two or more cytoreductive treatments (OR 2.9; 95% CI 1.4-5.9).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Results of a Danish population-based cohort study indicated a significant increase in the risk of development of both hematologic and non-hematologic malignancies in patients with PV, ET, and CML [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/40\">",
"     40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The standardized incidence ratios for hematologic malignancies were 5.0, 3.8, and 5.2 for ET, PV, and CML, respectively.",
"     </li>",
"     <li>",
"      The standardized incidence ratios for non-hematologic malignancies were 1.2, 1.4, and 1.6 for ET, PV, and CML, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The frequency of lymphoproliferative neoplasms in two series of patients with MPNs was 1.3 to 1.6 percent, with a cumulative risk of LPN development between 1 and 3 percent at 5 to 10 years of follow-up, corresponding to a standardized incidence ratio (SIR) &gt;4 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. This risk was significantly higher in those harboring the JAK2 V617F mutation and was increased as much as 12-fold for the development of chronic lymphocytic leukemia.",
"    <span class=\"nowrap\">",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5166016\">",
"    <span class=\"h4\">",
"     Treatment of MPN-associated acute leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukemic/blast",
"    phase transformation (LT) of an MPN is difficult to treat. Current consensus is to induce such patients into complete remission using AML-like induction chemotherapy followed by allogeneic hematopoietic cell transplantation (HCT).",
"   </p>",
"   <p>",
"    However, few reports suggest the potential value of such an approach. As one example, in a single center report of 75 patients with MPN-associated LT, the two-year overall survival was 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/43\">",
"     43",
"    </a>",
"    ]. Selected patients with a reasonable fitness level achieved long-term control after curative intent chemotherapy followed by allogeneic hematopoietic cell transplantation (HCT). Two-year overall survivals were as follows for the following sub-groups:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Treated with non-curative regimens: 3 percent",
"     </li>",
"     <li>",
"      Complete remission following curative intent chemotherapy: 15 percent",
"     </li>",
"     <li>",
"      Complete remission following curative intent chemotherapy followed by HCT: 47 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2181747\">",
"    <span class=\"h3\">",
"     Thrombosis and bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another biologic complication shared among the MPNs is the significant risk of thrombohemorrhagic complications, most pronounced in PV and ET [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The thrombotic complications include arterial and venous thromboses and microcirculatory disorders such as erythromelalgia (",
"      <a class=\"graphic graphic_picture graphicRef81121 \" href=\"UTD.htm?17/25/17808\">",
"       picture 1",
"      </a>",
"      ) and visual and neurologic symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/45\">",
"       45",
"      </a>",
"      ]. Why this occurs is not well understood, although serial in vivo activation of leukocytes, vascular endothelium, platelets, and the coagulation system has been postulated [",
"      <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/46,47\">",
"       46,47",
"      </a>",
"      ]. Erythromelalgia is associated with platelet consumption and platelet thrombi in the microvasculature; both the shortened platelet survival and symptoms can be ameliorated by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      but not",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or coumadin, suggesting that a prostaglandin synthase product in platelets plays an important role [",
"      <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The bleeding episodes are usually mild, with spontaneous bleeding primarily occurring in patients with high platelet counts; both quantitative and qualitative changes in platelet function may contribute [",
"      <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/45,49\">",
"       45,49",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because of the variable risks of blastic transformation and thrombosis-associated deaths, overall survival in the MPNs ranges from a \"near-normal\" life expectancy in patients with essential thrombocythemia to a median of less than five years in patients with PMF [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Symptoms and quality of life",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the major complications noted above (eg, thrombosis, hemorrhage, evolution to AML), patients with MPN also suffer from a number of debilitating symptoms, interfering with their quality of life (QOL). These issues were evaluated in an Internet-based symptom survey of 1179 patients with MPN [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/51\">",
"     51",
"    </a>",
"    ]. The frequency of self-reporting for the following complaints were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fatigue &mdash; 81 percent",
"     </li>",
"     <li>",
"      Pruritus &mdash; 52 percent",
"     </li>",
"     <li>",
"      Night sweats &mdash; 49 percent",
"     </li>",
"     <li>",
"      Bone pain &mdash; 44 percent",
"     </li>",
"     <li>",
"      Fever &mdash; 14 percent",
"     </li>",
"     <li>",
"      Weight loss &mdash; 13 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among each of the MPNs, fatigue was the most common complaint, being present in 85, 72, and 84 percent of those with PV, ET, and PMF, respectively. Approximately one-third of the respondents needed assistance with activities of daily living and 11 percent reported MPN-related medical disability.",
"   </p>",
"   <p>",
"    A Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) has been devised and prospectively validated as an assessment tool for patients with MPNs embarking on clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/52\">",
"     52",
"    </a>",
"    ]. This form has been further modified to include an abbreviated version (the MPN-SAF Total symptom score) that focuses on the most representative and clinically relevant MPN symptoms, which include the following 10 items: fatigue, early satiety, abdominal discomfort, inactivity, concentration problems, night sweats, itching, bone pain, fever, and weight loss [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Role of hematologic growth factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of hematologic growth factors in either the development or propagation of the clonal process in MPN remains undefined. Growth factor independence of the clonal process in MPN is suggested by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      These diseases are characterized by spontaneous (without the addition of a growth factor) hematopoietic colony formation [",
"      <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Erythropoietin (Epo) levels in patients with PV are appropriately downregulated, and molecular studies have not revealed genetic mutations involving the Epo receptor [",
"      <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/55\">",
"       55",
"      </a>",
"      ]. The demonstration of overexpression of Bcl-x, an inhibitor of apoptosis, in erythroid precursors from patients with PV provides a possible explanation for how these cells can grow autonomously in the absence of Epo [",
"      <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/56\">",
"       56",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29978?source=see_link\">",
"       \"Molecular pathogenesis of congenital polycythemic disorders and polycythemia vera\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Molecular lesions have not been identified for either thrombopoietin (TPO) or the TPO receptor (c-Mpl) in essential thrombocythemia (ET), implying that the clonal process is TPO-independent [",
"      <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/57\">",
"       57",
"      </a>",
"      ]. However, serum thrombopoietin (TPO) concentrations in patients with ET are either normal or above normal, suggesting defective feedback regulation [",
"      <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/58\">",
"       58",
"      </a>",
"      ]. Consistent with this observation, TPO receptor expression in platelets and megakaryocytes is reduced in patients with ET [",
"      <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    TPO receptor expression in platelets and megakaryocytes is also absent or markedly reduced in PV [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/60\">",
"     60",
"    </a>",
"    ]. Thus, the proliferation of platelets in this disorder is presumably independent of TPO as it is in ET.",
"   </p>",
"   <p>",
"    While growth factors have not been implicated in the neoplastic process, they are believed to contribute to the pathogenesis of bone marrow fibrosis associated with the MPNs. In an experiment in mice, lethal irradiation was followed by grafting of bone marrow cells infected with a retrovirus carrying murine TPO cDNA [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/61\">",
"     61",
"    </a>",
"    ]. The initial phase was characterized by marked elevations in the platelet and white blood cell counts followed by a syndrome of bone marrow fibrosis, extramedullary hematopoiesis, hepatosplenomegaly, anemia, and leukemic transformation. The PMF-like illness is thought to be mediated by a megakaryocyte-derived overproduction of transforming growth factor (TGF)-beta, which has previously been implicated in human myelofibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Gene expression profiling",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a study of 40 patients with PV, gene expression profiling (GEP) uncovered overexpression of a number of transcription factors, including NF-E2 (nuclear factor-erythroid derived 2) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/63\">",
"     63",
"    </a>",
"    ]. Overexpression of NF-E2 was noted in bone marrow megakaryocytic, erythroid, and granulocytic precursors, leads to the development of Epo-independent erythroid colonies, and may control lineage commitment, resulting in overproduction of red cells and platelets.",
"   </p>",
"   <p>",
"    GEP in patients with EP showed a heterogeneous molecular signature, with an upregulation of inflammatory markers that could participate in neutrophil activation and thrombosis in one group, and a significantly lower expression of these genes in the second group [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/64\">",
"     64",
"    </a>",
"    ]. The significance of these findings is not clear at this time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Mutations in PV, ET, and PMF",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     JAK2 mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;An explanation for the hypersensitivity of hematopoietic progenitor cells in the myeloproliferative disorders to growth factors and other cytokines [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/65-68\">",
"     65-68",
"    </a>",
"    ] has been provided by a study of the cytoplasmic tyrosine kinase Janus kinase 2 (JAK2), a gene found on the short arm of chromosome 9 (9p) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/69-73\">",
"     69-73",
"    </a>",
"    ]. A mutation in the JAK2 gene leads to constitutive tyrosine phosphorylation activity that promotes hypersensitivity to cytokines and induces erythrocytosis in a mouse model [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/69\">",
"     69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29978?source=see_link&amp;anchor=H26#H26\">",
"     \"Molecular pathogenesis of congenital polycythemic disorders and polycythemia vera\", section on 'JAK2 (JAK2V617F) mutation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9738?source=see_link&amp;anchor=H24#H24\">",
"     \"Diagnostic approach to the patient with suspected polycythemia vera\", section on 'JAK2 mutations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This mutation arises preferentially on a common constitutional JAK2 haplotype (variously called",
"    <span class=\"nowrap\">",
"     46/1",
"    </span>",
"    or GGCC) found in approximately 50 percent of normal persons [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/74-76\">",
"     74-76",
"    </a>",
"    ]. When found, the JAK2 mutation is most abundant in erythroid and myeloid cells, although its presence in other cell lines (eg, lymphoid cells of B cell, T cell, and NK cell lineages, endothelial cells) is still debated [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/47,77-82\">",
"     47,77-82",
"    </a>",
"    ]. In one study of 115 patients with MPN, the JAK2 mutation, when present, was found slightly more often in platelets than in granulocytes (72 versus 62 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This mutation in exon 14 of JAK2 substitutes a bulky phenylalanine for a conserved valine at position 617 in the JH2 or pseudokinase domain (Val617Phe, V617F), which negatively regulates the kinase domain, causing cytokine-independent activation of JAK-STAT, other pathways implicated in erythropoietin-receptor signaling, and the phosphatidylinositide-3 kinase (PI3K) pathway which regulates apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/84,85\">",
"     84,85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20555374\">",
"    <span class=\"h4\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;This single gain-of-function point mutation in JAK2 has been identified in 95 to 97 percent of patients with PV, 23 to 75 percent of those with ET, and 43 to 57 percent of those with PMF [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/70,86-88\">",
"     70,86-88",
"    </a>",
"    ]. Its presence in EPO-independent erythroid colonies links this mutation to growth factor hypersensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/89\">",
"     89",
"    </a>",
"    ]. Further, a study of JAK2 and the STAT pathway might allow for a more reliable",
"    <span class=\"nowrap\">",
"     classification/diagnostic",
"    </span>",
"    system for the myeloproliferative neoplasms [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/84,90,91\">",
"     84,90,91",
"    </a>",
"    ], as well as a more complete understanding of their pathophysiology [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/92,93\">",
"     92,93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A discussion of refractory anemia with ringed sideroblasts and thrombocytosis (RARS-T), a myelodysplastic variant with myeloproliferative features and a high frequency of the JAK2 V617F mutation, can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=see_link&amp;anchor=H1583841#H1583841\">",
"     \"Clinical manifestations and diagnosis of the myelodysplastic syndromes\", section on 'RARS with thrombocytosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As an example, the JAK2 V617F mutation has been found only infrequently in other chronic myeloid disorders (eg, MDS, chronic myelomonocytic leukemia, systemic mastocytosis, chronic neutrophilic leukemia), but has been seen in some patients with acute myeloid leukemia following a prior MPN, strengthening the specific association between this mutation and the classical",
"    <span class=\"nowrap\">",
"     BCR/ABL-negative",
"    </span>",
"    MPNs (ie, PV, ET, PMF) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/94-97\">",
"     94-97",
"    </a>",
"    ]. Of interest, one strain of transgenic mice highly expressing this JAK2 mutation developed phenotypes closely resembling ET and PV, and developed PMF-like symptoms as they aged [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The finding of dysregulated tyrosine kinase (TK) activity also suggests a possible therapeutic approach to these disorders, via the use of small molecule JAK2 TK inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/99-105\">",
"     99-105",
"    </a>",
"    ], similar to those successfully employed in CML and other malignancies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36922?source=see_link&amp;anchor=H28#H28\">",
"     \"Prognosis and treatment of primary myelofibrosis\", section on 'JAK2 inhibitors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40474?source=see_link&amp;anchor=H2791725#H2791725\">",
"     \"Cellular and molecular biology of chronic myeloid leukemia\", section on 'BCR-ABL1 signaling'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20555381\">",
"    <span class=\"h4\">",
"     Allele burden",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism(s) through which this single gene mutation is associated with such phenotypic variability is unknown, although gene dosage effects (allele burden), occurrence of other genetic events, and genetic instability have been postulated [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/106\">",
"     106",
"    </a>",
"    ]. As an example, many patients with PV and PMF harbor this mutation in homozygous form, whereas those with ET appear to be heterozygous for this mutation in the vast majority of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Documenting the presence or absence of this mutation, as well as its allele burden, should be of value in the differential diagnosis between PV and secondary polycythemia as well as between ET and reactive thrombocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/108,109\">",
"     108,109",
"    </a>",
"    ], may serve as a marker to measure minimal residual disease following treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/110\">",
"     110",
"    </a>",
"    ], and may help in the understanding of thrombotic risk in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/111\">",
"     111",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A number of studies have found the JAK2 V617F mutation in a high percentage of patients with Budd-Chiari syndrome, many of whom had negative results from standard testing for one of the myeloproliferative neoplasms. It has been suggested that patients with this syndrome, in whom no underlying disorder can be identified, be tested for this mutation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31575?source=see_link&amp;anchor=H3#H3\">",
"       \"Etiology of the Budd-Chiari syndrome\", section on 'Myeloproliferative disorders'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11930?source=see_link&amp;anchor=H31#H31\">",
"       \"Evaluation of the patient with established venous thrombosis\", section on 'JAK2 mutation screening'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with primary myelofibrosis undergoing hematopoietic cell transplantation, achievement of JAK2 V617F negativity was significantly associated with a decreased incidence of relapse. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36922?source=see_link&amp;anchor=H10#H10\">",
"       \"Prognosis and treatment of primary myelofibrosis\", section on 'Allogeneic HCT'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In a prospective study of 26 patients with PV and 21 with ET, treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      was able to achieve a partial molecular response in 57 percent, as indicated by a significant decrease in JAK2 V617F allele load after 36 months of treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/112\">",
"       112",
"      </a>",
"      ]. In contrast, a control group not treated with hydroxyurea showed a slight increase in allele load over this same period of time.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     MPL mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Activating mutations of MPL, the thrombopoietin receptor, have been found in patients with familial essential thrombocythemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/28/18890?source=see_link&amp;anchor=H26#H26\">",
"     \"Diagnosis and clinical manifestations of essential thrombocythemia\", section on 'Familial essential thrombocythemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16680?source=see_link&amp;anchor=H11#H11\">",
"     \"Biology and physiology of thrombopoietin\", section on 'Familial thrombocythemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, such mutations have not been commonly observed in patients with MPN and their overall clinical significance is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/113,114\">",
"     113,114",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one large study, novel somatic activating mutations in the thrombopoietin receptor (MPL mutations W515L and W515K) were found in approximately 5 percent of patients with PMF, 1 percent of those with ET, and in none of the patients with PV [",
"      <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/115\">",
"       115",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second study, MPL mutations were seen in 16 of 143 patients (11 percent) with ET and 3 of 32 patients (9 percent) with PMF [",
"      <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/116\">",
"       116",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 603 patients with PMF, mutant MPL was detected in 8.1 percent and JAK2V617F in 58 percent. Multivariate analysis disclosed no significant difference in overall or leukemia-free survival between MPL-mutated, JAK2-mutated, and",
"      <span class=\"nowrap\">",
"       JAK2/MPL",
"      </span>",
"      mutated groups [",
"      <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/117\">",
"       117",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 508 subjects with MPNs, a MPL exon 10 somatic mutation was found in 7 percent. Unlike the finding in those with the JAK2 V617F mutation, MPL mutations were not significantly associated with the JAK2 GGCC haplotype, suggesting a different genetic background for these two molecular lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23235668\">",
"    <span class=\"h3\">",
"     Other mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A subset of patients with PV, ET, and PMF harbor mutations in LNK (Src homology 2 B3, SH2B3), CBL (Casitas B-lineage lymphoma), TET2 (TET oncogene family member 2), ASXL1 (Additional sex combs-like 1), IDH (Isocitrate dehydrogenase), IKZF1 (IKAROS family zinc finger 1), EZH2 (histone H3 lysine 27 methyltransferase), or DNMT3A (a DNA methyltransferase) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/118-122\">",
"     118-122",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study of 22 genes in 53 patients with leukemic transformation after a MPN identified mutations in some of the above genes (eg, JAK2, TET2, ASXL1,",
"    <span class=\"nowrap\">",
"     IDH1/2,",
"    </span>",
"    MPL) as well as in the",
"    <span class=\"nowrap\">",
"     serine/arginine-rich",
"    </span>",
"    splicing factor 2 (SRSF2) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/123\">",
"     123",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The precise pathogenetic contribution of these and other mutations is unclear at this time [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/124-126\">",
"     124-126",
"    </a>",
"    ], although they may be the consequences of inherent genomic instability [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/127\">",
"     127",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study of 422 patients with PV and ET, a polymorphism in the DNA repair gene XPD showed a strong association with both leukemic transformation (OR 4.9; 95% CI 2.0-12) and the development of non-myeloid malignancies (OR 4.2; 95% CI 1.5-12) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/128\">",
"     128",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Potential significance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The significance of JAK2 and MPL mutations in the genesis of the MPNs as well as their relative roles in determining disease phenotype, leukemic transformation, and the level of involvement of stem cells in these disorders are unclear at present [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/80,81,117,129-134\">",
"     80,81,117,129-134",
"    </a>",
"    ]. However, a number of observations suggest that clonal myelopoiesis may antedate acquisition of JAK2 or MPL mutations, and that the latter are acquired in a lympho-myeloid progenitor cell [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/80,135-137\">",
"     80,135-137",
"    </a>",
"    ]. Mutations in the TET2 gene are commonly seen in older MPN patients with or without JAK2 mutations; their pathogenetic and prognostic relevance is similarly uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/118,138-141\">",
"     118,138-141",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some patients with a MPN have both JAK2 and MPL mutations, and it is possible that homozygosity or heterozygosity for a JAK2 mutation, presence or absence of a MPL mutation, the balance between the sizes of their respective clones (ie, allele burden), MPL receptor expression,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other host genetic variations (eg, single nucleotide polymorphisms [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/142\">",
"     142",
"    </a>",
"    ] or specific haplotypes within the JAK2 gene) may determine predisposition to development of a JAK2 mutation, the clinical phenotype (eg, degree of thrombocytosis, leukocytosis, and erythrocytosis, splenic size, pruritus, transformation to myelofibrosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/107,136,143-157\">",
"     107,136,143-157",
"    </a>",
"    ], as well as the response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/158\">",
"     158",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Accordingly, quantitative assays for the JAK2 V617F mutation are preferred because they enable better estimation of allele burden as well as molecular monitoring of treatment response [",
"    <a class=\"abstract\" href=\"UTD.htm?20/52/21322/abstract/159\">",
"     159",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20555381\">",
"     'Allele burden'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/14/12513?source=see_link\">",
"       \"Patient information: Polycythemia vera (PV) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The myeloproliferative neoplasms (MPNs) exhibit terminal myeloid cell expansion in the peripheral blood, resulting in various combinations of erythrocytosis, leukocytosis, thrombocytosis, bone marrow",
"    <span class=\"nowrap\">",
"     hypercellularity/fibrosis,",
"    </span>",
"    and splenomegaly.",
"   </p>",
"   <p>",
"    The MPNs are predisposed to clonal evolution and disease transformation (eg, myelofibrosis, myelodysplastic syndrome, acute leukemia), along with a significant risk of thrombohemorrhagic complications. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Complications'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Classification",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The classic MPNs include polycythemia vera (PV), essential thrombocythemia (ET), chronic myeloid leukemia (CML), primary myelofibrosis (PMF), chronic neutrophilic leukemia, chronic eosinophilic leukemia, and mast cell disease.",
"     </li>",
"     <li>",
"      Atypical MPNs include those chronic myeloid disorders which are currently not classifiable as belonging to either the myelodysplastic syndrome or classical MPN. These include chronic myelomonocytic leukemia, juvenile myelomonocytic leukemia, atypical CML, and unclassifiable myelodysplastic syndrome",
"      <span class=\"nowrap\">",
"       (MDS)/MPN.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CML is characterized by a reciprocal chromosomal translocation between chromosomes 9 and 22 (ie, t(9;22)). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19609?source=see_link\">",
"       \"Clinical manifestations and diagnosis of chronic myeloid leukemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      PV is diagnosed when an otherwise unexplained increased",
"      <span class=\"nowrap\">",
"       hematocrit/red",
"      </span>",
"      blood cell mass is accompanied by the presence of a JAK2 mutation along with a decreased erythropoietin level. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9738?source=see_link\">",
"       \"Diagnostic approach to the patient with suspected polycythemia vera\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      PMF is characterized by a leukoerythroblastic blood picture, splenomegaly, and bone marrow fibrosis that cannot be attributed to another myeloid disorder. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1018?source=see_link\">",
"       \"Clinical manifestations and diagnosis of primary myelofibrosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      ET is a diagnosis of exclusion, representing clonal or autonomous thrombocytosis not classifiable as PV, PMF, CML, or MDS. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/28/18890?source=see_link\">",
"       \"Diagnosis and clinical manifestations of essential thrombocythemia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/1\">",
"      Tefferi A. The history of myeloproliferative disorders: before and after Dameshek. Leukemia 2008; 22:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/2\">",
"      Vannucchi AM, Guglielmelli P, Tefferi A. Advances in understanding and management of myeloproliferative neoplasms. CA Cancer J Clin 2009; 59:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/3\">",
"      Abkowitz JL, Catlin SN, Guttorp P. Evidence that hematopoiesis may be a stochastic process in vivo. Nat Med 1996; 2:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/4\">",
"      McCulloch EA. Stem cell renewal and determination during clonal expansion in normal and leukaemic haemopoiesis. Cell Prolif 1993; 26:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/5\">",
"      Tefferi A. Chronic myeloid disorders: Classification and treatment overview. Semin Hematol 2001; 38:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/6\">",
"      Kouides PA, Bennett JM. Morphology and classification of the myelodysplastic syndromes and their pathologic variants. Semin Hematol 1996; 33:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/7\">",
"      Raza A, Alvi S, Broady-Robinson L, et al. Cell cycle kinetic studies in 68 patients with myelodysplastic syndromes following intravenous iodo- and/or bromodeoxyuridine. Exp Hematol 1997; 25:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/8\">",
"      Dickstein JI, Vardiman JW. Hematopathologic findings in the myeloproliferative disorders. Semin Oncol 1995; 22:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/9\">",
"      Tefferi A, Thiele J, Vardiman JW. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer 2009; 115:3842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/10\">",
"      Tefferi A, Thibodeau SN, Solberg LA Jr. Clonal studies in the myelodysplastic syndrome using X-linked restriction fragment length polymorphisms. Blood 1990; 75:1770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/11\">",
"      Raskind WH, Fialkow PJ. The use of cell markers in the study of human hematopoietic neoplasia. Adv Cancer Res 1987; 49:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/12\">",
"      Tsukamoto N, Morita K, Maehara T, et al. Clonality in chronic myeloproliferative disorders defined by X-chromosome linked probes: demonstration of heterogeneity in lineage involvement. Br J Haematol 1994; 86:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/13\">",
"      Champion KM, Gilbert JG, Asimakopoulos FA, et al. Clonal haemopoiesis in normal elderly women: implications for the myeloproliferative disorders and myelodysplastic syndromes. Br J Haematol 1997; 97:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/14\">",
"      Levine RL, Belisle C, Wadleigh M, et al. X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood 2006; 107:4139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/15\">",
"      Rumi E, Passamonti F, Della Porta MG, et al. Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation. J Clin Oncol 2007; 25:5630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/16\">",
"      Landgren O, Goldin LR, Kristinsson SY, et al. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden. Blood 2008; 112:2199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/17\">",
"      Hemminki K, Sundquist J, Bermejo JL. Associated cancers in parents and offspring of polycythaemia vera and myelofibrosis patients. Br J Haematol 2009; 147:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/18\">",
"      Cario H, Goerttler PS, Steimle C, et al. The JAK2V617F mutation is acquired secondary to the predisposing alteration in familial polycythaemia vera. Br J Haematol 2005; 130:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/19\">",
"      Bellann&eacute;-Chantelot C, Chaumarel I, Labopin M, et al. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood 2006; 108:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/20\">",
"      Rumi E, Passamonti F, Pietra D, et al. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. Cancer 2006; 107:2206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/21\">",
"      Pardanani A, Lasho T, McClure R, et al. Discordant distribution of JAK2V617F mutation in siblings with familial myeloproliferative disorders. Blood 2006; 107:4572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/22\">",
"      Kralovics R, Stockton DW, Prchal JT. Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease. Blood 2003; 102:3793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/23\">",
"      Bellann&eacute;-Chantelot C, Jego P, Lionne-Huyghe P, et al. The JAK2(V617F) mutation may be present several years before the occurrence of overt myeloproliferative disorders. Leukemia 2008; 22:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/24\">",
"      Teofili L, Giona F, Martini M, et al. The revised WHO diagnostic criteria for Ph-negative myeloproliferative diseases are not appropriate for the diagnostic screening of childhood polycythemia vera and essential thrombocythemia. Blood 2007; 110:3384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/25\">",
"      NOWELL PC, HUNGERFORD DA. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst 1960; 25:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/26\">",
"      Reilly JT. Pathogenetic insight and prognostic information from standard and molecular cytogenetic studies in the BCR-ABL-negative myeloproliferative neoplasms (MPNs). Leukemia 2008; 22:1818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/27\">",
"      Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/28\">",
"      Bench AJ, White HE, Foroni L, et al. Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations. Br J Haematol 2013; 160:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/29\">",
"      Nielsen C, Birgens HS, Nordestgaard BG, Bojesen SE. Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49&nbsp;488 individuals from the general population. Br J Haematol 2013; 160:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/30\">",
"      Cervantes F, Colomer D, Vives-Corrons JL, et al. Chronic myeloid leukemia of thrombocythemic onset: a CML subtype with distinct hematological and molecular features? Leukemia 1996; 10:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/31\">",
"      Buhr T, Georgii A, Choritz H. Myelofibrosis in chronic myeloproliferative disorders. Incidence among subtypes according to the Hannover Classification. Pathol Res Pract 1993; 189:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/32\">",
"      Singh M, Bofinger A, Taylor K, Ba Pe R. Myelodysplasia with myelofibrosis--a distinct subgroup within the myelodysplastic syndromes. Pathology 1994; 26:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/33\">",
"      Neuwirtov&aacute; R, Mocikov&aacute; K, Musilov&aacute; J, et al. Mixed myelodysplastic and myeloproliferative syndromes. Leuk Res 1996; 20:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/34\">",
"      Hussein K, Bock O, Theophile K, et al. Chronic myeloproliferative diseases with concurrent BCR-ABL junction and JAK2V617F mutation. Leukemia 2008; 22:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/35\">",
"      Cambier N, Renneville A, Cazaentre T, et al. JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders. Leukemia 2008; 22:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/36\">",
"      Gaidano G, Guerrasio A, Serra A, et al. Molecular mechanisms of tumor progression in chronic myeloproliferative disorders. Leukemia 1994; 8 Suppl 1:S27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/37\">",
"      Noor SJ, Tan W, Wilding GE, et al. Myeloid blastic transformation of myeloproliferative neoplasms--a review of 112 cases. Leuk Res 2011; 35:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/38\">",
"      Najean Y, Rain JD. The very long-term evolution of polycythemia vera: an analysis of 318 patients initially treated by phlebotomy or 32P between 1969 and 1981. Semin Hematol 1997; 34:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/39\">",
"      Bj&ouml;rkholm M, Derolf AR, Hultcrantz M, et al. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol 2011; 29:2410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/40\">",
"      Frederiksen H, Farkas DK, Christiansen CF, et al. Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study. Blood 2011; 118:6515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/41\">",
"      Vannucchi AM, Masala G, Antonioli E, et al. Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. Cancer Epidemiol Biomarkers Prev 2009; 18:2068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/42\">",
"      Chintapatla R, Battini R, Wiernik PH. Chronic lymphocytic leukemia with essential thrombocythemia: asbestos exposure association? Clin Adv Hematol Oncol 2012; 10:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/43\">",
"      Kennedy JA, Atenafu EG, Messner HA, et al. Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms. Blood 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/44\">",
"      Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 2005; 128:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/45\">",
"      Landolfi R, Marchioli R, Patrono C. Mechanisms of bleeding and thrombosis in myeloproliferative disorders. Thromb Haemost 1997; 78:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/46\">",
"      Falanga A, Marchetti M, Evangelista V, et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 2000; 96:4261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/47\">",
"      Teofili L, Martini M, Iachininoto MG, et al. Endothelial progenitor cells are clonal and exhibit the JAK2(V617F) mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms. Blood 2011; 117:2700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/48\">",
"      van Genderen PJ, Lucas IS, van Strik R, et al. Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generation. Thromb Haemost 1996; 76:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/49\">",
"      Patrono C, Rocca B, De Stefano V. Platelet activation and inhibition in polycythemia vera and essential thrombocythemia. Blood 2013; 121:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/50\">",
"      Rozman C, Giralt M, Feliu E, et al. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 1991; 67:2658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/51\">",
"      Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer 2007; 109:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/52\">",
"      Scherber R, Dueck AC, Johansson P, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood 2011; 118:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/53\">",
"      Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol 2012; 30:4098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/54\">",
"      Siitonen T, Zheng A, Savolainen ER, Koistinen P. Spontaneous granulocyte-macrophage colony growth by peripheral blood mononuclear cells in myeloproliferative disorders. Leuk Res 1996; 20:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/55\">",
"      Gregg XT, Prchal JT. Erythropoietin receptor mutations and human disease. Semin Hematol 1997; 34:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/56\">",
"      Silva M, Richard C, Benito A, et al. Expression of Bcl-x in erythroid precursors from patients with polycythemia vera. N Engl J Med 1998; 338:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/57\">",
"      Kiladjian JJ, Elkassar N, Hetet G, et al. Study of the thrombopoitin receptor in essential thrombocythemia. Leukemia 1997; 11:1821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/58\">",
"      Pitcher L, Taylor K, Nichol J, et al. Thrombopoietin measurement in thrombocytosis: dysregulation and lack of feedback inhibition in essential thrombocythaemia. Br J Haematol 1997; 99:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/59\">",
"      Horikawa Y, Matsumura I, Hashimoto K, et al. Markedly reduced expression of platelet c-mpl receptor in essential thrombocythemia. Blood 1997; 90:4031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/60\">",
"      Moliterno AR, Hankins WD, Spivak JL. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. N Engl J Med 1998; 338:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/61\">",
"      Villeval JL, Cohen-Solal K, Tulliez M, et al. High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. Blood 1997; 90:4369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/62\">",
"      Martyr&eacute; MC. TGF-beta and megakaryocytes in the pathogenesis of myelofibrosis in myeloproliferative disorders. Leuk Lymphoma 1995; 20:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/63\">",
"      Goerttler PS, Kreutz C, Donauer J, et al. Gene expression profiling in polycythaemia vera: overexpression of transcription factor NF-E2. Br J Haematol 2005; 129:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/64\">",
"      Puigdecanet E, Espinet B, Lozano JJ, et al. Gene expression profiling distinguishes JAK2V617F-negative from JAK2V617F-positive patients in essential thrombocythemia. Leukemia 2008; 22:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/65\">",
"      Dai CH, Krantz SB, Dessypris EN, et al. Polycythemia vera. II. Hypersensitivity of bone marrow erythroid, granulocyte-macrophage, and megakaryocyte progenitor cells to interleukin-3 and granulocyte-macrophage colony-stimulating factor. Blood 1992; 80:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/66\">",
"      Kobayashi S, Teramura M, Hoshino S, et al. Circulating megakaryocyte progenitors in myeloproliferative disorders are hypersensitive to interleukin-3. Br J Haematol 1993; 83:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/67\">",
"      Axelrad AA, Eskinazi D, Correa PN, Amato D. Hypersensitivity of circulating progenitor cells to megakaryocyte growth and development factor (PEG-rHu MGDF) in essential thrombocythemia. Blood 2000; 96:3310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/68\">",
"      Fleischman AG, Aichberger KJ, Luty SB, et al. TNF&alpha; facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood 2011; 118:6392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/69\">",
"      James C, Ugo V, Le Cou&eacute;dic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/70\">",
"      Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/71\">",
"      Kaushansky K. On the molecular origins of the chronic myeloproliferative disorders: it all makes sense. Blood 2005; 105:4187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/72\">",
"      Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/73\">",
"      Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007; 7:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/74\">",
"      Jones AV, Campbell PJ, Beer PA, et al. The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms. Blood 2010; 115:4517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/75\">",
"      Smalberg JH, Koehler E, Darwish Murad S, et al. The JAK2 46/1 haplotype in Budd-Chiari syndrome and portal vein thrombosis. Blood 2011; 117:3968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/76\">",
"      Pietra D, Casetti I, Da Vi&agrave; MC, et al. JAK2 GGCC haplotype in MPL mutated myeloproliferative neoplasms. Am J Hematol 2012; 87:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/77\">",
"      Ishii T, Bruno E, Hoffman R, Xu M. Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera. Blood 2006; 108:3128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/78\">",
"      Delhommeau F, Dupont S, Tonetti C, et al. Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. Blood 2007; 109:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/79\">",
"      Larsen TS, Christensen JH, Hasselbalch HC, Pallisgaard N. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. Br J Haematol 2007; 136:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/80\">",
"      Pardanani A, Lasho TL, Finke C, et al. Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes. Stem Cells 2007; 25:2358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/81\">",
"      Pardanani A, Lasho TL, Finke C, et al. Demonstration of MPLW515K, but not JAK2V617F, in in vitro expanded CD4+ T lymphocytes. Leukemia 2007; 21:2206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/82\">",
"      Rosti V, Villani L, Riboni R, et al. Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation. Blood 2013; 121:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/83\">",
"      Toyama K, Karasawa M, Yamane A, et al. JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets. Br J Haematol 2007; 139:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/84\">",
"      Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med 2006; 355:2452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/85\">",
"      Grimwade LF, Happerfield L, Tristram C, et al. Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms. Br J Haematol 2009; 147:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/86\">",
"      Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352:1779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/87\">",
"      Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005; 106:2162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/88\">",
"      Lippert E, Boissinot M, Kralovics R, et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood 2006; 108:1865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/89\">",
"      Goerttler PS, Steimle C, M&auml;rz E, et al. The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients. Blood 2005; 106:2862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/90\">",
"      Tefferi A, Gilliland DG. The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis. Mayo Clin Proc 2005; 80:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/91\">",
"      Teofili L, Martini M, Cenci T, et al. Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation. Blood 2007; 110:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/92\">",
"      Yan D, Hutchison RE, Mohi G. Critical requirement for Stat5 in a mouse model of polycythemia vera. Blood 2012; 119:3539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/93\">",
"      Walz C, Ahmed W, Lazarides K, et al. Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice. Blood 2012; 119:3550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/94\">",
"      Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both \"atypical\" myeloproliferative disorders and myelodysplastic syndromes. Blood 2005; 106:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/95\">",
"      Jelinek J, Oki Y, Gharibyan V, et al. JAK2 mutation 1849G&gt;T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 2005; 106:3370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/96\">",
"      Levine RL, Loriaux M, Huntly BJ, et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 2005; 106:3377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/97\">",
"      Fr&ouml;hling S, Lipka DB, Kayser S, et al. Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7. Blood 2006; 107:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/98\">",
"      Xing S, Wanting TH, Zhao W, et al. Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood 2008; 111:5109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/99\">",
"      Pardanani A. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia 2008; 22:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/100\">",
"      Liu PC, Caulder E, Li J, et al. Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity. Clin Cancer Res 2009; 15:6891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/101\">",
"      Chen AT, Prchal JT. JAK2 kinase inhibitors and myeloproliferative disorders. Curr Opin Hematol 2010; 17:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/102\">",
"      Apostolidou E, Kantarjian HM, Verstovsek S. JAK2 inhibitors: A reality? A hope? Clin Lymphoma Myeloma 2009; 9 Suppl 3:S340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/103\">",
"      Wadleigh M, Tefferi A. Preclinical and clinical activity of ATP mimetic JAK2 inhibitors. Clin Adv Hematol Oncol 2010; 8:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/104\">",
"      Agrawal M, Garg RJ, Cortes J, et al. Experimental therapeutics for patients with myeloproliferative neoplasias. Cancer 2011; 117:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/105\">",
"      Stein BL, Crispino JD, Moliterno AR. Janus kinase inhibitors: an update on the progress and promise of targeted therapy in the myeloproliferative neoplasms. Curr Opin Oncol 2011; 23:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/106\">",
"      Levine RL, Gilliland DG. Myeloproliferative disorders. Blood 2008; 112:2190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/107\">",
"      Scott LM, Scott MA, Campbell PJ, Green AR. Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood 2006; 108:2435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/108\">",
"      Tefferi A, Sirhan S, Lasho TL, et al. Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia. Br J Haematol 2005; 131:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/109\">",
"      Spivak JL. Narrative review: Thrombocytosis, polycythemia vera, and JAK2 mutations: The phenotypic mimicry of chronic myeloproliferation. Ann Intern Med 2010; 152:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/110\">",
"      Kiladjian JJ, Cassinat B, Turlure P, et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood 2006; 108:2037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/111\">",
"      Austin SK, Lambert JR. The JAK2 V617F mutation and thrombosis. Br J Haematol 2008; 143:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/112\">",
"      Besses C, Alvarez-Larr&aacute;n A, Mart&iacute;nez-Avil&eacute;s L, et al. Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients. Br J Haematol 2011; 152:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/113\">",
"      Xu W, Li JY, Xia J, et al. MPL W515L mutation in Chinese patients with myeloproliferative diseases. Leuk Lymphoma 2008; 49:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/114\">",
"      Rumi E, Pietra D, Guglielmelli P, et al. Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms. Blood 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/115\">",
"      Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006; 108:3472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/116\">",
"      Boyd EM, Bench AJ, Goday-Fern&aacute;ndez A, et al. Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis. Br J Haematol 2010; 149:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/117\">",
"      Pardanani A, Guglielmelli P, Lasho TL, et al. Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients. Leukemia 2011; 25:1834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/118\">",
"      Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol 2011; 29:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/119\">",
"      Abdel-Wahab O. Genetics of the myeloproliferative neoplasms. Curr Opin Hematol 2011; 18:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/120\">",
"      Abdel-Wahab O, Pardanani A, Rampal R, et al. DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms. Leukemia 2011; 25:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/121\">",
"      Rao N, Butcher CM, Lewis ID, et al. Clonal and lineage analysis of somatic DNMT3A and JAK2 mutations in a chronic phase polycythemia vera patient. Br J Haematol 2012; 156:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/122\">",
"      Ricci C, Spinelli O, Salmoiraghi S, et al. ASXL1 mutations in primary and secondary myelofibrosis. Br J Haematol 2012; 156:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/123\">",
"      Zhang SJ, Rampal R, Manshouri T, et al. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. Blood 2012; 119:4480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/124\">",
"      Tefferi A. Mutations galore in myeloproliferative neoplasms: would the real Spartacus please stand up? Leukemia 2011; 25:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/125\">",
"      Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA. New mutations and pathogenesis of myeloproliferative neoplasms. Blood 2011; 118:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/126\">",
"      Tefferi A, Jimma T, Sulai NH, et al. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia 2012; 26:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/127\">",
"      Scott LM, Rebel VI. JAK2 and genomic instability in the myeloproliferative neoplasms: a case of the chicken or the egg? Am J Hematol 2012; 87:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/128\">",
"      Hern&aacute;ndez-Boluda JC, Pereira A, Cervantes F, et al. A polymorphism in the XPD gene predisposes to leukemic transformation and new nonmyeloid malignancies in essential thrombocythemia and polycythemia vera. Blood 2012; 119:5221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/129\">",
"      Theocharides A, Boissinot M, Girodon F, et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 2007; 110:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/130\">",
"      Kilpivaara O, Levine RL. JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science. Leukemia 2008; 22:1813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/131\">",
"      Plo I, Chaligne R, James C, Vainchenker W. New insights into the molecular pathogenessis of Bcr-Abl-negative myeloproliferative disorders. Clin Leuk 2009; 3:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/132\">",
"      Beer PA, Delhommeau F, LeCou&eacute;dic JP, et al. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood 2010; 115:2891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/133\">",
"      Thoennissen NH, Krug UO, Lee DH, et al. Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood 2010; 115:2882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/134\">",
"      Plo I, Vainchenker W. Molecular and genetic bases of myeloproliferative disorders: questions and perspectives. Clin Lymphoma Myeloma 2009; 9 Suppl 3:S329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/135\">",
"      Kralovics R. Genetic complexity of myeloproliferative neoplasms. Leukemia 2008; 22:1841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/136\">",
"      Cross NC, Daley GQ, Green AR, et al. BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features. Leukemia 2008; 22:1975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/137\">",
"      Beer PA, Jones AV, Bench AJ, et al. Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones. Br J Haematol 2009; 144:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/138\">",
"      Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009; 360:2289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/139\">",
"      Tefferi A, Pardanani A, Lim KH, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009; 23:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/140\">",
"      Saint-Martin C, Leroy G, Delhommeau F, et al. Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms. Blood 2009; 114:1628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/141\">",
"      Schaub FX, Looser R, Li S, et al. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood 2010; 115:2003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/142\">",
"      Klampfl T, Harutyunyan A, Berg T, et al. Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. Blood 2011; 118:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/143\">",
"      Lasho TL, Pardanani A, McClure RF, et al. Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time. Br J Haematol 2006; 135:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/144\">",
"      Moliterno AR, Williams DM, Rogers O, Spivak JL. Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression. Blood 2006; 108:3913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/145\">",
"      Guglielmelli P, Pancrazzi A, Bergamaschi G, et al. Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. Br J Haematol 2007; 137:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/146\">",
"      Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical profile of homozygous JAK2 617V&gt;F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 2007; 110:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/147\">",
"      Dupont S, Mass&eacute; A, James C, et al. The JAK2 617V&gt;F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood 2007; 110:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/148\">",
"      Williams DM, Kim AH, Rogers O, et al. Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis. Exp Hematol 2007; 35:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/149\">",
"      Spivak JL, Moliterno AR. The roles of genetics and epigenetics in the diagnosis of chronic myeloproliferative disorders. Clinical Leukemia 2007; 1:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/150\">",
"      Pardanani A, Fridley BL, Lasho TL, et al. Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood 2008; 111:2785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/151\">",
"      Tiedt R, Hao-Shen H, Sobas MA, et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 2008; 111:3931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/152\">",
"      Kota J, Caceres N, Constantinescu SN. Aberrant signal transduction pathways in myeloproliferative neoplasms. Leukemia 2008; 22:1828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/153\">",
"      Hussein K, Bock O, Theophile K, et al. Biclonal expansion and heterogeneous lineage involvement in a case of chronic myeloproliferative disease with concurrent MPLW515L/JAK2V617F mutation. Blood 2009; 113:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/154\">",
"      Jones AV, Chase A, Silver RT, et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet 2009; 41:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/155\">",
"      Olcaydu D, Harutyunyan A, J&auml;ger R, et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet 2009; 41:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/156\">",
"      Kilpivaara O, Mukherjee S, Schram AM, et al. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet 2009; 41:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/157\">",
"      Hsiao HH, Liu YC, Tsai HJ, et al. JAK2V617F mutation is associated with special alleles in essential thrombocythemia. Leuk Lymphoma 2011; 52:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/158\">",
"      Sirhan S, Lasho TL, Hanson CA, et al. The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea. Am J Hematol 2008; 83:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/52/21322/abstract/159\">",
"      Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia 2008; 22:1299.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4511 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-118.195.65.248-57510F31CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_52_21322=[""].join("\n");
var outline_f20_52_21322=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION OF HEMATOLOGIC MALIGNANCIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      The chronic myeloid disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clonal studies in the chronic myeloid disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Familial disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      THE CLASSIC MYELOPROLIFERATIVE DISEASES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2181740\">",
"      - Malignancies and clonal evolution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5166016\">",
"      Treatment of MPN-associated acute leukemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2181747\">",
"      - Thrombosis and bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Symptoms and quality of life",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Role of hematologic growth factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Gene expression profiling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Mutations in PV, ET, and PMF",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - JAK2 mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H20555374\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H20555381\">",
"      Allele burden",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - MPL mutations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23235668\">",
"      - Other mutations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Potential significance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4511\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4511|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/16/24835\" title=\"figure 1\">",
"      Organiz heme malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4511|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/25/17808\" title=\"picture 1\">",
"      Erythromelalgia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16680?source=related_link\">",
"      Biology and physiology of thrombopoietin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40474?source=related_link\">",
"      Cellular and molecular biology of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19609?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1018?source=related_link\">",
"      Clinical manifestations and diagnosis of primary myelofibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=related_link\">",
"      Clinical manifestations and diagnosis of the myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/28/18890?source=related_link\">",
"      Diagnosis and clinical manifestations of essential thrombocythemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9738?source=related_link\">",
"      Diagnostic approach to the patient with suspected polycythemia vera",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31575?source=related_link\">",
"      Etiology of the Budd-Chiari syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11930?source=related_link\">",
"      Evaluation of the patient with established venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31512?source=related_link\">",
"      Molecular genetics of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29978?source=related_link\">",
"      Molecular pathogenesis of congenital polycythemic disorders and polycythemia vera",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25064?source=related_link\">",
"      Pathogenetic mechanisms in primary myelofibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/14/12513?source=related_link\">",
"      Patient information: Polycythemia vera (PV) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28554?source=related_link\">",
"      Prognosis and treatment of polycythemia vera",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36922?source=related_link\">",
"      Prognosis and treatment of primary myelofibrosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_52_21323="Adoption resources";
var content_f20_52_21323=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F65533&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F65533&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Adoption resources",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Books for children:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Entering adoptive home from foster care:",
"       <em>",
"        Zachary's New Home",
"       </em>",
"       by GM Blomquist",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Of school age:",
"       <em>",
"        So You're Adopted",
"       </em>",
"       by F Powledge",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       In adolescence:",
"       <em>",
"        Who is David?",
"       </em>",
"       by E Nerlove",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Books for adoptive parents:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <em>",
"        Raising Adopted Children: A Manual for Adoptive Parents",
"       </em>",
"       by LR Melina",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <em>",
"        Talking With Young Children About Adoption",
"       </em>",
"       by M Watkins and S Fisher",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <em>",
"        The Essential Adoption Handbook",
"       </em>",
"       by CT Alexander-Roberts",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Internet resources:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Adoption book catalog: www.tapestrybooks.com",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       National Adoption Information Clearinghouse: www.adoption.org/adopt/national-adoption-clearinghouse.php",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_52_21323=[""].join("\n");
var outline_f20_52_21323=null;
var title_f20_52_21324="Diff dx preeclampsia";
var content_f20_52_21324=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F64296&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F64296&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Frequency of various signs and symptoms among imitators of preeclampsia-eclampsia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Signs and symptoms",
"       </td>",
"       <td class=\"subtitle1\">",
"        HELLP syndrome, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        AFLP, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        TTP, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        HUS, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Exacerbation of SLE, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypertension",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        20-75",
"       </td>",
"       <td>",
"        80-90",
"       </td>",
"       <td>",
"        80 with APA, nephritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Proteinuria",
"       </td>",
"       <td>",
"        90-95",
"       </td>",
"       <td>",
"        30-50",
"       </td>",
"       <td>",
"        With hematuria",
"       </td>",
"       <td>",
"        80-90",
"       </td>",
"       <td>",
"        100 with nephritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fever",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"       <td>",
"        25-32",
"       </td>",
"       <td>",
"        20-50",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        Common during flare",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Jaundice",
"       </td>",
"       <td>",
"        5-10",
"       </td>",
"       <td>",
"        40-90",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nausea and vomiting",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        50-80",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Only with APA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdominal pain",
"       </td>",
"       <td>",
"        60-80",
"       </td>",
"       <td>",
"        35-50",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Only with APA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Central nervous system",
"       </td>",
"       <td>",
"        40-60",
"       </td>",
"       <td>",
"        30-40",
"       </td>",
"       <td>",
"        60-70",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        50 with APA",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     HELLP: hemolysis, elevated liver enzymes, low platelets; AFLP: acute fatty liver of pregnancy; TTP: thrombotic thrombocytopenic purpura; HUS: hemolytic uremic syndrome; SLE: systemic lupus erythematosus; APA: antiphospholipid antibodies with or without catastrophic antiphospholipid syndrome; NR: values not reported; Common: reported as the most common presentation.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sibai BM. Imitators of severe preeclampsia. Obstet Gynecol 2007; 109:956. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_52_21324=[""].join("\n");
var outline_f20_52_21324=null;
var title_f20_52_21325="Dofetilide in AF and HF";
var content_f20_52_21325=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F69648&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F69648&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dofetilide increases the probability of maintaining sinus rhythm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 394px; height: 290px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In patients with heart failure and atrial fibrillation or atrial flutter at baseline that was successfully pharmacologically or electrically cardioverted to sinus rhythm, the probability of remaining in sinus rhythm is increased with dofetilide; compared to placebo, the hazard ratio for the dofetilide group was 0.35 (p",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Torp-Pedersen C, Moller M, Bloch-Thomsen et al, for the Danish Investigations of Arrhythmia and Mortality on Dofetilide Study investigators, N Engl J Med 1999; 341:857.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_52_21325=[""].join("\n");
var outline_f20_52_21325=null;
var title_f20_52_21326="Contents: Pediatrics calculators";
var content_f20_52_21326=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?17/55/18302\">",
"       Pediatrics",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Pediatrics calculators",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Pediatrics calculators",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Clinical Criteria",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/24/13697\">",
"           Calculator: Apgar score",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/63/5109\">",
"           Calculator: Newborn hyperbilirubinemia assessment",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Medical Equations",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/15/9463\">",
"           Calculator: Blood pressure percentiles for boys (2 to 17 years)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/33/9751\">",
"           Calculator: Blood pressure percentiles for girls (2 to 17 years)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/14/36070\">",
"           Calculator: Body Mass Index (BMI) percentiles for boys (2 to 20 years)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/60/35782\">",
"           Calculator: Body Mass Index (BMI) percentiles for girls (2 to 20 years)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/27/4529\">",
"           Calculator: Body Surface Area (Mosteller, square root method)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/49/43796\">",
"           Calculator: Body mass index for boys (Patient information)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/19/12596\">",
"           Calculator: Body mass index for girls (Patient information)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/47/22262\">",
"           Calculator: CDC height for age percentiles for boys (2 to 20 years)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/7/22646\">",
"           Calculator: CDC height for age percentiles for girls (2 to 20 years)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/50/35619\">",
"           Calculator: CDC weight for height percentiles for boys (77 to 121 cm tall)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/37/2644\">",
"           Calculator: CDC weight for height percentiles for girls (77 to 121 cm tall)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/25/16788\">",
"           Calculator: CDC/NCHS infant head circumference for age percentiles (&lt;36 months)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/34/34339\">",
"           Calculator: CDC/NCHS infant length for age percentiles (&lt;36 months)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/10/162\">",
"           Calculator: CDC/NCHS infant weight for age percentiles (&lt;36 months)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/53/6997\">",
"           Calculator: CDC/NCHS infant weight for length percentiles (&lt;36 months)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/40/24193\">",
"           Calculator: Glomerular filtration rate estimate by Schwartz formula",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/60/8129\">",
"           Calculator: Maintenance fluid calculation for children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/3/30769\">",
"           Calculator: Mid-parental target height prediction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/40/9860\">",
"           Calculator: PELD score for end-stage liver disease (patients less than 12 years old)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/40/36485\">",
"           Calculator: WHO Assessment of Malnutrition in Boys 0 to 2 Years Old",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/32/30213\">",
"           Calculator: WHO Assessment of Malnutrition in Boys 2 to 5 years Old",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/1/36885\">",
"           Calculator: WHO Assessment of Malnutrition in Girls 0 to 2 Years Old",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/48/30469\">",
"           Calculator: WHO Assessment of Malnutrition in Girls 2 to 5 years Old",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/31/35315\">",
"           Calculator: WHO Infant Head Circumference for Age Percentiles (&lt; 24 months)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/51/10035\">",
"           Calculator: WHO Infant Length for Age Percentiles (&lt; 24 months)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/46/12003\">",
"           Calculator: WHO Infant Weight for Age Percentiles (&lt; 24 months)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/54/23398\">",
"           Calculator: WHO Infant Weight for Length Percentiles (&lt; 24 months)",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-1FC716E5AE-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f20_52_21326=[""].join("\n");
var outline_f20_52_21326=null;
var title_f20_52_21327="Clotting factor consumption and hypofibrinogenemia";
var content_f20_52_21327=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F60690&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F60690&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 613px\">",
"   <div class=\"ttl\">",
"    Clotting factor consumption and hypofibrinogenemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 593px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Citrated rapid-TEG reflecting clotting factor consumption and hypofibrinogenemia. The red line indicates a normal study.",
"    <br>",
"     This study shows a prolonged ACT, R time, and K time, reflecting enzymatic hypocoagulability; markedly low alpha angle, MA, and G, reflecting platelet hypocoagulability and poor fibrin deposition; normal LY30.",
"     <div class=\"footnotes\">",
"      R (reaction time): time from sample placement or activation until the tracing amplitude reaches 2 mm; K (clot formation time): time elapsed between the R-time and the point where the tracing amplitude reaches 20 mm; alpha angle: angle between the middle line of the tracing and a tangential line to the developing \"body\" of the tracing; MA (maximal amplitude): the maximal amplitude reached after clot initiation; G: a calculated measure of total clot strength based on amplitude; LY30: the amount of clot lysis detected 30 minutes after the maximal amplitute (MA) is reached; SP (split point): time from sample placement (or activation with an exogenous procoagulant) until the earliest detectable resistance.",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_52_21327=[""].join("\n");
var outline_f20_52_21327=null;
